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Chapter 1
General introduction
Growth impairment is considered a relatively early sign of poor health in children. 
Depending on its setting and the age of the child the impairment is expressed in several 
ways. Failure to thrive is a term often used in the first years of life and is either defined as 
poor weight for age, poor weight for length or poor length for age.1,2 In older children one 
speaks more of growth retardation or short stature. Other definitions of growth impairment 
are stunting (low height for age) or a decline in height velocity. 
In developing countries the principal cause of growth failure is malnutrition. In 
industrialized countries a great diversity of congenital or acquired conditions, such as 
Turner syndrome, Growth Hormone Deficiency (GHD), can underlie growth failure (see 
table 1).  Here the largest and most important groups to be detected are GHD, Turner 
syndrome and celiac disease, as others are either rare or accompanied by other symptoms.  
Whatever the cause of the restricted growth is, an early diagnosis and treatment is 
important not only to prevent further health damage, but also to create an optimal effect 
on adult height and an extension of the period of a better quality of life of those who are 
treated. 
A proper treatment of children with abnormal growth depends both on the early 
identification of these children in the community (by growth monitoring) and on an accurate 
diagnostic work-up in the hospital after referral.
Table 1. Causes of short stature:
1. Primary growth disorders: 2.  Secondary growth disorders: 3.  Idiopathic short stature:
a. Skeletal dysplasias a.  Disorders in specific systems: 
Cardiac disease 
Pulmonary disorder 
Liver disorder 
Intestinal disorder 
Renal disorder 
Chronic anemia 
Chronic inflammatory disorder 
Malnutrition disorders
a.  Familial short stature
b.  Clinically defined syndromes with 
chromosomal aberrations 
Turner syndrome 
Mixed gonadal dysgenesis 
Down syndrome 
Other
b.  Endocrine disorders 
Growth hormone deficiency 
Thyroid disorders 
Adrenal disorders 
Gonadal disorder 
Diabetes mellitus 
Precocious Puberty
b.  Non-familial short stature
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c.  Clinically defined syndromes without 
chromosomal aberrations 
Noonan syndrome 
Silver-Russel syndrome 
Von Recklinhausen syndrome 
Cornelia de Lange syndrome 
Prader-Labhardt-Willi syndrome 
Williams syndrome 
Bloom syndrome 
Rubinstein syndrome 
Other
c.  Metabolic disorder 
Disorder of carbohydrate metabolism 
Disorder of lipid metabolism 
Disorder of amino acids 
Disorder of calcium and phosphate 
metabolism 
Disorder of bone metabolism
d.  Small for gestational age (SGA) with 
persisting short stature
d.  Iatrogenic short stature 
Medication 
Total body irradiation
e.  Psychogenic short stature 
Psychosocial short stature 
Anorexia nervosa
History of growth monitoring
To facilitate the detection of growth disorders, growth monitoring, implying regular 
measurements of weight and length, is essential. Nowadays growth monitoring is widely 
accepted and almost every child is measured regularly during childhood. The earliest 
citation of growth dates from the sixth century B.C. It was mentioned in a poem by the 
Greek Solon the Athenian.3 The poem deals with the division of human lifespan into ten 
successive seven-year periods (“hebdomads”). The translation by Tanner of the first four 
hebdomads is at follows:3
A young boy acquires his first ring of teeth  
as an infant [literally while unable to speak] and  
sheds them before he reaches the age of 7 years.  
When the god brings to an end the next seven-year period,  
the boy shows the signs of beginning puberty [or: of beginning pubic hair].  
In the third hebdomad, the body enlarges,  
the chin becomes bearded and the bloom of the boy’s complexion is lost.  
In the fourth hebdomad physical strength is at its  
peak and is regarded as the criterion of manliness.
It took until the 18th century before the first growth studies took place. Initially these 
studies were done for military purposes as the body size of guards and soldiers was of 
interest. During that century other individual growth studies, like the study of P.G de 
Montbeillard´s son (1759 - 1777) and the study on the pupils of the Carlschule in Stuttgart 
(1772 – 1777) were performed. With the increasing interest in public health in the 
nineteenth century there was a change towards general growth studies.
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The relationship between political state and health had become stronger since the decline 
of mortality due to epidemics and increasing wealth in industrialized countries in the 
18th century. The most important influence on this relation was however “the declaration 
of health as a right of democratic citizenship”, first declared by revolutionaries in 1791 
in France.4 Disease prevention became politically and economically a major subject 
and by the end of the nineteenth century one began to understand the importance of 
child health care for the general welfare. As a result the 20th century was declared as 
“the century of the child”, in which child health and welfare was not only medicalized 
but was also serving as a powerful tool for the state to expand its power in health and 
welfare in general.5 This resulted in the establishment of compulsory school systems and 
abandonment of child labor in the western world. With this development, children turned 
into attractive research subjects and children have been measured regularly in schools 
and infant welfare clinics ever since.  At the same time the recurrence of wars played an 
important role in the development of growth monitoring, for it led to concerns about the 
quality of the health status of populations, and brought as a consequence the mathematical 
basis for growth studies.3 
In the Netherlands growth studies were performed since 1850, but it took until 1955 
for these studies to become nationally representative and to cover the complete age 
group of childhood (0-18 years). The first well baby clinic was established in 1901 by 
the paediatrician B.P.B. Plantenga in The Hague.6 In the beginning children were only 
weighed but since 1972 nearly every child is monitored for length (measured in supine 
position, usually below 2 years of age), height (measured in standing position, usually 
from 2 years onwards) and weight from birth till the age of 16-18 years. Since 1978 these 
measurements are registered in a “book of growth” (Groeiboek). 
During the 1970s several health organizations, including the World Health Organization 
and UNICEF, promoted the monitoring of growth worldwide as part of the “Child Survival 
and Development Revolution”.7 Since then growth monitoring, even in underdeveloped 
countries, has become a central activity in child health care, but its effectiveness and its 
performance remain subject of debate.8
In this discussion it is important to realize that there is a difference in purposes and 
objectives of growth monitoring programs depending on its setting. In developing countries 
the principal aim of growth monitoring is to detect malnutrition. In industrialized 
countries, where there is much less malnutrition, growth monitoring is aimed at detecting 
other acquired or congenital causes of growth retardation, and is increasingly used to 
detect overweight.
The effect of routine growth monitoring in developing countries has recently been 
questioned.9 The efficacy and efficiency of height monitoring in developed countries has 
hardly been studied. 
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Auxological screening 
Auxology comes from the greek word Auxe¯ –logia¯ and means the science or study of 
growth. Auxological screening is therefore often used to describe growth monitoring and 
implies regular height and weight measurements. 
After height and weight measurements are taken they should be plotted on a growth chart 
for the child’s growth to be monitored over time. Many different growth charts are being 
used around the world, not only different in reference population but also in parameters 
and units (percentiles or SD-scores). In developing countries weight for age is the usual 
parameter, whereas in industrialized countries growth monitoring may be conducted less 
frequently and the preferred parameter is height for age.10, 11 Many charts are expressed 
in percentiles but more and more charts have turned to standard deviation scores (SDS) 
((Height – mean height for the same age and sex) / (SD for the same age and sex). Using 
SD scores has several advantages: 1) It is easier to express measurements far below P3 
as SDS than as a percentile; 2) The distance between SD scores is equal, whereas the 
distance between the usual percentiles differs; 3) percentiles cannot be used to compare 
growth between subpopulations or between different international populations, as they are 
unsuitable for statistical purposes. Percentiles can however easily be transformed into SD 
scores and the other way around, if the measurements have a Gaussian distribution.
Other parameters that are directly involved in growth monitoring are target height, bone 
age and stages of puberty. After the age of approximately 3 years, target height SDS is 
strongly correlated with the child’s height SDS. It is a mathematical approach of the 
estimated final height of a boy or a girl on the basis of their genetic potential. Using the 
Dutch reference growth data, target height and target height SDS can be calculated with 
the following formulas: 12
1) for males: TH (cm) = [(Height Father + Height Mother +13)/2] +4.5; 
 TH SDS= (TH-184.0)/7.1 
2) for females TH = [(Height Father + Height Mother -13)/2] +4.5; 
 TH SDS= (TH-170.6)/6.5. 
The term 13 cm represents the difference between male and female final height,13 , 
whereas the term 4.5 cm represents the height difference per generation (30 years).14 
Bone age in combination with height can be used to predict final height, using various 
methods.15,16 Puberty is assessed using the stages of Tanner and Whitehouse.17 As short 
children with a body proportion outside the normal range, are prone to have a primary 
growth disorder, body proportions are indirectly involved in growth monitoring, especially 
in industrialized countries where the aim of growth monitoring is the detection of growth 
disorders. The most suitable parameter for body proportions is the sitting height/ height 
ratio.18
For an early identification of children with abnormal growth it is important to have correct 
and well-defined referral criteria next to a good growth monitoring system, with accurate 
growth charts. In the literature, however, mainly arbitrary referral criteria are used to 
express growth failure in experimental studies on growth monitoring.19-21 For failure to 
thrive, often used in infancy and early childhood to describe growth impairment, there 
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is even no consensus on the choice of anthropometric indicators or their criteria for 
abnormality.1,2
Only a few guidelines have been published on referral criteria for children with impaired 
growth.22,23 One of those guidelines, the UK-consensus, concentrates on the referral of 
children with short stature after a single height measurement at school entrance (a height 
< P 0.4 ( -2.66 SDS) at 5 years of age).22 According to the other guideline, the Dutch 
Consensus Guideline, seven referral criteria should be used (see paragraph on growth 
monitoring in the Netherlands).23 Both guidelines are however based on consensus 
meetings rather than on experimental evidence, and specific information on their 
sensitivity and specificity to detect growth disorders is lacking. Although the authors 
of the Dutch Consensus guideline had aimed at promoting early diagnosis of aberrant 
growth as well as at preventing unnecessary referral and interventions, it was shown later 
that if this guideline would be followed, an unacceptable percentage of healthy children 
would be referred.24 This high percentage seems mainly due to the rule based on height 
deflection. The United Kingdom guideline must lead to a better specificity, as it has only 
one strict referral criterion and does not use deflection. However, it has an unknown 
sensitivity to detect disorders timely.22,25
Diagnostic work-up in children with short stature
A diagnostic work-up is a thorough medical examination for diagnostic purposes and 
in case of short stature consists of several components, i.e. medical history, physical 
examination, laboratory investigations, radiographic investigations, specific tests for 
suspected diseases and genetic analyses. 
As the outcome of the assessment of short stature is very heterogeneous, a good routine 
diagnostic work up for screening purposes depends on the frequency of the underlying 
medical disorder, the severity of the disease, its clinical presentation - including 
symptoms and signs other than auxological ones-, and the invasiveness and costs of the 
tests to be used. 
Aside from the scarce evidence on referral criteria there is little experimental evidence on 
the diagnostic work-up in secondary health care for children with poor growth. Although 
there are a number of consensus guidelines on the diagnosis of GHD,26-30 and some 
articles on the analysis of short stature in general,31-38 these articles are primarily expert-
based reviews on how to deal with short stature rather than experimental studies about 
the outcome of laboratory investigations. One study evaluated the outcome of the analysis 
of short stature in a growth clinic, but did not use a standard protocol for the diagnostic 
work-up.39 The only guideline reported so far which addresses the diagnostic work-up 
for short stature in general is the Dutch Consensus Guideline (see paragraph on growth 
monitoring in the Netherlands).23 But again, this guideline is based on consensus rather 
than on experimental evidence. 
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Growth monitoring in the Netherlands
To promote early diagnosis and treatment of aberrant growth and to prevent unnecessary 
referral and interventions, a consensus meeting was held on “Diagnosis of short stature 
in childhood” in 1996 by general practitioners, well-baby clinic doctors, school doctors, 
paediatricians and paediatric endocrinologists.40 Consensus was achieved on referral and 
diagnostic work-up of children with short stature. This Dutch consensus guideline (DCG) 
was then published in a Dutch medical journal and a book.23,40
In the analysis of short stature the DCG addresses five stages. First of all it focuses on 
seven auxological referral criteria (table 2 and appendix for further explanation).  When 
a child is referred according to these criteria, the pediatrician is subsequently advised to 
follow four diagnostic steps: 
•	 	The patient’s history, the physical examination, growth data and a hand radiograph 
should be collected to determine signs or symptoms that may indicate a specific 
disease. 
•	 	In the presence of specific clinical clues, appropriate further specific investigations 
are done. When there are no signs or symptoms leading to the suspicion of a 
certain disease, a list of laboratory investigations is advised for screening of several 
pathological conditions (table 3).  
•	 	Dependent on the abnormalities in the screening laboratory investigations further, more 
specific tests can be performed to establish the final diagnosis. 
•	 	If there is no indication of a certain disease after the preceding procedures the three 
following tests should still be considered: chromosomal analysis for Turner syndrome 
in girls, a biopsy to prove or rule out celiac disease and the determination of zinc to 
investigate zinc deficiency in children with failure to thrive.41
However, it is not known how many doctors are aware of the guideline and whether or not 
it changed medical practice, as the implementation was limited to a single publication in a 
medical journal, a book and a couple of postgraduate courses.23,40 Moreover the guideline 
is based on consensus and lacks experimental evidence. Van Buuren et al showed that if 
the guideline would be followed, an unacceptable percentage of healthy children would be 
referred,24 and specific information on the sensitivity is not available.
Table 2. Seven auxological referral criteria taken from the Dutch Consensus Guidelines.23
Description rule Criteria Rule nr.
Absolute height HSDS* < -2.5 1
Clinical symptoms HSDS* < -1.3 AND (dysmorphic features OR 
disproportions)
2
Persistent short stature after born SGA** SGA** AND  HSDS* < -1.88 after the age of 2 years 3
HSDScor
† ?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
HSDS* < -1.3 AND HSDS-THSDS < -1.3 4
Pubertal agen:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
HSDS* < -1.3 AND HSDS-THSDS§ < -1.3
With pubertal signs 
5
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Deflection‡ ?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
T2 – T1 > 1(1)
(SDS1 – SDS2)/(T2-T1) < -0.25
6a
T2 – T1 > 1
(SDS1 – SDS2)< -1
6b
Pubertal agen:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
T2 – T1 > 1(1)
(SDS1 – SDS2)/(T2-T1) < -0.25
With pubertal signs
7a
T2 – T1 > 1
(SDS1 – SDS2)< -1
With pubertal signs
7b
*  HSDS= Height Standard Deviation Score (Height – mean height for the same age and 
sex / SD for the same age and sex (see appendix)).
**  SGA = Small for Gestational Age
§  THSDS= Target Height Standard Deviation Score ( Target height = (height of mother 
(+height of father +13) + 4.5) / 2 (see appendix))
†  HSDScor= HSDS corrected for parental height (see appendix)
‡  Deflection:  Deflection is either expressed as an SDS decrease (SDS1-SDS2) per year 
(T1-T2) (7a), or as a cumulative deflection over an unspecified time interval (7b).  In 
the categories 3-10 and 10-18, T1 >= 3 years, in the other categories T1> 0. (see 
appendix)
n  Pubertal age: When a child does not show any pubertal signs (?: genital stage  >= 
Tanner stage 2 OR testis volume >= 4 ml; /:  breast>= Tanner stage 2 ) at this age 
referral is not necessary.
 
Table 3. Laboratory investigations in the diagnostic work up according the DCG
Laboratory investigations  In order to diagnose Category
Blood   
Hb, Ht, Leukocytes, Cellindices, Leukocyte 
differentiation, ESR (Ferritin) 
Anemia / infections (and celiac disease and 
cystic fibrosis)
I
ALAT, ASAT, y GT Liver diseases II
Albumin, Creatinine, Sodium, Potassium, 
Calcium, Phosphate, Alkaline phosphatase, 
acid-base equilibrium
Renal diseases III
IgA-anti endomysium, IgA- antigliadin, 
Anti-tissue glutaminase*, Total IgA
Celiac disease IV
TSH, FT4 Hypothyroidism V
IGF-I Growth hormone deficiency VI
FSH** Turner’s syndrome VII
Urine   
pH, glucose, protein, blood and 
sedimentation
Renal diseases VIII
*  At the moment the consensus meeting took place, anti tissue glutaminase as a 
diagnostic tool for celiac disease was not yet introduced nation wide.
**  Only in girls.
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Aim of this thesis
The aim of this thesis is to collect evidence and create new guidelines for the assessment 
of short stature in children, including both referral criteria and diagnostic procedures. 
Outline this thesis
In this first chapter we have explored the definition of impaired growth in the literature, 
given an overview of the history of growth monitoring, explained the importance of 
auxological screening and diagnostic work up in the assessment of short stature and set 
out some general principles of these two processes.
In the remainder of the thesis we have gathered the evidence needed for a new guideline 
for the assessment of short stature in children.
Part A reviews the importance of testing for two growth related diseases (Celiac Disease 
or Cystic Fibrosis) in the routine diagnostic work up for short stature. Starting off from 
these diseases the literature is searched for evidence for the  disease to be taken into 
account in the screening of short stature. In chapter two we study the prevalence of 
celiac disease in children with short stature and no gastrointestinal symptoms and in 
chapter 3 the prior-probability of CF in infants and children with short stature and/or 
poor weight gain. 
In Part B the current practice of growth monitoring and diagnostic work-up of short 
stature in practice are described. Chapter 4 describes the results of an inquiry among 
pediatric endocrinologists in Europe and most industrialized countries around the world 
about the referral criteria advised for growth monitoring in primary care, and about 
diagnostic procedures for short stature in secondary care. Chapter 5  aims at getting 
more information on the current policy of growth monitoring, the definition of failure to 
thrive and the use of guidelines (especially the DCG) among well-baby-clinic doctors and 
school doctors (doctors of Primary Health Care 0-19 years) and general practioners in the 
Netherlands.
Part C is concerned with an evaluation of existing guidelines. Chapter 6  is an evaluation 
of the referral pattern of short stature in primary health care using the Dutch Consensus 
guidelines and the consensus guidelines from the UK, comparing it with cut-off values 
mentioned in the WHO Global Database on Child growth and Malnutrition.42 Chapter 7 
contains the results of a study in two hospitals, in which we investigated how many children 
were correctly referred to secondary health care according to existing consensus guidelines; 
evaluated the diagnostic work-up in secondary health care; and assessed the frequency 
of underlying medical disorders. As the Dutch Consensus Guideline (DCG) is the only 
guideline addressing referral criteria as well as diagnostic work-up, the analyses are based 
on its seven auxological referral criteria to determine whether children are correctly referred 
or not and on all elements of the diagnostic work up.
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Part D contains biometrical studies to determine cut-off points of auxological criteria to 
be used in the decision whether growth-retarded children should be referred for further 
investigations. First, insight is gained into the diagnostic performance of a broad set of 
referral criteria for auxological screening for Turner syndrome in the open population in 
chapter 8. Thereafter optimal auxological referral criteria for detecting celiac disease are 
determined in chapter 9. Thirdly, the diagnostic efficiency of several auxological criteria 
(including both weight and length) for the detection of children with cystic fibrosis are 
explored in chapter 10. 
Part E consist of chapter 11 and describes the radiographic evaluation in literature of 
children with growth problems.
New evidence-based guidelines for growth monitoring on a population basis are presented 
in Part F (chapter 12).
Finally, we discuss in chapter 13  the evidence collected for the algorithm for  referral 
of children with short stature and the collected evidence for the diagnostic work up. 
We also make recommendations for the diagnostic work up after referral, discuss the 
implementation process of the new guideline in the Netherlands, and offer some proposals 
for future research.
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Clinical scenario
An 8-year old girl is referred to the paediatrician because of her stunted growth. Her 
height SDS is –2.3 (≈0.4%ile), her weight for height ratio is + 0.9 SDS (≈75%ile). At the 
age of 3 years, her height SDS was + 0.3 (just over 50%ile). Her weight for height ratio 
had not changed considerably. At the age of four to five years, she had several episodes 
of constipation and anaemia. There were no other complaints. A diagnostic work-up 
was performed: IgA anti-endomysium (IgA EmA) antibodies were positive. A small 
intestinal biopsy (gold standard) showed total villous atrophy, consistent with coeliac 
disease. During follow-up, she fulfilled the ESPGAN criteria for coeliac disease (finding 
of characteristic small bowel mucosa abnormalities in a small bowel biopsy, and a clinical 
remission when placed on a gluten free diet).
Structured clinical question
What is the prevalence of coeliac disease [outcome] in children with short stature and no 
gastrointestinal symptoms [patients]? 
Search strategy and outcome
Pubmed – (body height AND (short OR little OR small OR abnormal) OR short stature 
OR dwarfism) OR failure to thrive AND coeliac disease (limited by: Ages: All child 0-18 
year, Language: English) – 120 references of which 11 relevant and of sufficient quality 
(see table).
Embase – same search strategy – no additional relevant references
Cochrane database – same search strategy – none relevant
The way study groups were selected varied. Articles with the least selective study groups 
are reported higher in the table than studies with a more selective study group.
Citation, 
country
Study group Study Type 
(Level of 
evidence)
Outcome Key Results Comments
Knudtzon J, 
et al (1991), 
Norway1
168 children  
(50 girls; 93 boys; 
age 0.5 – 17.2 
years) with short 
stature without 
significant 
abdominal 
symptoms.
Prospective 
cohort study 
(level 2b)
Proportion 
of coeliac 
disease in 
the study 
group
2.9% (5/168) 
of the children 
with short stature 
were diagnosed 
as having coeliac 
disease.
‘Short stature’ was not defined.
Results are not internally 
consistent.
Diagnosis was not based on 
ESPGAN-criteria.
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Stenhammer 
L, et al. 
(1986), 
Sweden2
87 children (32 
girls, 55 boys; age 
1.0-16.5 years) 
with short stature 
(height more 
than 2SD below 
the mean for age 
and sex) and no 
gastrointestinal 
symptoms, signs of 
systemic disease or 
malabsorption
Prospective 
cohort-study 
(level 1b)
Proportion 
of coeliac 
disease in 
the study 
group
5% (4/87) children 
with short stature 
were diagnosed 
as having coeliac 
disease.
There is an 
overrepresentation 
of coeliac disease 
among short 
children admitted 
to hospital for 
examination.
Diagnosis was made based on 
ESPGAN-criteria
Gold standard was applied to 
all children.
Results are not fully 
described.
Cacciari E, 
et al. (1985), 
Italy3
108 patients (30 
girls, 78 boys; age 
2.8 – 16.7 years) 
with short stature 
(height below third 
centile) and no 
gastrointestinal 
symptoms
Prospective 
cohort study 
(level 1b/2b)
Proportion 
of coeliac 
disease in 
study group
8.3% (9/108) 
patients with 
short stature 
were diagnosed 
as having coeliac 
disease.
Gold standard was applied to 
all patients. 
Diagnosis of coeliac disease 
was not according to 
ESPGAN-criteria.
Possible overlap in patients in 
the two studies of Cacciari?
Cacciari E, 
et al. (1983), 
Italy4
60 children (21 
girls, 39 boys) 
with short stature 
(height below third 
centile) and no 
gastrointestinal 
symptoms
Prospective 
cohort study 
(level 1b/2b)
Proportion 
of coeliac 
disease in 
study group
8.3% (5/60) 
patients with 
short stature 
were diagnosed 
as having coeliac 
disease.
Gold standard applied to all 
patients.
Diagnosis of coeliac disease 
was not according to 
ESPGAN-criteria.
Rossi TM, et 
al. (1993), 
USA5
117 children 
(age: 2 – 17 
years) with height 
more than 2SD 
below the mean 
for age. Of these 
children, 57 were 
diagnosed with 
GH-deficiency. 
All children 
were clinically 
and chemically 
euthyroid.
Prospective 
cohort study 
(level 2b)
Proportion 
of coeliac 
disease in 
a group of 
children 
with short 
stature
1.7% (2/117) of 
children with short 
stature had biopsy 
proven coeliac 
disease.
There is an 
association 
between idiopathic 
short stature and 
coeliac disease.
Basic data are not 
adequately described (no sex 
differentiation)
Gold standard was not applied 
to all patients.
Diagnosis of coeliac disease 
was not according to 
ESPGAN-criteria
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Bonamico M, 
et al. (1992), 
Italy7
49 children (27 
girls, 22 boys; 
mean age 112 
months (SD: 39)) 
with short stature 
(height below the 
third centile) and 
no gastrointestinal 
symptoms. None 
of the 49 patients 
showed somatic, 
cardiac, renal 
or chromosomal 
disorders
Prospective 
cohort study 
(level 1b)
Proportion 
of coeliac 
disease in 
the study 
group
59.1% (29/49) 
children with 
short stature 
were diagnosed 
as having coeliac 
disease.
Gold standard was applied to 
all patients.
Diagnosis of coeliac disease 
was made according to 
ESPGAN-criteria.
Groll A, et 
al. (1980), 
United 
Kingdom8
34 children (16 
girls, 18 boys; age 
2.5 – 17.0 years) 
with short stature 
(more than 2SD 
below the mean 
for age) and no 
gastrointestinal 
symptoms. 
There were no 
dysmorphic 
features, and 
endocrine 
investigations were 
normal.
Prospective 
cohort study 
(level 1b/2b)
Proportion 
of coeliac 
disease in 
the study 
group
21% (8/34) 
children with 
short stature 
were diagnosed 
as having coeliac 
disease 
Diagnosis was not according to 
ESPGAN-criteria.
Rosenbach 
Y, et al. 
(1986), 
Israel9
23 children (12 
girls, 11 boys; age 
6-16 years) below 
third centile for 
age and a bone age 
delay of at least 
25%. Extensive 
preliminary work 
up (including 
hypothalamic, 
pituitary, adrenal, 
and gonadal 
functions, 
sweat test, stool 
examination for 
ova and parasites) 
was found to be 
negative.
Prospective 
cohort study 
(level 2b)
Proportion 
of coeliac 
disease in 
the study 
group
48.7% (11/23) 
of the patients 
with short stature 
were diagnosed 
as having coeliac 
disease.
Gold standard was applied to 
all patients.
Diagnosis was not according to 
the ESPGAN-criteria.
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Lecea A de, 
et al. (1996), 
Spain10
118 children (49 
girls, 69 boys; age 
11 months to 14 
years), with height 
less than third 
centile for age. 
Preliminary work 
up (absorption, 
hormonal and 
genetic studies, 
sweat test, X-ray 
for bone age, serum 
IgA AGA) was 
performed.
Prospective 
cohort study
(level 2b)
Proportion 
of coeliac 
disease in 
the study 
group
18.6% (22/118) of 
children with short 
stature had biopsy 
proven coeliac 
disease.
Results were not presented. 
Numbers do not add up 
properly.
Gold standard was not applied 
to all children.
Diagnosis was not according to 
ESPGAN-criteria.
Basic data were not 
adequately described.
Altuntas B, 
et al. (1998), 
Turkey11
47 patients (18 
girls, 29 boys; age 
4-16 years) of short 
stature (below 
third centile for 
height) without 
gastrointestinal 
tract symptoms or 
endocrinologic, 
cardiac, renal 
or chromosomal 
disorders. There 
were no symptoms 
associated with 
coeliac disease or 
signs of cow’s milk 
allergy.
Cross-
sectional 
study
(level 1b/2b)
Proportion 
of coeliac 
disease in 
the study 
group
55.3% (26/ 47) of 
the short children 
had biopsy proven 
coeliac disease
All children were biopsied.
Results are not presented 
clearly; the reader cannot 
make his own conclusions.
Diagnosis of coeliac disease 
was not according to 
ESPGAN-criteria.
Tumer L. et 
al (2001), 
Turkey12
84 children (46 
girls, 38 boys; age 
16 months – 14 
years) with height 
less than third 
centile for age; 
preliminary work-
up to evaluate 
other causes of 
short stature 
was found to be 
negative. 
Prospective 
cohort study 
(level 2b)
Proportion 
of coeliac 
disease in 
the study 
group
Proportion of 
coeliac disease was 
found to be 8.3% 
(7/84).
There is an 
association between 
coeliac disease and 
idiopathic short 
stature. 
The IgA EmA test was not 
verified by a gold standard test 
(biopsy) in all patients.
Diagnosis of coeliac disease 
was not according to 
ESPGAN-criteria
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Commentary
Growth retardation in childhood may be one of the earliest signs of an underlying disease, 
such as coeliac disease. In the Netherlands, the growth of nearly every child is monitored. 
When growth is retarded, the child is referred to secondary health care. After referral it 
has been advised to perform a diagnostic work-up containing routine laboratory tests to 
search for diagnostic clues for, among others, coeliac disease. The tests presently used for 
coeliac disease are IgA EmA and IgA antitissue transglutaminase antibodies. The total 
immunoglobulin A count is determined as well, because coeliac disease is associated with 
IgA deficiency. It was questioned if diagnostic investigations for coeliac disease should be 
performed in all children with short stature, even without gastro-intestinal complaints.
Studies 1-5 were based on study groups, in which no preliminary (endocrine) work-up 
to exclude other causes for short stature had been performed. The proportion of coeliac 
disease in children with short stature and no gastrointestinal symptoms in these studies 
ranged from 1.7% to 8.3%. When a group of children was studied, in which endocrine 
causes for short stature had been excluded6-11, the proportion of coeliac disease increased 
to a range of 18.6% to 59.1%. The characteristics of the preliminary work-up used in 
study 12 were not described. 
The wide range of these percentages is probably mainly caused by the different methods of 
selecting the patients. The true variation in prevalences of coeliac disease throughout the 
world appears to be limited13.
Screening on coeliac disease in the general population shows a prevalence of 1:300 
to 1:100. About 50% of these children are completely symptomless13. In two British 
population-based studies on short stature14,15, where coeliac disease was not specifically 
investigated, the prevalence of coeliac disease was 2:180 (one patient was already 
known with coeliac disease) and 0:149 respectively. In children with short stature and no 
gastrointestinal symptoms investigated for coeliac disease, the prevalence increases to 
2-8%. When other (endocrine) causes for short stature are excluded, the prevalence might 
rise to even 59%.
Clinical bottom line
•	 	In 2% to 8% of the children with short stature and no gastrointestinal symptoms, 
coeliac disease may be the underlying cause.
•	 	Excluding other causes for short stature increases the risk of having coeliac disease by 
19% to 59%.
• Children with short stature should be evaluated for coeliac disease.
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Clinical scenario
A boy of one and a half years old is referred to the paediatrician because of failure to 
thrive. At this clinic visit his length is –0.55 SDS (≈ 30% tile) and weight  –2.3 SDS (≈1% 
tile). His target height is 194 cm (1.37 SDS ≈ 90% tile). He was born at a gestational age 
of 40 weeks with a length standard deviation score (SDS) of 0.33 SDS (≈ 60% tile) and 
a weight SDS of  –0.12 SDS (≈ 45% tile). There were no problems during pregnancy or 
labor. After growing well during the first 3 months he started to fall behind in weight and 
length increase. There is no report of repeated pulmonary infections or severe gastro-
intestinal problems. The family history is uninformative for hereditary diseases. The 
paediatrician considers to include a sweat test into the diagnostic workup. He knows that 
the sensitivity and specificity of this test are high, but for an accurate interpretation of the 
predictive value he would need the baseline risk of cystic fibrosis in children with failure 
to thrive.
Structured clinical question
What is the prior-probability of CF [outcome] in infants and children with short stature 
and/or poor weight (Failure to thrive FTT (SDS <-1.5; <-2.0; <-2.5)) [patients]?
Search strategy and outcome
Pubmed - “Cystic Fibrosis AND (body height OR failure to thrive OR short stature OR 
dwarfism)”. Only articles were included if they contained data on either length or weight 
before treatment and more than just birth weight and length; 226 references of which 11 
relevant and of sufficient quality. 
Embase – Same search strategy; 211 references of which 1 new, relevant and of sufficient 
quality. 
Cochrane database - Same search strategy; no additional relevant articles.
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Table 1: Studies evaluating either length or weight at the diagnosis of CF patients
Citation Patient group Study type 
(level of 
evidence)
Outcome Key results Estimated 
percentages 
of low length 
or weight† in 
patient group 
(%)
Comments*
Screened CF population
Giglio et 
al (1997), 
Italy1
n=103 between ‘82-’92, in 
North-East-Italy 
median age: 1.07 months 
(0.60 to 4.53)
Retrospective 
cohort study 
(2a-b)
Proportion of 
children poor 
weight-gain at 
diagnosis
68.9% 
of study 
population 
grew less than 
15 g/day 
21.7
Waters et 
al (1999), 
Australia2
n=60 between July ‘81 
and July ‘84 in New South 
Wales Newborn Screening 
Programme median age 
(range) screened: 1.80 
months (0.10 to 81.0)
Retrospective 
cohort study 
(2b)
Average length 
at diagnosis:
-0.2 SDS 9.9 Method of 
diagnosis not 
reported
Average weight 
at diagnosis:
-0.1 SDS 6.9
Farrell et 
al (2001), 
USA3
n=56 between 15/4/85 
and 30/6/94 median age 
(range): Screened: 1.63 
months (0.93 to 65.57)
Randomized 
controlled trial 
(2a)
Average length 
at diagnosis:
Z-score -0.21 10.1
Average weight 
at diagnosis:
Z-score -0.5 12.1
Bronstein et 
al (1992), 
USA4
n=29 between July ‘84 and 
June ‘89 in Colorado
median age (range): 1.40 
months
Prospective 
cohort study 
(2b)
Average length 
at diagnosis:
Z-score -0.69 17.5 Only children 
whose 
weight was 
appropriate 
for gestational 
age at birth
Average weight 
at diagnosis:
Z-score -0.69 15.3
Abman et 
al (1985), 
USA5
n=27 between 1982 and 
1984, in Colorado
mean age (range): 1.28 
months (0.70 to 1.87)
Prospective 
cohort study 
(2b)
Proportion of 
children with 
poor weight
Average 
of study 
population 
on 32nd 
percentile
9.2
Greer et 
al (1991), 
Australia6
n=20 between Nov ‘85 and 
July ‘89 in Queensland 
median age (range): 1.26 
months
Prospective 
cohort study 
(2b)
Average length 
at diagnosis:
Z-score -0.52 
 
14.5
Average weight 
at diagnosis:
Z-score -0.82 17.8
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Non-screened CF population
Lai et al 
(1998), 
USA7
n=790 newly diagnosed 
CF patients in 1993 as 
reported to the 1993 
National CF Patient 
Registry median age: 6 
months
Retrospective 
cohort study 
(2a-b)
Proportion of 
children with 
short stature:
34.4 % 
of study 
population 
below 5th 
percentile 
25.5
Proportion of 
children with 
poor weight
35.9 % 
of study 
population 
below 5th 
percentile
26.2
Haeusler et 
al (1994), 
Austria8
n=103 between 1955-
1989,  97% of CF-
population in Paediatric 
Department of University 
of Vienna mean age 
(range): 17.5 months (0 
to 144)
Retrospective 
cohort study 
(2a-b)
Average length 
at diagnosis:
Z-score -1.10 26.0
Average weight 
at diagnosis:
Z-score -1.52 35.4
Reisman et 
al (1989), 
Canada9
n=81 between ‘75- and 
‘86 at Hospital for Sick 
Children (Ontario) mean 
age (range): 1 month (0 
to 7)
Prospective 
cohort study 
(2b)
Proportion of 
children with 
short stature:
56% of study 
population 
below 3rd 
percentile 
52.7
Proportion of 
children with 
poor weight
48% of study 
population 
below 3rd 
percentile
44.3
Kreamer et 
al (2000), 
Switzerland 
10
n=80 
mean age (range): 4.6 
months (0.1 to 12.7)
Prospective 
cohort study 
(2a-b)
Average length 
at diagnosis:
-1.49 SDS 35.8 Method of 
diagnosis not 
reportedAverage weight 
at diagnosis:
-1.55 SDS 36.3
Waters et 
al (1999), 
Australia2
n=57 between ‘78-’81.
median age (range) : 5.7 
months (0.1-51.5) 
Retrospective 
cohort study 
(2b)
Average length 
at diagnosis:
-1.2 SDS 28.4 Method of 
diagnosis not 
reportedAverage weight 
at diagnosis:
-1.2 SDS 26.6
Farrell et 
al (2001), 
USA3
n=48 between 15/4/85 and 
30/6/94 
median age (range): 6.53 
months (0.7 – 86.8)
Randomized 
controlled trail 
(2a)
Average length 
at diagnosis:
Z-score -1.0 23.8
Average weight 
at diagnosis:
Z-score -1.0 21.7
Ranganathan 
et al (2004), 
UK11
n=37 between Jan ‘99 and 
May ‘01
median age (range): 6.63 
months (3.9 to 10.0)
Prospective 
cohort study 
(2a-b)
Average length 
at diagnosis:
Z-score -0.73 18.2
Average weight 
at diagnosis:
Z-score -1.78 43.2
†  length for age < -2 SDS or weight for age < -2 SDS. For each study we estimated the 
percentage of infants or children with a length or weight below -2 SDS. This was 
done in several steps (see appendix II). First, the Standard deviations scores (SDS) 
for mean length and weight at diagnosis were either directly derived from the data or 
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by converting percentiles into SD-scores. Second, a weighted average SD for length 
and weight in newly diagnosed CF patients was calculated from data given in the 
articles2, 3, 11. This led to an SD for length of 1.41 and for weight of 1.28. Thus, the 
distribution is wider than in the general population. Third, for each study the mean 
SD-scores for length and weight were subtracted from the chosen cut-off point for low 
weight and short stature (in this case -2) and divided by the weighted average SD. This 
gave the SDS for length or weight in that patient sample that concurred with -2 SDS 
in the general population. Fourth, this sample-specific SDS value was converted into 
percentiles and the percentages of children with a low length or weight was calculated. 
Table 2: Prior-probabilities of CF in infants and children with failure to thrive (with 
different cut-off points for weight and length). 
Weight Length
< -1.5 SDS < -2.0 SDS < -2.5 SDS < -1.5 SDS < -2.0 SDS < -2.5 SDS
Prior probability of CF  
(non-screened) (%)▲
0.21 0.42 0.91 0.20 0.40 0.90
Prior probability of CF 
(screened) (%)▲
0.12 0.20 0.38 0.10 0.17 0.32
▲  Prior-probabilities of CF in infants and children with failure to thrive were recalculated using a 
‘two-by-two table’ (see appendix II) based on the assumption that the average incidence of CF is 
1:3000 in the Caucasian population.12 A weighted average from the estimated percentages of low 
length or weight in table 1 was used as percentage of children with FTT in a CF-population. The 
percentage of low length or weight in a normal population was directly calculated from the SDS 
used as cut-off. The recalculation was done for several cut-offs for FTT (we used –1.5, -2 and 
–2.5 SDS as cut-offs). 
Commentary
The term failure to thrive is mostly used to describe growth impairment, but a clear 
definition is lacking; there is no consensus on the choice of anthropometric indicators 
or their criteria for abnormality.13 The term implies that growth parameters (length and/
or weight) decrease over time, i.e. cross the centiles of SD lines on a growth diagram. 
The best objective expression of failure to thrive would therefore be an index of change of 
length or weight over time. In our literature search we did not encounter studies which had 
analysed longitudinal growth in CF patients. We therefore had to use a proxy parameter for 
failure to thrive, i.e. a low length or weight for age. 
Failure to thrive can be the first sign of malnutrition, but also the first symptom of a 
congenital disease like CF. This is the most common life shortening hereditary disease in 
the Caucasian population, with a prevalence of 1:3000.12, 14, 15 In other ethnic groups the 
prevalence varies considerably. Patients with CF are known to have gastro-intestinal and 
pulmonary problems besides failure to thrive, but some patients with CF only present with 
failure to thrive.1, 11, 16, 17, 18, 19
Early diagnosis of CF improves the patient condition and probably increases survival, 
so that several countries have initiated a newborn screening (NBS) program for CF.20, 21 
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In countries where such screening program has not been implemented, CF is detected 
on clinical grounds. Besides respiratory and gastrointestinal symptoms and signs, failure 
to thrive is one of the key clinical cues, but there are no data available indicating at 
which cut-off point of which growth parameter the physician should consider a specific 
diagnostic test for CF. 
The standard test for the diagnosis of CF is the sweat test. By collecting at least 50 mg 
of sweat with pilocarpine iontophoresis the chloride concentration can be chemically 
determinated.22 We wondered what the prior-probablity is of CF in children with failure to 
thrive, so that a rational decision could be made as to perform a sweat test. 
Only one study was found on the prior-probability of CF in infants and children with 
short stature. Oliveira et al. reported in this Brazilian article on a group of children with 
monosymptomatic short stature (height SDS below -1.9 or a growth rate less than 5 cm 
per year) a prior-probability of 7.8 % and concluded that CF besides celiac disease must 
be included in the differential diagnosis of short stature.17 We then decided to search 
for scientific reports on length and weight in groups of patients with CF (see table 1). 
These studies were divided into two groups; screened and non-screened. The screened 
study-population was up to two months old when diagnosed, whereas the non-screened 
population were on average older than 6 months. Most children had respiratory and 
gastro-intestinal problems, but some presented themselves with failure to thrive as main 
complaint. 
The prior-probability of CF in children with a low length or weight for age derived 
from the studies on children with CF is low (<1%) (see table 2). This contrasts with the 
observations of Oliviera et al, who showed a considerably higher proportion (7.8%). 
The difference may be explained by differences in auxological criteria (growth rate versus 
weight and length for age) and in populations (a group of children with monosymptomatic 
FTT, referred to a specialised clinic versus a group of children with FTT, disregarding 
other symptoms, taken from a general population). 
Given the low prior probability of CF in infants with a low length or weight for age, the 
sweat-test will only provide a reliable result if the positive likelihood ratio (and therefore 
the sensitivity and specificity) of the test would be very high. This is apparently not the 
case, as there is a widely variable practice of, and standards in sweat testing resulting in 
inconsistent test accuracies.23, 24 Even under the assumption that the test is performed 
under the best conditions with a sensitivity of 98% and a specificity of 98%, the 
probability of having CF for a child with a positive sweat test, who was not screened for CF 
and has a length or weight < -2.5 SDS, would still be less than 35%. 
We therefore conclude that in an infant with a low length or weight for age the prior 
probability of CF is less than 1%, so that we can assume that in an asymptomatic infant 
the probability will be (much) lower. This would argue against performing a sweat test. 
Parameters of poor longitudinal growth may be more predictive, but this has not been 
studied so far. If clinical symptoms or signs suggestive for CF are found in combination 
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with growth faltering, the prior probability is expected to be higher, so that obviously 
further diagnostic steps are warranted.
Clinical bottom line
•	 	The underlying cause of a low length or weight for age in an infant or a child with no 
other symptoms can be CF. (Grade A)
•	 	The prior-probability of CF in infants or children with a low weight or length for age is 
0.20-0.91 percent (depending on the cut-off point). (Grade B)
Acknowledgements
The study is part of a larger project to establish evidence-based guidelines on referral 
criteria for growth monitoring and diagnostic work-up for children with short stature. 
This project was supported by an educational grant from Pfizer.
Competing interests: none declared.
 
Grote_opm_H1_H8_v4.indd   37 22-01-2007   14:03:48
3
Chapter 3
References
1.  Giglio L, Candusso M, D’Orazio C, Mastella G, Faraguna D. Failure to thrive: the earli-
est feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr 
1997;86(11):1162-5.
2.  Waters DL, Wilcken B, Irwing L, Van Asperen P, Mellis C, Simpson JM et al. Clinical out-
comes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80(1):
F1-F7.
3.  Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC et al. Early diagnosis of 
cystic fibrosis through neonatal screening prevents severe malnutrition and improves 
long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 
2001;107(1):1-13.
4.  Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambidge KM et al. 
Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as 
having cystic fibrosis. J Pediatr 1992;120(4 Pt 1):533-40.
5.  Abman SH, Reardon MC, Accurso FJ, Hammond KB, Sokol RJ. Hypoalbuminemia at di-
agnosis as a marker for severe respiratory course in infants with cystic fibrosis identified by 
newborn screening. J Pediatr 1985;107(6):933-5.
6.  Greer R, Shepherd R, Cleghorn G, Bowling FG, Holt T. Evaluation of growth and changes in 
body composition following neonatal diagnosis of cystic fibrosis. J Pediatr Gastroenterol Nutr 
1991;13(1):52-8.
7.  Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG et al. Growth status 
in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: 
evaluation of various criteria used to identify malnutrition. J Pediatr 1998;132(3 Pt 1):478-85.
8.  Haeusler G, Frisch H, Waldhor T, Gotz M. Perspectives of longitudinal growth in cystic fibro-
sis from birth to adult age. Eur J Pediatr 1994;153(3):158-63.
9.  Reisman J, Petrou C, Corey M, Stringer D, Durie P, Levison H. Hypoalbuminemia at initial 
examination in patients with cystic fibrosis. J Pediatr 1989;115(5 Pt 1):755-8.
10.  Kraemer R, Aebi C, Casaulta AC, Gallati S. Early detection of lung disease and its associa-
tion with the nutritional status, genetic background and life events in patients with cystic 
fibrosis. Respiration 2000;67(5):477-90.
11.  Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S et al. The evolution of airway 
function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit 
Care Med 2004;169(8):928-33.
12.  Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of 
CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 
2002;19(6):575-606.
13.  Wilcox WD, Nieburg P, Miller DS. Failure to thrive. A continuing problem of definition. Clin 
Pediatr (Phila) 1989;28(9):391-4.
14.  Sarles J, Barthellemy S, Ferec C, Iovanna J, Roussey M, Farriaux JP et al. Blood concentra-
tions of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic 
fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80(2):F118-F122.
15.  Wilson DC, Pencharz PB. Nutrition and cystic fibrosis. Nutrition 1998;14(10):792-5.
16.  Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respi-
ratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 
1995;310(6994):1571-2.
17.  Oliveira MC, Reis FJ, Chagas AJ, Brasileiro FG, Bahia M, Silva LD et al. [Study of intes-
tinal malabsorption diseases as cause of monosymptomatic short stature]. J Pediatr (Rio J ) 
1998;74(3):213-6.
18.  Tepper RS, Hiatt P, Eigen H, Scott P, Grosfeld J, Cohen M. Infants with cystic fibrosis: pulmo-
nary function at diagnosis. Pediatr Pulmonol 1988;5(1):15-8.
Grote_opm_H1_H8_v4.indd   38 22-01-2007   14:03:48
3
The probability of Cystic Fibrosis in infants and children with poor growth
19.  Wesley AW, Horne AM, Elliott RB. Problems in diagnosis of cystic fibrosis. N Z Med J 
1984;97(767):773-5.
20.  Dankert-Roelse JE, Merelle ME. Review of outcomes of neonatal screening for cystic fibrosis 
versus non-screening in Europe. J Pediatr 2005;147(3 Suppl):S15-S20.
21.  Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG et al. Evidence on improved 
outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! 
J Pediatr 2005;147(3 Suppl):S30-S36.
22.  Denning CR, Huang NN, Cuasay LR, Shwachman H, Tocci P, Warwick WJ et al. Cooperative 
study comparing three methods of performing sweat tests to diagnose cystic fibrosis. Pediat-
rics 1980;66(5):752-7.
23.  Baumer JH. Evidence based guidelines for the performance of the sweat test for the investiga-
tion of cystic fibrosis in the UK. Arch Dis Child 2003;88(12):1126-7.
24.  Leigh MW. Diagnosis of CF despite normal or borderline sweat chloride. Paediatr Respir Rev 
2004;5 Suppl A:S357-S359.
Grote_opm_H1_H8_v4.indd   39 22-01-2007   14:03:49
Grote_opm_H1_H8_v4.indd   40 22-01-2007   14:03:49
Part B
Current methods of growth monitoring and 
diagnostic work-up of short stature
Grote_opm_H1_H8_v4.indd   41 22-01-2007   14:03:54
Grote_opm_H1_H8_v4.indd   42 22-01-2007   14:03:54
Growth monitoring and diagnostic work-up of 
short stature: an international inventorisation.
F.K. Grote1, W. Oostdijk1, S.M.P. F. de Muinck Keizer-Schrama2, F.W. Dekker3, P.H. Verkerk4, J.M. Wit1
1 Dept of Pediatrics, Leiden University Medical Center,  Leiden, The Netherlands
2 Dept of Pediatrics, Erasmus University Medical Centre / Sophia Children’s Hospital, Rotterdam, The Netherlands
3 Dept of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands 
4 TNO Prevention and Health, Leiden, The Netherlands
J Pediatr Endocrinol Metab 2005;18:1031-8.
Chapter 4
Grote_opm_H1_H8_v4.indd   43 22-01-2007   14:03:58
44
Chapter 4
Summary
Background/ Aims: Growth monitoring is almost universally performed, but little data 
is available on which referral criteria and diagnostic work-up are used worldwide for 
children with short stature.
Methods: A short questionnaire, containing questions on auxological screening and 
on diagnostic criteria for short stature was sent to all members of the European Society 
of Paediatric Endocrinology (ESPE) and to several pediatric endocrinologists outside 
Europe.
Results: A response was received from 36 countries. In 27 (75 %) a child health care 
program existed and in 14 (39%) there was a protocol for referral of growth-retarded 
children. Height for age was mostly used as a referral criterion. Sixteen countries (45%) 
reported having a guideline in secondary health care for the diagnostic work-up. Although 
all countries agreed on having biochemical, radiological and/or genetic tests in the 
diagnostic work-up, there was a wide variety in recommended tests. 
Conclusions: There is little consensus on referral criteria and diagnostic work-up of 
children with short stature among industrialized countries. There is a need to establish 
evidence-based guidelines.
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Introduction
Short stature or growth retardation is considered a relatively early sign of poor health in 
children. Growth monitoring is therefore widely accepted, although no reliable evidence 
was found to support this activity.1
Short stature has many causes and the purposes and objectives of growth monitoring 
programs are therefore different, depending on its setting. In developing countries the 
principle aim of growth monitoring is to detect malnutrition. Given this aim the WHO 
promotes growth monitoring and research to improve the monitoring itself.2,3
In industrialized countries, where there is less malnutrition, growth monitoring is aimed 
at detecting other causes of growth retardation, of which Turner syndrome and Growth 
Hormone deficiency are most prevalent. Because early diagnosis and treatment of 
children with growth disorders favorably influences outcome, there is a need for correct 
referral criteria and diagnostic work-up for children with short stature. However, only few 
guidelines have been published,4,5 and these are based on consensus meetings rather than 
on experimental evidence. Only recently, we reported on the predictive value of various 
auxological criteria for detecting Turner syndrome.6
One of those guidelines4 concentrates on the referral of children with short stature 
after a single height measurement at school entrance (at age 5) only and does not offer 
information on the diagnostic work-up afterwards. According to the Dutch consensus 
guideline5 seven referral criteria should be used, but we recently reported that strictly 
adhering to this guideline would lead to too many referrals.7 In this guideline also the 
diagnostic work-up is described, including biochemical and radiological tests.
In view of the possible discrepancy between the widespread practices of growth monitoring 
and the scarcity of experimental or observational data, we started a project to establish 
new, and more evidence-based guidelines on referral criteria for growth monitoring and 
diagnostic work-up for children with short stature. As part of this effort, we performed 
an inquiry among pediatric endocrinologists in Europe and most industrialized countries 
around the world about the referral criteria advised for growth monitoring in primary care, 
and about diagnostic procedures for short stature in secondary care. 
Material and methods
In the Spring of 2002 a short questionnaire was sent to all members of the European 
Society of Paediatric Endocrinology (ESPE) and to several pediatric endocrinologists 
in the USA, Canada, Brazil, Japan, Australia and New Zealand. The total number of 
countries approached was 45. If a first reminder was unsuccessful, we tried to increase the 
response rate by directly asking individuals from the missing countries to be instrumental 
in collecting the information. 
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The questionnaire contained questions on auxological screening in child health programs 
and on diagnostic criteria for short stature in specialist centers, including biochemical 
and radiological tests. If any formal guidelines/protocols for auxological screening or 
diagnostic procedures in children with short stature were used the respondents were 
requested to send copies with their reply.
For the questions on the diagnostic procedures in specialist centers, we used the Dutch 
consensus guideline as baseline. According to this guideline, short children without 
any suspicion of a particular diagnosis after the auxological diagnostic work-up, should 
undergo the laboratory investigations shown in table 1. The guideline also includes that 
if in a short girl no explanation for her shortness is found, chromosomal analysis for 
excluding Turner syndrome should be performed.
After data collection, the answers were checked with the copies of the existing protocols/ 
guidelines. From each country only one returned survey was selected for further analysis. 
The selected survey either corresponded most with the existing protocols or with responses 
from other pediatric endocrinologists from the same country. 
All data were entered into Access 2000 and analyzed both in Access and SPSS 11.
Table 1. Routine laboratory investigations for short stature according to the Dutch 
consensus
Laboratory investigations  In order to diagnose 
Blood
Hb, Ht, leukocytes, celindices, leukocyte differentiation, 
erythrocyte sedimentation rate (ESR), (ferritin)
Anemia, Infections, Celiac disease, Cystic fibrosis
ALAT, ASAT, γ GT Liver diseases
albumin, creatinine, sodium, potassium, calcium, 
phosphate, alkaline phosphate, acid-base equilibrium
Renal diseases
IgA-anti endomysium, IgA- antigliadin, anti-tissue 
glutaminase*, total IgA
Celiac disease
TSH, FT4 Hypothyroidism
FSH** Turner’s syndrome
insulin-like-growth factor (IGF-I) Growth hormone deficiency
Urine
pH, glucose, protein, blood and sedimentation Renal diseases
*  At the moment the consensus meeting took place, anti tissue glutaminase was not yet 
nation wide introduced as a diagnostic tool for celiac disease.
**  Only in girls <2 years of age and >9 years of age.
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Table 2. References of growth charts used in the responding 36 countries 
Reference of growth chart n = 36 (100%)
National/ Local 18 (50)
NCHS 4   (11)
Other 2   (6)
Unknown 2   (6)
Tanner 1   (2.5)
Prader 1   (2.5)
No use of growth chart reported 8  (22)
Results
The availability of programs and protocols on growth monitoring and  
diagnostic work-up
Responses were received from 36 countries. Figure 1 shows the availability of programs 
on growth monitoring and protocols for referral and diagnostic work-up of children with 
short stature. In 5 (14%) countries no organized growth monitoring appeared to take place. 
In 27 countries (75%) a child health care program was present and 14 countries (39%) 
reported having a primary health care protocol for referral of children with short stature. 
From 16 countries (45%) guidelines for diagnostic procedures in children with short 
stature in secondary health care were reported. Not all of these programs or protocols were 
nationally implemented. 
Response 36
5A
31
No Yes
No
Yes
4 27*
No Yes YesNo
Protocol for referral 3 1** 14 13**
YesYesYesYes No No
Guideline for 
diagnostic work-up
3*** 1*** 10B 4*** 5 8***/C
Health care program
Availability of growth monitoring
Fig. 1. The availability of programs and protocols on growth monitoring in the responding 
36 countries.
* Countries with child health care program (total = 27 (75%))
**  Countries with protocol for referral of children with short stature (total = 14 (39%))
***  Countries with guideline for diagnostic work up of children with short stature (total = 
16 (45%))
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A. Countries without any organized growth monitoring (total = 5 (14%))
B. Countries with only a child health care program (total = 10 (28%))
C.  Countries with both a child health program and protocols for referral and guidelines for 
the diagnostic work up (total = 8 (22%)) 
Charts used throughout the world
On the question if growth charts are used for the growth monitoring/ screening, 28 
countries (78 %) responded affirmative. Most of the other countries did not respond to this 
question because of a lack of a growth monitoring/ screening program. In 18 countries (50 
%) national reference charts were used, in others British,8 Swiss9 or other international 
reference charts.10-12
Auxological referral criteria
Height for age, either expressed as centile position or as standard deviation score, was 
mostly used as a referral criterion by countries with referral-protocols for children with 
short stature, followed by the deviation of height either expressed as height velocity 
or delta height SDS. The distance to target height appeared to be used less frequently 
(table 3). Clinicians from countries without auxological screening criteria also considered 
the deviation of height more important than the distance to target height. A wide variety 
of cut-off points were described for the different criteria. For height for age cut-off limits 
were reported but varied from –3 SDS (~ P0.2) to –1.28 SDS (~ P10). For deviation of 
height however different methods were reported like changing canals or percentiles, cm 
per year, deviation of SDS (-2 to -0.25 SDS) or even percentages of deviation. The cut-off 
for the distance to target height was either expressed in cm (7-8) or in SDS (-2 SDS) and 
the target height itself or the lower limit of the target range was taken as reference point.
Table 3. The use and/or consideration of auxological criteria for the referral of a child with 
short stature.
Auxological criterion Countries with protocol
n=14 (100%)
Countries without protocol
n=22 (100%)
Height for age 14 (100) 19 (86)
Deviation of height 7 (50) 10 (46)
Distance to target height 6 (43) 5 (23)
Weight 3 (21) 6 (27)
Delta weight 2 (14) 3 (14)
Laboratory investigations in the diagnostic work-up of short stature
Sixteen countries (46%) reported having guidelines in secondary health care for the 
diagnostic work-up of children with short stature. In all these countries biochemical tests 
were used in the diagnostic work-up. Out of the 27 proposed biochemical investigations, 
6 were considered useful in 25-50% of all countries, 14 in 50-75% and 7 in 75-100% 
(fig 2). Clinicians of countries without existing guidelines reported a similar pattern in the 
laboratory investigations in the diagnostic work-up for short stature as given in figure 2. 
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The reported use of the various tests was about 10% less than in the countries with 
existing guidelines.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hb
Ht
celindices
leucocytes
leucocyt differentiate
ESR
ferritin
ALAT
ASAT
gamma GT
alkalin phosphate
albumin
creatinine
sodium
potassium
calcium
phosphate
acid-base equilibrium
IgA-anti endomysium
IgA-antigliadin
antiglutaminase
total IgA
TSH
FT4
IGF1
IGFBP3
FSH *
Fig 2. The routine use of various biochemical tests in the diagnostic work-up for short 
stature in countries with a guideline. (*Only in girls <2 years of age and >9 years of age).
Chromosomal analysis, genetic tests and bone age determination in the diagnostic 
work-up of a child with short stature. 
Genetic and/or chromosomal investigations are widely (100%) proposed in the diagnostic 
work-up of short stature in countries with a guideline. From 50% of the countries it was 
reported that chromosomal analysis should always be part of the diagnostic work-up in 
girls. From 35% of the countries tests for the short stature homeobox-containing gene 
(SHOX) and/or uniparental disomy (UPD) were reported (table 4). It was also generally 
accepted (100%) that determining bone age should be part of the diagnostic work-
up (table 4). The method of Greulich and Pyle was reported most, either alone (in 19 
countries (53%)) or in combination with the method of Tanner and Whitehouse (in 11 
countries (31%)). Clinicians of countries without existing guidelines reported a similar 
pattern in the diagnostic work-up for short stature (table 4).
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Table 4. The use and/or consideration of chromosomal, genetic tests and determination 
of bone age in the diagnostic work up of a child with short stature in countries with a 
guideline for diagnostic work up. 
countries with guideline
n=16 (100%)
Chromosomal and/or genetic tests
General use 16 (100)
Chromosomal analyses in girls 8 (50)
SHOX/UPD 6 (38)
Determination of bonage
General use 16 (100)
Greulich and Pyle (GP) 14 (88)
Tanner and Whitehouse (TW) 8 (50)
GP & TW 6 (38)
Discussion
We conducted an international survey to investigate referral criteria in primary care 
growth monitoring and the diagnostic procedures for short stature in secondary care used 
throughout the world. A child health care system was available in 75% of the responding 
countries. In 39% of the countries protocols for the referral of children with short stature 
existed and in 45% guidelines for a diagnostic work-up. In general height for age was 
considered as the most important referral criterion followed by height velocity and 
distance to target height. Although all countries reported on the inclusion of biochemical, 
radiological and/or genetic tests in the diagnostic work-up, there were substantial 
differences between countries with respect to the tests of choice. 
In developing countries, growth monitoring is widely accepted as a screening tool for 
detecting malnutrition, and strongly supported by health professionals. There, weight for 
age is the usual parameter, and only in 41% of the countries length and height for age (H/
A) is used for growth monitoring.13 In industrialized countries growth monitoring may be 
conducted less frequently, the preferred parameter is H/A, the purpose is to detect other 
causes of growth failure than malnutrition alone, and the anticipated outcomes are less 
severe.14 In fact, in 14% of the countries participating in our study no organized growth 
monitoring took place. In these countries growth monitoring may occur in specialized 
settings in a selected sample of the population. 
With respect to the reference charts used, in our study 50 % of the countries based their 
charts on national/ local reference populations. This percentage is comparable to the data 
for Europe collected by Onis et al., 13 but considerably higher than the 17 % found in 
the same study for 202 countries all over the world. Outside of Europe the NCHS/WHO 
reference population is frequently used. 
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The choice of the principal referral criterion may differ in function of the principal 
aim of growth monitoring. In our survey, height for age was generally considered the 
most important referral criterion in our study. The deviation of height, either expressed 
as height velocity or delta HSDS was considered the second most important criterion, 
followed by the distance to target height. In the UK guidelines, target height is not taken 
into account at all, because it is felt that parental height is unreliable.4 In contrast to this 
opinion, we have recently shown that the best decision rule to detect children with Turner 
syndrome, one of the major causes of short stature, is the distance between height SDS 
and target height.6
Although there is agreement on using biochemical, radiological and genetic tests in the 
diagnostic work-up for short children, our study shows that there is no full consensus on 
the tests to be used among specialists. Apart from the Dutch consensus guideline there is 
no literature on the general diagnostic work-up for short stature in secondary health care, 
although specific guidelines on the diagnosis of growth hormone deficiency in childhood 
and adolescence have been published.15,16 However, these guidelines cover only part of 
the diagnostic work-up, since they start from the assumption that other causes of short 
stature have been excluded earlier. 
With respect to radiological investigations, we only collected information about bone 
age determination, which are apparently universally used. We assume that in case 
of disproportionate shortness, clinicians usually perform additional radiological and 
genetic investigations as part of a multidisciplinary approach for the diagnosis of skeletal 
dysplasias,17 but we have not investigated this. An increasing number of genetic causes 
of short stature are being found and several genetic tests are available in the diagnosis 
of short stature nowadays.18 However, according to our survey, genetic analysis for UPD 
or SHOX is only considered in 30-39% of the cases. Meanwhile treatment with growth 
hormone in children with SHOX seems to be effective and therefore early diagnosis is of 
great importance.19 In 50% of the countries routinely screening for Turner syndrome in 
short girls has been recommended. 
Even though the results presented in this paper are derived from the responses of a 
relatively small group of pediatric endocrinologists to questionnaires, and thus potentially 
biased, we believe that they give a good impression of the diversity in the growth 
monitoring process and the diagnostic work-up of growth disorders in industrialized 
countries. This is not astonishing, because little experimental data has been published on 
these topics. We believe that more studies are needed on the diagnostic value and cost-
effectiveness of auxological screening for the diagnosis of various diseases, similarly to 
the recent report on Turner syndrome.6 Secondly, we believe that the prevalence of the 
disorders known to cause short stature has to be established in short children without any 
abnormal symptoms or signs. This prevalence, in combination with the severity of the 
disorder and possibilities for treatment, should be taken into account for the decision to 
use certain diagnostic tests in the work-up. For example, in a recent study we showed that 
the prevalence of celiac disease is considerable in asymptomatic short children, so that all 
children with short stature should be evaluated for celiac disease.20 Thirdly, data should 
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be collected about the diagnostic performance of the various biochemical, radiological and 
genetic tests, so that evidence-based guidelines can be constructed with an acceptable 
cost-benefit ratio.
We conclude that there is little consensus on referral criteria and diagnostic work-up of 
children with short stature among industrialized countries and that there is a need for 
more research to establish evidence-based guidelines on the screening and diagnosis of 
growth disorders. 
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Samenvatting
Inleiding: In 1996 werd de CBO-richtlijn “Diagnostiek kleine lichaamslengte bij 
kinderen” opgesteld, maar het is onbekend in hoeverre deze richtlijn bekend is en wordt 
toegepast binnen de huisartsenpraktijk en Jeugdgezondheidszorg (JGZ). Het doel van 
deze studie was om middels enquetes hierover informatie verzamelen en tevens over de 
meningen over de waarde van de verschillende verwijscriteria en over de definitie “failure 
to thrive”. 
Methode: In 2002 werden enquêtes verstuurd aan 365 huisartsen uit de regio Zuid-
Holland Noord en 460 artsen JGZ uit geheel Nederland. 
Resultaten:  Door 207 huisartsen (57%) en 152 artsen JGZ (33%) werden bruikbare 
enquêtes geretourneerd. In de huisartsenpraktijk was de CBO-richtlijn (CBO-R) 
weinig bekend (16%) en werd zelden gebruikt. De meeste artsen JGZ (82%) kenden 
de CBO-R en 46% gaven aan deze te gebruiken. 49% van de artsen JGZ meende 
dat de verwijscriteria, met name afbuigende groei, tot teveel verwijzingen leiden. Zij 
vonden klinische symptomen (disproportie en dysmorfie) en extreem kleine lengte de 
belangrijkste verwijscriteria. “Failure to thrive” werd meestal gedefinieerd als afbuigend 
gewicht-naar-lengte.
Conclusie: De CBO-R is vrijwel onbekend bij huisartsen, maar wordt door circa 50% van 
de artsen JGZ gebruikt, ondanks dat velen menen dat strikte toepassing van de richtlijn 
zou leiden tot teveel verwijzingen. Inmiddels is een nieuwe evidence-based richtlijn 
opgesteld, waarmee een hoog percentage pathologie kan worden opgespoord bij een 
percentage verwijzingen van ongeveer 1%.  
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Inleiding
Het periodiek meten van lengte en gewicht van kinderen , in de Engelstalige literatuur 
aangeduid met de term “growth monitoring”, wordt sinds lange tijd wereldwijd 
uitgevoerd. Desondanks zijn er maar weinig gegevens beschikbaar over de effectiviteit1 
In tegenstelling tot ontwikkelingslanden, waar signalering van ondervoeding het primaire 
doel is van groei-monitoring, is in de westerse wereld het opsporen van onderliggende 
pathologie, zoals het syndroom van Turner, groeihormoondeficiëntie en coeliakie, een 
belangrijk doel. Voor optimale behandeling van deze en andere groeigerelateerde 
aandoeningen is het van belang dat de diagnose zo vroeg mogelijk wordt gesteld.2,3
Voor vroege opsporing van groeistoornissen zijn er naast een goed groei-monitoring 
systeem duidelijke verwijscriteria voor afwijkende groei en goede protocollen voor verdere 
diagnostiek nodig. In de literatuur worden slechts enkele richtlijnen vermeld. 3,4 Deze zijn 
gebaseerd op consensus en maken gebruik van verschillende criteria voor verwijzing met 
verschillende afkappunten voor afwijkende lengtegroei. 5-7  Bij jonge kinderen wordt 
vaak de term “failure to thrive” gebruikt om een afwijkende groei bij jonge kinderen aan 
te geven, maar hiervan bestaat geen eenduidige definitie: zowel gewicht naar leeftijd, 
gewicht naar lengte en lengte naar leeftijd worden gebruikt om “failure to thrive” te 
objectiveren.8,9
Om vroegtijdige opsporing van een afwijkende lengtegroei te bevorderen en onnodige 
verwijzingen te voorkómen vond in 1996 in Nederland de consensusbijeenkomst 
‘Diagnostiek kleine lichaamslengte bij kinderen’ plaats, waarin een multidisciplinaire 
richtlijn werd vastgesteld. Consensus werd bereikt over de diagnostiek en verwijzing van 
met name kinderen ouder dan 3 jaar met kleine lichaamslengte. Aangezien er, behoudens 
het verschijnen van  deze CBO-richtlijn (CBO-R) in boekvorm, een publicatie in het 
Nederlands Tijdschrift voor Geneeskunde (NTVG) en meerdere nascholingscursussen, 
weinig publiciteit is gegeven aan de resultaten van de consensus-bijeenkomst, is het 
onbekend in hoeverre de CBO-R gebruikt wordt en hoe de huidige praktijk van groei-
monitoring is.4,10 Daarnaast concludeerden Van Buuren et al. spoedig na het verschijnen 
van de CBO-richtlijn dat de verwijscriteria , indien strikt toegepast, in de praktijk teveel 
verwijzingen geven, met name door het verwijscriterium afbuigende groei.11
Om deze redenen werd er een project gestart om de CBO-R te evalueren en uiteindelijk 
met een nieuwe evidence-based richtlijn te komen. In dit artikel beschrijven wij de 
resultaten van een inventarisatie onder huisartsen en artsen Jeugdgezondheidszorg 
(JGZ 0-19 jaar) over de huidige praktijk met betrekking tot groei-monitoring, in het 
bijzonder de mening over de huidige CBO-R en diverse verwijscriteria. Tevens werd 
geinventariseerd welke definitie van “failure to thrive” werd gehanteerd. Op basis van 
deze inventarisatie en aanvullend onderzoek naar de effectiviteit van verschillende 
verwijscriteria, is inmiddels een nieuwe richtlijn opgesteld die kort wordt besproken.
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Materiaal en methode
Begin December 2002 werden vragenlijsten gestuurd aan 365 huisartsen in de regio 
Zuid-Holland Noord, een regio met zowel plattelands als stedelijke gemeenten, waarin 
artsen qua geslacht en leeftijdsverdeling overeen komen met alle ingeschreven huisartsen 
uit geheel Nederland.12 Aansluitend werd voorafgaande aan het symposium “te klein, te 
lang, te dun, te dik” op 12 december 2002 bij TNO Preventie en Gezondheid in Leiden 
enquêtes verstuurd aan de verschillende Thuiszorgorganisaties (kinderen 0-4 jaar) en 
GGD’en (kinderen 4-19 jaar), bestemd voor in totaal 460 artsen JGZ verspreid over geheel 
Nederland. 
De enquête bestond uit  4 onderdelen. In het eerste onderdeel werden algemene gegevens 
van de artsen verzameld met betrekking tot het aantal jaren werkervaring, de functie, 
het geslacht en de leeftijd. In het tweede onderdeel werd gevraagd naar presentatie, 
diagnostiek en verwijzing van kinderen met kleine lengte in de praktijk. In het derde 
onderdeel werd gevraagd naar richtlijnen voor kleine lichaamslengte (m.n. CBO-
consensus ‘Diagnostiek kleine lichaamslengte bij kinderen’). De artsen JGZ werden 
daarbij extra naar hun mening gevraagd over de 8 verschillende verwijscriteria van de 
CBO-consensus (tabel 1) 4,10 
Tabel 1 Verwijscriteria volgens de CBO-richtlijn “Diagnostiek kleine lichaamslengte bij kinderen” uit 1996. 10
Omschrijving regel Criteria Regel  nr.
Extreem kleine lengte lengte SDS* < -2,5 1.
Klinische symptomen lengte SDS < -1,3 en (dysmorfie of disproportie) 2.
Intra-uteriene groeivertraging zonder 
inhaalgroei 
IUGR en lengte SDS < -1,88 na de leeftijd van 
2 jaar
3.
Lengte beneden de 
target range†
?: < 10 jr en  > 13,4 jr; 
/: < 9 jr en  > 12,3 jr 
Lengte SDS < -1,3 en Lengte SDS-THSDS‡ < -1,3 4.
?: 10 – 13,4 jr; 
/: 9 – 12,3 jr
Lengte SDS < -1,3 en Lengte SDS-THSDS < -1,3 
en puberteitskenmerken n
5.
Afbuiging ?: < 10 jr en  > 13,4 jr; 
/: < 9 jr en  > 12,3 jr 
Delta lengte SDS<-0,25 per jaar of delta lengte 
SDS <-1SDS over een langere periode
6.
?: 10 – 13,4 jr; 
/: 9 – 12,3 jr
Delta lengte SDS<-0,25 per jaar of delta 
lengte SDS <-1 over een langere periode en 
puberteitskenmerken n
7.
Psychogene kleine gestalte Emotionele deprivatie 8.
*  Lengte SDS (lengte standaarddeviatiescore) = [lengte (in cm) – gemiddelde lengte voor leeftijd en geslacht]/
SD voor leeftijd en geslacht
‡  TH-SDS: TH (Target height) zoon/dochter (in cm) = [(vaderlengte + moederlengte +/- 13)/2] + 4,5) TH-SDS 
zoon/dochter = (TH – P50 volwassen man/vrouw)/SD volwassen man/vrouw)
†  Target range = TH ±1,3 SD (ofwel ongeveer 9 cm boven of onder de TH)
IUGR= Intrauteriene Groei Retardatie
n  Puberteitskenmerken: ?: Pubesbeharing >= Tannerstadium 2 of Testisvolume >= 4 ml; /: borstontwikkeling 
>= Tannerstadium 2.
Grote_opm_H1_H8_v4.indd   58 22-01-2007   14:04:09
5
Signalering van groeistoornissen binnen de Huisartsgeneeskunde en Jeugdgezondheidszorg
In het vierde onderdeel van de enquête werd ingegaan op de definitie van failure to thrive 
bij kinderen jonger dan 3 jaar. Voor de definitie van failure to thrive kon uit de volgende 
4 criteria worden gekozen (combinaties waren ook mogelijk): afbuigende lengte naar 
leeftijd, afbuigend gewicht naar lengte, afbuigend gewicht naar leeftijd en vertraagde 
psychomotore ontwikkeling. Eveneens werd gevraagd naar het beleid bij “failure to 
thrive” in de praktijk. 
De enquêtes werden geanalyseerd met behulp van SPSS (11.0). De frequenties van 
vergelijkbare vragen in de enquêtes van de artsen JGZ en huisartsen werden getoetst op 
statistische significantie p < 0,05 (chi kwadraat toets).
Resultaten
Respons
In totaal hebben 216 van de 365 aangeschreven huisartsen de vragenlijst geretourneerd. 
Door 9 niet-praktiserende huisartsen werd de vragenlijst leeg teruggestuurd (2%). Er 
bleven 207 bruikbare vragenlijsten over voor analyse (57%). Daarnaast werd de enquête 
door 152 van de 460 artsen JGZ ingevuld en teruggestuurd (33%). Algemene gegevens 
van de respondenten zijn weergegeven in tabel 2.
Tabel 2 Algemene gegevens van de huisartsen (n=207) en artsen JGZ (n=152)
Huisartsen Artsen JGZ
n (%)  n (%)
geslacht man 150 (72) 17 (11)
leeftijd <30 jaar  0 (0)  5 (3)
 30-39 jaar  31 (15) 28 (18)
 40-50 jaar  86 (42) 74 (49)
 >50 jaar  89 (43) 45 (30)
aantal jaren werkzaam <5 jaar  22 (11) 21 (14)
 5-9 jaar  24 (12) 17 (11)
 10-20 jaar  72 (35) 64 (42)
 >20 jaar  89 (43) 49 (32)
vakgebied JGZ(0-4jr) 79 (52)
 JGZ(4-19jr) 73 (48)
ander specialisme JGZ(0-19jr)  7 (3)
 Anders*  11 (5)
*  huisartsen werkzaam binnen ander specialisme: arts JGZ, arts voor verstandelijk 
gehandicapten, militair-, offshore-, palliatief-, tropen- of manueel arts, onderzoeker of 
medisch adviseur
Diagnostiek en/of verwijzing van kleine lengte bij kinderen in de praktijk
Vrijwel alle artsen, zowel huisartsen (92%) als artsen JGZ (91%) vermeldden dat 
afbuigende groei een belangrijke reden was om een kind met kleine lengte daadwerkelijk 
door te sturen (tabel 3). Door de  meeste huisartsen werd vervolgens extreem kleine 
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lengte (82%) als belangrijke verwijsreden ervaren, gevolgd door lengte beneden de target 
range (64%). Onder de artsen JGZ daarentegen werd lengte beneden de target range 
(81%) belangrijker ervaren dan extreem kleine lengte (76%). Onrust bij ouders werd door 
huisartsen significant vaker als belangrijke reden voor verwijzing vermeld dan bij artsen 
JGZ (p< 0,01). De artsen JGZ spraken vaker dan huisartsen een extra controle af na een 
periode variërend van 2 weken tot 1 jaar, afhankelijk van de leeftijd van het kind en de 
ernst van de situatie. In vergelijking met de huisartsen gaven artsen JGZ vaker andere 
redenen, zoals disproportie, dysmorfe kenmerken, uitblijvende inhaalgroei na de leeftijd 
van 2 jaar of een afwijkend puberteitsstadium, aan als reden voor verwijzing (p=0,01). 
Bijna een kwart van de huisartsen verwees automatisch door naar de specialist als een 
kind met een groeistoornis verwezen werd door een arts JGZ. De overige huisartsen (76%) 
gaf aan dat zij eerst zelf nader onderzoek wilden doen, door bijvoorbeeld de groeicurve 
op te vragen, de familieanamnese uit te vragen, lichamelijk onderzoek te verrichten, 
laboratoriumonderzoek te doen of een handfoto aan te vragen.
Tabel 3 Belangrijke redenen voor verwijzing volgens huisarten (n=207) en  
artsen JGZ (n=152)*
Huisartsen Artsen JGZ 
n (%) n (%)
Onrust bij de ouders 106 (51) 36 (24)
Extreem kleine lengte 170 (82) 116 (76)
 <P3 (= -1,88 SDS) 51 (25) 26 (17)
 <-2,5 SDS (nieuwe curve) 29 (14) 85 (56)
 Anders† 3 (1) 16 (11)
Afbuigende groei 190 (92) 139 (91)
Lengte beneden target range 133 (64) 124 (82)
Anders† 16 (8) 25 (16)
* meerdere redenen voor verwijzing mogelijk 
† andere redenen voor verwijzing
CBO-richtlijn 
De CBO-R was bekend bij 16% van de huisartsen. Zij waren op de hoogte gesteld via de 
publicatie in het NTvG (8%) en/of via een nascholingscursus (6%) en/of via een collega 
(3%) en/of via de CBO-website (3%). Slechts 5% van de huisartsen had de consensus in 
zijn bezit en 4% gebruikte deze in de praktijk. Het merendeel van de huisartsen maakte 
geen gebruik van de consensus, omdat zij er nog nooit van gehoord hadden (71%). 
Andere redenen waren dat men de consensus niet ter beschikking had of de incidentie 
van kleine lichaamslengte te laag was binnen hun patiëntenpopulatie. Het bestaan van 
goede richtlijnen voor verwijzing van kleine lichaamslengte binnen de huisartsenpraktijk 
werd wel belangrijk gevonden door 83% van de huisartsen. Door 4% werd aangegeven 
dat de verwijzing rechtstreeks vanuit de JGZ naar de specialist moest plaatsvinden en dat 
richtlijnen voor huisartsen niet nodig waren. Ook de grote meerderheid van de artsen JGZ 
vonden duidelijke richtlijnen van groot belang. 
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Bij het overgrote deel van de artsen JGZ (82%) was de CBO-consensus wel bekend. 
Zij waren veelal op de hoogte gesteld via een collega (36%) en/of via de publicatie 
in het NTvG (32%) en/of via een nascholingscursus (24%). 49% van de artsen JGZ 
rapporteerden dat zij de CBO-R in hun bezit hadden en 46% dat deze in de praktijk 
werd gebruikt. Bij 27% van de artsen JGZ bestond binnen de organisatie een protocol 
gebaseerd op de consensus en bij 7% een protocol los van de consensus. De meeste artsen 
JGZ, die geen gebruik van de consensus maakten, werkten volgens een eigen protocol of 
hadden geen beschikking over de consensus. Andere redenen voor geen gebruik van de 
consensus waren, dat men nog nooit van de consensus gehoord had, men het oneens was 
met de inhoud, of dat de consensus veel te uitgebreid of te ingewikkeld was.
Mening van artsen JGZ over verwijscriteria CBO-consensus
De artsen JGZ gaven hun mening over het belang van de 8 verwijscriteria van de 
CBO-R in de besluitvorming (tabel 4). Zij waren van mening dat klinische symptomen 
(disproportie/dysmorfie) (24%), extreem kleine lengte (21%) en prepubertair afbuigende 
groeicurve (19%) de belangrijkste drie verwijscriteria waren. De toepasbaarheid van de 
verwijscriteria werd als redelijk ervaren door 49% van de artsen JGZ, als moeizaam door 
29% en gemakkelijk door 9%. Ongeveer de helft van de artsen JGZ (49%) gaf aan dat 
strikte toepassing van de verwijscriteria tot teveel verwijzingen zou leiden, 28% dat tot het 
juiste aantal verwijzingen zou leiden en 4% tot te weinig verwijzingen. 
Tabel 4 Belang dat artsen JGZ (n=152) aan de verwijscriteria CBO-consensus hechten 
Belangrijkste 
verwijscriterium (%)
Extreem kleine lengte 21
Dysmorfe kenmerken en/of disproportie 24
IUGR zonder inhaalgroei 7
Lengte beneden target range prepubertair 9
Lengte beneden target range postpubertair 1
Afbuigende groeicurve prepubertair 19
Afbuigende groeicurve postpubertair 3
Psychogene kleine gestalte 1
“Failure to thrive”
De criteria afbuigend gewicht naar lengte en afbuigende lengte naar leeftijd werden 
het meest gebruikt door de huisartsen en de artsen JGZ voor de definitie van “failure 
to thrive” (tabel 5). Door 71% van de huisartsen en door 43% van de artsen JGZ werd 
aangegeven dat er behoefte was aan specifieke richtlijnen voor de verwijzing van kinderen 
met “failure to thrive”. 
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Tabel 5 Definitie van “failure to thrive” volgens huisartsen (n=207) en artsen JGZ 
(n=152)* 
Huisartsen Artsen JGZ
n (%) n (%)
Afbuigende lengte naar leeftijd 88 (43) 72 (47)
Afbuigend gewicht naar lengte 95 (46) 72 (47)
Afbuigend gewicht naar leeftijd 67 (32) 30 (20)
Vertraagde psychomotorische ontwikkeling 53 (26) 30 (20)
* meerdere criteria konden worden aangegeven
Beschouwing
Voor een vroege opsporing van groeistoornissen is het van belang dat er naast een goed 
groei-monitoring systeem duidelijke verwijscriteria voor afwijkende groei en goede 
protocollen voor verdere diagnostiek bestaan. Uit enquêtes aan huisartsen en artsen JGZ 
naar het huidige beleid van groeimonitoring blijkt dat de CBO-richtlijn “Diagnostiek 
kleine lichaamslengte bij kinderen”  bij weinig huisartsen bekend is en nog minder wordt 
toegepast. Binnen de jeugdgezondheidszorg is de CBO-R in het algemeen wel bekend (bij 
82%) en wordt door circa 50% van de artsen JGZ gebruikt. Met name afbuigende groei leidt 
in de praktijk tot daadwerkelijke verwijzing, gevolgd door extreem kleine lengte en lengte 
beneden de target range. De meeste artsen JGZ zijn van mening dat de belangrijkste criteria 
van de CBO-R klinische symptomen, extreem kleine lengte en prepubertair afbuigende 
groeicurve zijn. Als definitie van “failure to thrive” worden door zowel huisartsen als JGZ 
artsen voornamelijk de criteria afbuigende lengte naar leeftijd en afbuigend gewicht naar 
lengte gehanteerd. Beide groepen artsen vinden het bestaan van goede evidence-based 
richtlijnen van belang voor zowel kleine lichaamslengte als “failure to thrive”.
De helft van de artsen JGZ was van mening dat de verwijscriteria van de CBO-R, indien 
strikt toegepast, in de praktijk tot teveel verwijzingen leiden.  Dit is in overeenstemming 
met bevindingen van Van Buuren et al.11 Met name onder de leeftijd van 3 jaar zouden 
er veel te veel kinderen verwezen moeten worden (Hoofdstuk 6). Dit is waarschijnlijk te 
wijten aan het feit dat de lengte van kinderen tot de leeftijd van 2-3 jaar migreert in de 
richting van het genetisch bepaalde groeikanaal, waarin het kind uiteindelijk gewoonlijk 
zal blijven groeien (kanalisatie). Dit groeikanaal wordt beïnvloed door de geslachts-
gecorrigeerde gemiddelde lengte van de ouders, die kan worden uitgedrukt als “target 
height”.13 Zowel huisartsen als artsen JGZ noemen een vertraagde groei van lengte of 
gewicht bij jonge kinderen vaak “failure to thrive”. 
Het aantal verschillende definities voor “failure to thrive” (gewicht-naar-leeftijd, gewicht- 
naar-lengte en lengte-naar-leeftijd) die in de enquete werden ingevuld reflecteert het 
gebrek aan overeenstemming welke groeiparameter het best gebruikt kan worden.14 Naar 
onze mening dient de term “failure to thrive” te worden beperkt tot een  groeipatroon 
waarbij door ondervoeding of ernstige aangeboren of verworven ziekten in eerste instantie 
de gewichtstoename stagneert, gewoonlijk pas later gevolgd door een afbuigende 
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lengtegroei (zoals bijvoorbeeld bij cystic fibrosis en coeliakie). Voor een vroege signalering 
van “failure to thrive” is dus de gewicht-naar-leeftijd curve het meest belangrijk. 
Uiteraard komt dat ook  in het  verloop van gewicht-naar-lengte tot uitdrukking, maar het 
ontbreken van referentiediagrammen daarvan voor de leeftijd van 0-15 maanden maakt 
deze parameter minder geschikt.
In een recente studie hebben wij laten zien dat de enige bruikbare verwijscriteria met 
betrekking tot de lengtegroei van kinderen onder de 3 jaar een extreem kleine lengte (< 
-3 SDS) of een herhaalde kleine lengte (<-2,5 SDS)zijn, alhoewel hiermee  slechts weinig 
pathologie wordt opspoort (Hoofdstuk 12). Dit kan worden afgelezen in het bijgaande 
flowdiagram, waarin ook alle andere verwijscriteria zijn opgenomen (figuur 1). In onze 
studies over opsporing van coeliakie en cystic fibrosis vonden wij dat gewicht op jonge 
leeftijd een betere parameter is dan lengte (Hoofdstuk 9 en 10). Bij een afbuigend gewicht 
op jonge leeftijd, moet men dus op deze ziekten bedacht zijn. Het verdient aanbeveling 
dat in de toekomst verwijsregels worden opgesteld voor het beloop van het gewicht naar 
leeftijd bij zuigelingen en peuters, analoog aan de “thrive lines” die zijn gerapporteerd 
vanuit het Verenigd Koninkrijk.15,16
 Zowel huisartsen als JGZ artsen geven aan dat  afbuigende groei de belangrijkste 
reden is voor verwijzing en een groot percentage van de artsen JGZ beoordeelt dit als 
het belangrijkste criterium uit de CBO-R.  Toch is het vooral dit verwijscriterium, 
dat tot een groot aantal onterechte verwijzingen leidt.11 Bovendien hebben meerdere 
studies uitgewezen dat groeiafbuiging als zodanig een lage sensitiviteit heeft voor 
het opsporen van pathologische groeiafwijkingen.7,17 Aangezien er toch meerdere 
voorbeelden te noemen zijn van kinderen met een groei-gerelateerde aandoening, zoals 
groeihormoondeficientie t.g.v. hersentumoren, juveniele hypothyroidie en Cushing 
syndroom, die initieel alleen ontdekt worden als men afbuiging in ogenschouw wordt 
genomen, blijft afbuiging een criterium voor de verwijzing van kinderen met vertraagde 
groei. Een afbuiging van meer dan 1 SD over een onbepaalde tijd in combinatie met een 
lengte SDS < -2 is daarbij het meest praktisch en geeft een redelijke sensitiviteit bij een 
acceptabel aantal onterecht verwijzingen. (Hoofdstuk 12)
Uit de enquête komt naar voren dat lengte beneden de target height een belangrijke 
reden is om een kind met kleine lengte daadwerkelijk door te verwijzen. Toch vindt men 
dit niet het belangrijkste criterium in de opsporing van pathologie. Dit is in tegenstelling 
met recent onderzoek waaruit blijkt dat criteria gebaseerd op target height juist effectief 
zijn om pathologie op te sporen,17 (Hoofdstuk 7) ook al zijn ouderlengtes niet altijd 
betrouwbaar.3 Een afstand tot target height van meer dan 2 SD in combinatie met een 
lengte SDS <-2 levert de meeste pathologie op en zorgt bovendien voor een acceptabel 
aantal onterecht verwezen kinderen. (Hoofdstuk 12). 
Naast auxologische regels zijn uiteraard klinische symptomen en informatie uit de 
anamnese, zoals vermeld in de CBO-R, belangrijk voor de opsporing van pathologie bij 
kinderen met een kleine lengte. Zo kan bij een kind met kleine lengte na een te kleine 
geboortelengte voor de zwangerschapsduur (Small for Gestational Age (SGA), vaak ook 
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aangeduid als Intrauterine Growth Retardation (IUGR)) de diagnose “aanhoudende kleine 
lengte na SGA (of IUGR)“ worden gesteld  In tegenstelling tot de CBO-R wordt in de nieuwe 
richtlijn gekozen voor een leeftijd van 3 jaar, waarna de aanhoudende kleine lengte  nog 
aanwezig moet zijn, aangezien er tot deze leeftijd inhaalgroei kan optreden. (Hoofdstuk 
12) Aan emotionele deprivatie moet gedacht worden als er aanwijzingen voor zijn in de 
anamnese.18-20 Aangezien meerdere primaire groeistoornissen (syndromen) gepaard gaan 
met afwijkende lichaamsproporties, is het belangrijk om hierop te letten bij lichamelijk 
onderzoek. Om praktische redenen is gekozen om een lengte SDS<-2  als afkappunt te 
combineren met de klinische symptomen en informatie uit anamnese bij kinderen met 
kleine lengte.
Nieuwe richtlijnen vinden vaak moeizaam hun weg naar de praktijk.21 Of en in welke 
mate een richtlijn wordt toegepast in de praktijk, is afhankelijk van de bekendheid, het 
gepresenteerde bewijs achter het aanbevolen handelen, de complexiteit van het gevraagde 
handelen, de vaardigheden of de veranderingen in de organisatie die ervoor nodig zijn 
en van vormgeving (helderheid, overzichtelijkheid).22 Hierbij kunnen grote verschillen 
optreden tussen beroepsgroepen, zoals bleek in ons onderzoek: de CBO-R,was slechts bij 
een klein deel van de huisartsen bekend, terwijl de artsen JGZ er veel beter mee bekend 
waren. Mogelijke knelpunten bij de implementatie waren, dat de richtlijn slechts in 
geringe mate op wetenschappelijke gegevens (“evidence”) gebaseerd was en dat artsen 
moeite hadden met het toepassen van de verwijscriteria, zoals uit de enquêtes naar voren 
kwam. De richtlijn werd bovendien niet uitgegeven door een eigen wetenschappelijke 
vereniging, zoals het Nederlands Huisartsen Genootschap (NHG). De middelen die 
werden gebruikt om de consensus bekend te maken waren mogelijk niet voldoende om 
het implementeren van een richtlijn tot een succes te maken. Met de nieuwe richtlijn 
die gebaseerd is op evidence en is verwerkt in een handzaam flowdiagram (figuur 1), 
hopen wij een groter publiek te bereiken en streven wij naar een gerichte, intensieve 
systematische aanpak voor implementatie.
Conclusie
Uit enquêtes aan huisartsen en artsen JGZ naar het huidige beleid van groeimonitoring 
blijkt dat de CBO-richtlijn “diagnostiek kleine lichaamslengte bij kinderen” bij weinig 
huisartsen bekend is. Bovendien hebben ervaringen uit de praktijk en onderzoek 
uitgewezen dat de huidige criteria toe zijn aan vernieuwing. In de vernieuwde evidence-
based richtlijn  krijgt de afstand tot target height een prominentere rol, zijn er aangepaste 
afkappunten en worden er andere criteria gehanteerd voor kinderen onder de 3 jaar. 
De richtlijn is samengevat in een handzaam flowdiagram.
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Fig 1. Flowdiagram van de nieuwe evidence based richtlijn voor verwijzing van kinderen 
met kleine lengte. (zie hoofdstuk 12) 
SDS = standaard deviatie score
TSDS = Target Height standaard deviatie score
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Abstract
Introduction: For early identification of children with abnormal growth good growth 
monitoring systems as part of preventive child health programs are needed as well as well-
defined and accurate referral criteria. In the Netherlands, a consensus meeting was held 
in 1996 to establish such referral criteria. This resulted in the Dutch Consensus Guideline 
(DCG). It is unknown to what extent this guideline is known and practiced in preventive 
health care (well-baby-clinic doctors and school doctors) and family practice. The aim of 
this study was to collect information on these elements, as well as on opinions about the 
value of the various referral criteria and about the definition of failure to thrive. 
Method: In 2002 questionnaires were sent to 365 general practioners from the region 
South-Holland North and 460 Primary Health Care physicians from the whole country.
Results: Analysable questionnaires were returned by 207 general practioners (57%) 
and 152 Primary Health Care physicians (33%). Few general practioners (16%) knew 
the DCG and even less used it in their practice. In contrast, most Primary Health Care 
physicians knew the DCG and 46% indicated that they used it. 49% of Primary Health 
Care physicians thought that the referral-criteria, especially height deflection, would lead 
to too many referrals. They thoughtthat clinical signs and symptoms (e.g. disproportion or 
dysmorphic features) and extreme short stature were the most important referral criteria. 
Failure to thrive was mostly defined as deflection of weight to length. 
Conclusion: The DCG is unknown to most general practitioners, but is used by 
approximately 50% of the primary health care physicians, although many of them think 
that strict application of the referral criteria would lead to too many referrals. In the 
meantime a new evidence-based guideline has been prepared, by which a high percentage 
of pathology can be detected at a referral percentage of about 1%.
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Abstract
Background: To promote early diagnosis and treatment of short stature, consensus 
meetings were held in the mid nineteen nineties in the Netherlands and the UK. This 
resulted in guidelines for referral. In this study we evaluate the referral pattern of short 
stature in primary health care using these guidelines, comparing it with cut-off values 
mentioned by the WHO. 
Methods: Three sets of referral rules were tested on the growth data of a random sample 
(n=400) of all children born between 01-01-1985 and 31-12-1988, attending school 
doctors between 1998 and 2000 in Leiden and Alphen aan den Rijn (the Netherlands): 
the screening criteria mentioned in the Dutch Consensus Guideline (DCG), those of the 
UK Consensus Guideline (UKCG) and the cut-off values mentioned in the WHO Global 
Database on Child growth and Malnutrition. 
Results: Application of the DCG would lead to the referral of too many children (almost 
80%). The largest part of the referrals is due to the deflection of height, followed by 
distance to target height and takes primarily place during the first 3 years. The deflection 
away from the parental height also leads to too many referrals. In contrast, the UKCG only 
leads to 0.3% referrals and the WHO-criteria to approximate 10%.
Conclusions: The current Dutch consensus guideline leads to too many referrals, mainly 
due to the deflection of length during the first 3 years of life. The UKCG leads to far less 
referrals, but may be relatively insensitive to detect clinically relevant growth disorders 
like Turner syndrome. New guidelines for growth monitoring are needed, which combine a 
low percentage of false positive results with a good sensitivity.
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Introduction
Monitoring children’s growth and development is fully integrated in preventive health care 
programmes throughout the world. In developing countries growth monitoring, implying 
regular height and weight measurements, is primarily aimed at identifying malnutrition to 
reduce mortality, whereas in industrialised countries it is mainly used to detect disorders 
associated with growth failure. The effect of routine growth monitoring in developing 
countries has recently been questioned.1 Its efficacy and efficiency in developed 
countries has hardly been studied, and a recent international inquiry showed that there is 
considerable variability in growth monitoring practices worldwide.2
The primary aim of growth monitoring in industrialised countries is to detect growth 
disorders at an early age, thus the sensitivity (a statistical measure of how well the test 
correctly identifies a condition) of the screening procedure should be high at a young 
age. Poor growth can be caused by a great diversity of congenital or acquired conditions, 
some of which present with additional symptoms and signs. In other conditions, such 
as Turner syndrome, Growth Hormone Deficiency (GHD) and celiac disease, additional 
clinical features may be absent. Still, in such disorders early diagnosis and treatment is 
important, because early treatment has an optimal effect on growth in childhood, as well 
as on final height, expectedly resulting in a better quality of life. The second aim of growth 
monitoring is to keep the number of healthy children referred for further investigation at a 
minimum, meaning that the specificity should be very high.
 
In order to diminish the uncertainty among health workers in preventive child health 
care about the auxological criteria (auxology is the scientific study of growth) on which 
the decision to refer a child for further diagnosis should be based, and the resulting wide 
variation in the way growth monitoring is carried out, in 1996 a consensus meeting was 
held in the Netherlands on “Diagnosis of short stature in childhood”. At this meeting 
representatives of general practitioners, well-baby clinic doctors, school doctors, 
paediatricians and paediatric endocrinologists came to a consensus guideline on referral 
criteria for aberrant growth.3 Although the authors had aimed at promoting early diagnosis 
of aberrant growth as well as at preventing unnecessary referral and interventions, it 
was shown later that if this guideline would be followed, an unacceptable percentage of 
healthy children would be referred.4 In the United Kingdom a similar consensus meeting 
on diagnosis of short stature was held, resulting in a guideline restricted to aberrant height 
at the age of 5 years, with assumingly a better specificity, but an unknown sensitivity to 
detect disorders timely.5,6
In the present study we wished to 1) study the performance of the Dutch Consensus 
Guideline (DCG) in a second sample with a wider age range; 2) count the actual referrals 
for short stature in that region; and 3) investigate the test characteristics of the UK 
Consensus Guideline (UKCG), WHO guideline and several other referral rules. This study 
was part of a larger program aimed at producing an evidence-based guideline on growth 
monitoring, in which we earlier investigated the best auxological criteria to detect Turner 
syndrome 7 Celiac Disease (van Dommelen et al, submitted), and Cystic Fibrosis (Grote et 
al, submitted).
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Material and methods
We performed a retrospective observational study in primary health care. A random 
sample (n=400) of all children born between 01-01-1985 and 31-12-1988, attending 
school doctors between 1998 and 2000 in Leiden and Alphen aan den Rijn (located in the 
northern part of the province Zuid-Holland, at the western side of the Netherlands) was 
drawn from files of the regional public health organization (every 15th file) . The DCG was 
believed to be well known to the health personnel during the study period. There were no 
exclusion criteria. 
The following baseline data and other observations, collected by the well-baby clinics 
and the school health services, were obtained from the medical records: date of birth; sex; 
height of parents; date and outcome of the different measurements of height and weight of 
the child since birth; presence of dysmorphic features or disproportion; birth weight and 
length, gestational age; and information about referral(s) to a specialist (date and reason).  
If ethnicity was not recorded, it was estimated based on the patient’s first and family name 
according to an algorithm reported earlier.8 If health records were incomplete, a short 
questionnaire was sent to all children in 2004 to obtain additional data on medical history, 
parental height and current height.
Three sets of referral rules were tested on the growth data: the auxological criteria 
mentioned in the DCG,3 those of the UKCG5 and the cut-off values mentioned in the 
WHO Global Database on Child growth and Malnutrition.9 While the UKCG concentrates 
only on one auxological referral criterion (Height < -2.67 SDS (= 0.4th centile) at the age 
of 5 years5), the DCG3 focuses on several referral criteria : Height in standard deviation 
score (SDS), clinical symptoms (indications of psycho-social growth retardation, dysmorfic 
or disproportionate features), Persistent short stature after born SGA (small for gestational 
age), HSDScor (the distance between height SDS and the target height SDS (the estimated 
final height SDS of a boy or a girl on the basis of their genetic potential)) and growth , 
deflection  (a downward movement of height SDS) (table 1) Target height (TH) for a boy 
is [father’s height + (mother’ s height +13)]/ 2+4.5 cm and for a girl: [mother’ s height 
+ (father’s height - 13)]/ 2+4.5 cm wherein 13 cm is the mean difference between final 
height of males and females, and 4.5 cm is the mean secular trend in one generation of 
30 years. Target height can also be expressed as SDS (z-score), by taking the difference 
between TH and the mean final height of a young adult of the same sex, and then devide 
by the SD at that age. By correcting for secular trend the actual population reference 
diagrams can be used for calculating THSDS. 
The WHO Global Database on Child growth and Malnutrition uses a cut-off point of -2 SD 
(≈ 2.3rd centle) to classify stunting (low height for age) and underweight at all ages.9
Because of the instability in growth pattern under the age of three years and the varying 
growth patterns in puberty caused by differences in pubertal timing, we decided to 
evaluate the guidelines in different age groups (0-3, 3-10 and 10-18 years), as well as 
over the whole age range. As it was hypothesized that in the age group 0-3 years a height 
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deflection in standard deviations scores (SDS) away from the target height SDS might be a 
good reason to refer, we decided to test this rule (| HSDSx2 – TH SDS | > | HSDSx1 
– TH SDS |) for both a delta HSDS (HSDSx2-HSDSx1) of -0.5 or -1 with x2 > x1(see table 4).
Table 1. Seven auxological referral criteria taken from the Dutch Consensus Guideline.3
Description rule Criteria Rule nr.
Absolute height HSDS* < -2.5 1
Clinical symptoms HSDS* < -1.3 AND (dysmorphic features OR 
disproportions)
2
Persistent short stature after born SGA** SGA** AND  HSDS* < -1.88 after the age of 2 years 3
HSDScor
†
?: < 10 jr en  > 13,4 jr; 
/: < 9 jr en  > 12,3 jr
HSDS* < -1.3 AND HSDS-THSDS < -1.3 4
Pubertal age n:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
HSDS* < -1.3 AND HSDS-THSDS§ < -1.3 AND 
pubertal signs (?: genit >= Tanner stage 2 OR 
testis volume >= 4 ml; /:  breast>= Tanner stage 
2 )
5
Deflection‡
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
T2 – T1 > 1(1)
(SDS1 – SDS2)/(T2-T1) < -0.25 6a
T2 – T1 > 1
(SDS1 – SDS2)< -1 6b
Pubertal age n:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
T2 – T1 > 1(1)
(SDS1 – SDS2)/(T2-T1) < -0.25
With pubertal signs
7a
T2 – T1 > 1
(SDS1 – SDS2)< -1
With pubertal signs
7b
* HSDS= Height Standard Deviation Score
** SGA = Small for Gestational Age
§ THSDS= Target Height Standard Deviation Score
† HSDScor= HSDS corrected for parental height 
‡  Deflection:  Deflection is divided into a slow deflection (7a) and a quick deflection (7b) 
The slow deflection represents a downward movement  of HSDS (HSDS2-HSDS1) over 
time (T2-T1), while the quick deflection is more a downward movement  of HSDS over 
a longer period (not specified). In the categories 3-10 and 10-18, T1 >= 3 years, in the 
other categories T1> 0.
n  Pubertal age: When a child does not show any pubertal signs (?: genit >= Tanner stage 
2 OR testis volume >= 4 ml; /:  breast>= Tanner stage 2 ) at this age referral is not 
necessary. 
All data were analysed in SPSS version 11 and S-plus version 7.0. Length (up to 2 years), 
height (from 2 years), weight and target height were expressed as standard deviation score 
(SDS), using the Dutch reference growth data for children of Dutch origin, children of 
Turkish origin, and children originating from Morocco, respectively.10-12 HSDS (Height 
SDS) is the distance between the individual’s height and the population’s mean height for 
Grote_opm_H1_H8_v4.indd   75 22-01-2007   14:04:24
76
Chapter 6
age and sex, devided by the standard deviation in the population for the same age and sex: 
[individual’s height - mean population height for the same age and sex]/ population’s SD 
for the same age and sex. 
A SDS can easily be converted to a percentile, using standard statistical tables. For growth 
SD lines are more suitable then percentiles a. o. because of the equidistance between the 
SDS lines. In the Dutch growth charts10 2.5, -2, -1, 0, +1, +2 and + 2.5 lines are drawn, 
corresponding withP 0.6, P 2.3, P 16, P 50, P 84, P 97.7, P 99.4. 
In preterm infants (gestational age < 37 weeks) length and weight SDS were corrected for 
gestational age. The intrauterine growth curve of the Swedish reference population13 was 
used to express SDS till the age corresponding with 40 weeks of gestation. Between 40 and 
42 weeks an interpolation between the growth curve of the Swedish reference population 
and that of the Dutch reference population was used. From 42 weeks of gestation till 
the age of 2 years, SDS was calculated for age corrected for gestation, using the Dutch 
reference growth data.
Parental height was missing in 53% of the children. We imputed these data under the 
assumption that the data were missing at random using Multivariate Imputation by 
Chained Equations (MICE).14 The method created multivariate imputations by applying 
sequential linear regressions, where each incomplete variable was imputed conditionally 
on all variables in an iterative fashion. The imputation model consisted of the height 
SDS, weight SDS, Body-mass-index SDS, age, gender, the height of the other parent, 
ethnicity, yes or no use of medication influencing growth and place of attendance of the 
school doctors. The number of iterations was set to 15. Predictive mean matching was 
used to create parental height imputations. The imputation method includes parameter 
uncertainty, preserves the multivariate structure in the data and has good coverage 
properties.15 
Small for gestational age (SGA) was defined as a birth weight and/ or length SDS< -2, 
comparing the present birth weights and lengths with gestational age-matched reference 
values from Niklasson et al.13
The study was approved by the Medical Ethical Committee of the Leiden University 
Medical Center and the Regional Public Health Service Hollands Midden.
Results
From the initial 400 children, 8 were excluded from the analyses because of incomplete 
growth data (for example no date of measurement). The general characteristics of the 
remaining 392 children are illustrated in table 2.
Tabel 3 shows the percentage of referrals in different age groups, which would have taken 
place if the Dutch consensus guideline (DCG) had been followed. Almost 80% of the sample 
would have been referred at some age between 0-18 years. Most referrals would take place 
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in the first 3 years (73.9%); The first height deflection referral rule (refer if length or height 
SDS changes more than 0.25 SD per year) would lead to most referrals (69%), followed by 
the second referral rule (refer if height SDS decreases by more than 1 SD) leading to another 
unacceptably high number of referrals (34%). Also the referral rule based on distance to 
target height SDS (refer if the child’s height SDS shows a distance of  more than 1.3 SD 
to target height SDS) would lead to a high percentage of referrals (15%).  In the other age 
groups, the deflection rules would also be responsible for the majority of referrals. 
Table 2. General characteristics of the study population
Total population
n = 392
Gender Male: n (%) 199 (50.8)
Ethnicity: n (%)
Dutch/European 334 (85.2)
Turkish 7 (1.8)
Moroccan 7 (1.8)
Others: 44 (11.3)
Dysmorphic features: n (%) 16 (4.1)
Disproportion: n (%) 18 (4.6)
Target height SDS: Mean (SD) 0.18 (0.86)
Number of measurements (median) 10
Table 3. Estimated percentage of  referrals according to the DCG
Description rule Rule nr. % referrals
0-3 years
N=330
% referrals
3-10 year
N=361
% referrals
10-18 year
N=345
% referrals
0-18years
N=392
Absolute height 1 1.8 0.8 1.4 3.3
Clinical symptoms 2 2.4 1.1 0.9 2.3
Persistent short stature after born SGA 3 0.0 0.0 0.0 0.0
HSDScor
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
4 15.2 5.0 4.9 16.8
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
5 na na 2.0 (2.0)* 2.0 (2.0)*
Deflection*
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
6a 69.4 21.6 9.3 73.5
6b 34.2 6.4 15.4 50.5
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
7a n.a. n.a. 3.8  (1.4)* 4.6 (1.3) *
7b n.a. n.a. 22.6 (5.5) * 23.0 (4.8) *
Total percentage of referrals 73.9 26.0 39.1 79.6
*  Data on stage of puberty were frequently missing. Therefore we assumed children with 
missing data were in puberty at the reference pubertal age-period. The number between 
brackets however represents the exact percentage of referrals in the pubertal age-
period, without the assumption.  
† n.a means not applicable
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Table 4 shows the percentage of referrals that had occurred if the UKCG or the WHO 
criteria would have been used. According to the UKCG only one child (0.3%) would have 
been referred, while 9-10% would have been referred according to the WHO. Like the 
DCG the criteria of the WHO are mainly met under the age of three years. 
Tabel 4. Estimated percentage of referrals according to the UKCG, the WHO guideline, 
and a parental height deflection rule 
Description rule Criteria % referrals
0-3 years
% referrals
3-10 years
% referrals
10-18 years
% referrals
0-18years
UKCG HSDS§  < -2.67 at age 5 n.a. 0.3 n.a 0.3
Low height for 
age (HSDS) ‡
HSDS§ < - 2 7.3 3.6 3.2 9.2
Low weight for 
age (WSDS) ‡
WSDS** < -2 10.0 2.5 3.2 10.5
Parental height 
deflection rule 
(0.5 SDS)
(HSDS2§ – HSDS1§) < -0.5, AND
| HSDS2§ – TH SDS† | > | HSDS1§ 
– TH SDS† |
58.8 18.3 28.7 62.0
Parental height 
deflection rule 
(1 SDS)
(HSDS2§ – HSDS1§) < -1, AND
| HSDS2§ – TH SDS† | > | HSDS1 –  
TH SDS† |
30.0 3.9 11.6 41.1
* UKCG = UK consensus guideline
§ HSDS= Height Standard Deviation Score
** WSDS= Weight Standard deviation score
† THSDS= Target Height Standard Deviation Score
‡ Rules described by WHO Global database on Child growth and malnutrition.
Theoretically one could imagine that a deflection away from the target height SDS in 
the first 2-3 years of life could be a suitable referral rule. In this sample, however, these 
adapted deflection rules would lead to high percentages of referrals (table 4).  
With respect to the actual number of referrals, 34 children were subject to extra visits to 
the well-baby clinic because of growth-retardation. Only one child was actually referred to 
a specialised centre for further diagnosis. This child had a deflection of length before the 
age of 1 year and was diagnosed with transient growth retardation due to dyspepsia. 
Discussion
We have confirmed the results of an earlier report in showing that implementing the 
Dutch consensus guideline for growth monitoring would lead to a high number of 
referrals, particularly before the age of 3 years. The actual number of referrals that was 
found in practice was just 1 out of 392 cases, so evidently the proposed guidelines were 
(fortunately) not properly followed. The specificity of the UK Consensus guideline (limited 
to one cut-off criterion, i.e. a height<-2.66 SDS (≈ 0.4th centile) at 5 years of age) would 
be better. On the other hand  in an earlier paper we showed that the sensitivity of a height 
SDS cut-off to detect Turner syndrome is lower than that of a cut-off of the distance to 
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target height.7 The WHO guideline, as well as two additional criteria with respect to 
height deflection away from the target height, would lead to too many referrals. 
To estimate the percentage of pathological conditions presenting with short stature and/or 
growth failure without further clinical symptoms or signs, one can refer to several studies. 
In the Wessex growth study 180 children (1.25 %) in whom height on screening at school 
entry was on or below the 3rd percentile, were further examined.16 Among this group 8 
children (4.4%) were newly identified as having an organic disease. Ahmed et al reported 
in the Oxford study 7 newly recognized children (3.0%) with organic disease among the 
260 children (1.3% of all screened children) whose height was below 2 SDS, measured at 
the ages of 3 and 4.5 years.17 From the 555 children (0.5% of the screened population) 
who were examined for their poor growth (height below the 3rd percentile and/or growth 
rate below 5 cm/yr) in the Utah growth study 25 children (4.5%) were newly discovered 
as having GHD, hypothyroidism or Turner syndrome, and another 53 children (9.5%) 
had other medical reasons.18 So, one can conclude that out of the (by definition) 2.3% 
short children (height <-2 SDS) in the population, 3-14% have a condition that warrants 
additional diagnostic tests, corresponding with 0.07 to 0.32% of the population. This 
low prevalence of pathology in children presenting with short stature implies that the 
specificity of the referral rules should be high, in the order of 98-99%, in order to keep the 
number of unnecessary referrals acceptable. 
This study confirmed and expanded the earlier analysis by Van Buuren et al of the 
consequences of following the DCG.4 In the earlier study the overall referral percentage 
until the age of 10 years was 38% (without deflection 0-3 years) or over 84% (including 
deflection 0-3 years). Even in de 38% most referrals would have occurred due to 
deflection. The present study found that almost 80% would have been referred in the age 
range 0-18 years. 
Short stature has many causes, and the relative prevalence of these causes varies 
considerably in the world. This implies that the objectives of growth monitoring programs 
heavily depend on the setting. In developing countries the principal aim of growth 
monitoring is to detect malnutrition. Given this aim the WHO promotes growth monitoring 
and research to improve the monitoring procedures.9,19 In industrialized countries, 
however, where there is less malnutrition, growth monitoring is aimed at detecting 
disorders associated with growth retardation without other clinical symptoms or signs, 
of which Turner syndrome, Growth Hormone deficiency and Celiac Disease are most 
prevalent. We have now shown that, given the low prevalence of such pathology (0.07 to 
0.32% of the population), also the WHO-criteria would lead to too many referrals.
Most experienced clinicians use three archetypal criteria in the analysis of growth: the 
distance of the child’s height to the mean of the population (either expressed as centiles 
or as SD scores), the distance between height SDS and the target height (the gender-
corrected mid-parental height) and growth retardation (i.e. deflection of the growth curve 
across the SD-lines or centiles). Our study confirmed that Height SDS deflection over time 
(“slow deflection”) leads to far too many referrals in our study. In earlier studies we have 
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shown that the height SDS deflection is a poor predictor of congenital growth hormone 
deficiency20 and Turner syndrome.7 On the other hand clinical experience teaches that 
crossing the SD-lines (or centiles) can be the first sign of an acquired GH deficiency 
(e.g. caused by a brain tumor), Cushing syndrome or hypothyroidism. The distance to 
target height is the best decision rule to detect children with Turner syndrome, one of 
the main causes of short stature,7 but it was left out of the UKCG because of practical 
and theoretical problems. For an optimally efficacious and efficient growth monitoring 
algorithm, a combination of the three main criteria should be sought. 
In conclusion, we have confirmed that the current Dutch consensus guideline would lead 
to too many referrals, mainly due to the deflection of length during the first 3 years of life. 
The UKCG leads to far less referrals, but may be relatively insensitive to detect Turner 
syndrome, and probably other clinically relevant growth disorders. New guidelines for 
growth monitoring are needed, which combine a low percentage of false positive results 
with a good sensitivity. To achieve these goals more studies are needed on the diagnostic 
value and cost-effectiveness of auxological screening for the diagnosis of various diseases. 
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Abstract
Background
As abnormal growth might be the first manifestation of undetected diseases, it is important 
to have accurate referral criteria and a proper diagnostic work-up. In the present paper 
we assess how many children are correctly referred to secondary health care according to 
existing consensus guidelines, evaluate the diagnostic work-up in secondary health care 
and study the frequency of underlying medical disorders. 
Methods:
Data on growth and additional diagnostic procedures were collected from medical records 
of new patients referred for short stature to the outpatient clinics of the general paediatric 
departments of two hospitals (Erasmus MC - Sophia Children’s Hospital, Rotterdam and 
Spaarne Hospital, Haarlem) between January 1998 and December 2002. As the Dutch 
Consensus Guideline (DCG) is the only guideline addressing referral criteria as well as 
diagnostic work-up, the analyses were based on its seven auxological referral criteria 
to determine whether children were correctly referred or not and on all elements of the 
diagnostic work up.
Results
Of children older than 3 years 76% was correctly referred (CR). 74-88% of these children 
were short corrected for parental height, 40-61% had a height SDS <-2.5 and 21% 
showed height deflection (∆ HSDS < -0.25/ yr or  ∆ HSDS < -1). In none of the children 
a complete detailed routine diagnostic work up was performed and in more than 30% no 
routine laboratory examination was done at all. Pathologic causes of short stature were 
found in 27 children (5%).
Conclusions
Although the DCG was poorly put into practice, it detects at least 5 % pathologic causes 
of growth failure in children referred for short stature. New guidelines for referral are 
required with a better sensitivity and specificity, wherein distance to target height should 
get more attention. The general diagnostic work up for short stature should include testing 
for celiac disease in all children and for Turner syndrome in girls. 
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Introduction
Short stature or a poor growth rate can be the first manifestation of undetected diseases 
in children.  Poor growth can be caused by a great diversity of congenital or acquired 
conditions, such as Turner syndrome, growth hormone deficiency (GHD) or celiac 
disease, for all of which early diagnosis and treatment are important. When treated at an 
early stage the effect on adult height is optimal and the quality of life will presumably 
improve. The possibility for proper treatment depends both on the early identification of 
these children in the community and on the accurate diagnostic work-up in the hospital 
afterwards. 
For an early identification of children with abnormal growth it is important to have 
accurate and well-defined referral criteria, in combination with a good growth monitoring 
system. In a previous study we performed an inquiry about advised referral criteria among 
pediatric endocrinologists in Europe as well as in most industrialized countries around 
the world.1 We concluded that there was little consensus. Moreover the literature provides 
only few guidelines for the analysis of short stature and these are based on consensus 
meetings rather than on experimental evidence.2, 3 In experimental studies on growth 
monitoring various arbitrary referral criteria were used.4-6
There is not only scarce evidence on referral criteria, but also on the diagnostic work-
up in secondary health care for children with poor growth. Although there are a number 
of consensus guidelines on the diagnosis of GHD7-11 and some articles on the analysis 
of short stature in general,12-19 the articles are primarily expert-based reviews on how 
to deal with short stature rather than experimental studies on the outcome of laboratory 
investigations. Only one study evaluated the outcome of the analysis of short stature in a 
growth clinic, but in this study no standard protocol for the diagnostic work-up was used 
20. The only guideline reported so far that addresses the diagnostic work-up for short 
stature is the Dutch Consensus Guideline (DCG).3
The DCG was prepared in 1996, containing a section on referral criteria and a section on 
diagnostic procedures. Its implementation consisted of a single publication in a Dutch 
medical journal, a book and a couple of courses.3, 21 It is not known how many doctors are 
aware of the guideline and whether or not it changed medical practices. 
In the present paper we wish to assess how many children were correctly referred to 
secondary health care according to the DCG, to evaluate the diagnostic work-up in 
secondary health care and to study the frequency of underlying medical disorders.
Material and methods
We performed a retrospective observational study in the outpatient clinics of the general 
paediatric departments of both a university hospital (Erasmus MC - Sophia Children’s 
Hospital, Rotterdam) and a general hospital (Spaarne Hospital, Haarlem). In both clinics 
the DCG was well known and used during the study period. All new patients referred for 
short stature between January 1998 and December 2002 were identified retrospectively. 
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The children in whom the cause of growth retardation was already known were excluded. 
A previously described problem-orientated patient classification system22 was used to 
identify the children in the university hospital. In the general hospital the children were 
identified by a local registration system, consisting of a hand written registry of reasons for 
referral of all new patients.
The following information was obtained from the medical records: date of birth, date 
of first presentation at the outpatient clinic, gender, ethnicity, perinatal information 
(birth weight, length, gestation, maternal obstetric problems etc.), family history, 
clinical presentation (symptoms and signs), information on puberty, longitudinal height 
measurements until the first presentation at the outpatient clinic, laboratory test results, 
radiological and pathological evaluations and final diagnosis. If the ethnicity was not 
recorded, it was assessed based on the patient’s first and family name according to an 
algorithm reported earlier.23
The DCG addresses five stages in the analysis of short stature. First of all it focuses on 
seven auxological referral criteria (table 1). When a child is referred according to these 
criteria, the paediatrician is subsequently advised to follow four diagnostic steps: 
•	 	The patient’s history, the physical examination, growth data and a hand radiograph should 
be collected to determine signs or symptoms that may indicate a specific disease. 
•	 	In the presence of specific clinical clues, appropriate further specific investigations 
are done. When there are no signs or symptoms leading to the suspicion of a 
certain disease, a list of laboratory investigations is advised for screening of several 
pathological conditions (table 2).  
•	 	Dependent on the abnormalities in the screening laboratory investigations further, more 
specific tests can be performed to establish the final diagnosis. 
•	 	If there is no indication of a certain disease after the preceding procedures the three 
following tests should still be considered: chromosomal analysis for Turner syndrome 
in girls, a biopsy to prove or rule out celiac disease and the determination of zinc to 
investigate zinc-deficiency in children with failure to thrive.24
For the evaluation of the diagnostic work up in this project all stages were taken into 
account. The auxological criteria as mentioned in the DCG were used to determine 
whether the children were correctly referred to the outpatient clinic. Since children under 
the age of three years may not yet show a stable growth pattern but are still seeking their 
individual growth channel (expressed as percentile or standard deviation score (SDS) 
position), most rules (1, 3-7) were not strictly applicable to this age group. Therefore it 
was decided to analyse this group separately. For the analyses we allowed a child to meet 
several criteria at the same time. Although plasma FSH in girls is only of diagnostic value 
in girls younger than 2 and older than 9 years, we analysed all ages in girls for this test, 
since there is no such specific recommendation in the current consensus. 
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Table 1. Seven auxological referral criteria taken from the Dutch Consensus Guideline.3
Description rule Criteria Rule nr.
Absolute height HSDS* < -2.5 1
Clinical symptoms
HSDS* < -1.3 AND (dysmorphic features OR 
disproportions)
2
Persistent short stature after born SGA** SGA** AND  HSDS* < -1.88 after the age of 2 years 3
Short for target 
height and 
population 
(HSDScorr)
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
HSDS* < -1.3 AND HSDS-THSDS§ < -1.3 4
Pubertal age‡:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
HSDS* < -1.3 AND HSDS-THSDS§ < -1.3
With pubertal signs 
5
Height 
deflection†
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
T2 – T1 > 1
(SDS1 – SDS2)/(T2-T1) < -0.25 OR  (SDS1 
– SDS2)< -1
6
Pubertal age‡:
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
T2 – T1 > 1
(SDS1 – SDS2)/(T2-T1) < -0.25 OR  (SDS1 
– SDS2)< -1
With pubertal signs
7
*  HSDS= Height Standard Deviation Score (Height – mean height for the same age and 
sex / SD for the same age and sex)
**SGA = Small for gestational age
§  THSDS= Target Height Standard Deviation Score  ( Target height = (height of mother 
(+height of father +13) + 4.5) / 2)
†  Height deflection:  Height deflection is formulated as Delta HSDS<-0.25 per year OR a 
delta HSDS <-1SDS over a longer period (not specified). 
‡  Pubertal age: When a child does not show any pubertal signs (?: genit ≥ Tanner stage 2 
OR testis volume ≥  4 ml; /:  breast>= Tanner stage 2 ) at this age referral is not necessary.
Table 2. Laboratory investigations in the diagnostic work up according the DCG
Laboratory investigations In order to diagnose Category
Blood   
Hb, Ht, Leukocytes, Cell indices, Leukocyte 
differentiation, ESR (Ferritin) 
Anemia / infections (and celiac disease and 
cystic fibrosis)
I
ALAT, ASAT, y GT Liver diseases II
Albumin, Creatinine, Sodium, Potassium,  
Calcium, Phosphate, Alkaline phosphatase,  
acid-base equilibrium
Renal diseases III
IgA-anti endomysium, IgA- antigliadin,  
Anti-tissue glutaminase*, Total IgA
Celiac disease IV
TSH, FT4 Hypothyroidism V
IGF-I Growth hormone deficiency VI
FSH** Turner syndrome VII
Urine   
pH, glucose, protein, blood and sedimentation Renal diseases VIII
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* At the moment the consensus meeting took place, anti tissue glutaminase as a diagnostic 
tool for celiac disease was not yet introduced nation wide.
**Only in girls.
All data were analysed in SPSS version 11. Height SDS was calculated using the 1997 
Dutch reference growth data.25 Small for gestational age (SGA) was defined as a birth 
weight and/or length SDS< -2 for gestational age, compared to recent Swedish reference 
values.26 Differences between the two hospitals were calculated using the chi-square test.
Results
Patients
Between January 1998 and December 2002, 742 children were referred to the two  
hospitals for short stature (university hospital: n = 467, general hospital: n = 275) (see fig 
1). Two hundred children were excluded either because the cause of growth retardation 
was already known before referral, the medical records were missing or there was another 
reason for referral than short stature. Hence, 542 cases were suitable for analysis. 
Fifty-nine children were under the age of 3 years at time of referral and were analysed 
separately. According to referral criteria mentioned in the DCG 76.4% (77.1% in the 
university and 73.9% in the general hospital) of the children older than 3 years were 
correctly referred (CR). In 5.6% children (5.7% in the university and 5.2% in the general 
hospital) there was insufficient information to assess whether the referral met the criteria 
(not classifiable (NC)) and in 18.0%  the children did not meet the referral criteria (not 
correctly referred, NCR) according to the DCG (17.1% in the university and 20.9% in the 
general hospital). 
Correctly
referred
284
Not correctly
referred
63
Not
classifiable
21
Correctly
referred
85
Not correctly
referred
24
Not
classifiable
6
467 new patients referred for
growth retardation to a
university hospital
Excluded because:
1. Cause of growth retardation already
known before referral
2. Medical records were missing
3. Another reason for referral
 for
275 new patients referred
for growth retardation to a
general hospital
13169
Children < 3 yrs
29
Children > 3 yrs
115
Children < 3 yrs
30
Children > 3 yrs
368
398 suitable for
analysis
144 suitable
analysis
Fig. 1. Population description
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Details of all patients are shown in table 3. The study groups were significantly different 
between the two hospitals for gender, ethnicity, height SDS (HSDS) at time of referral and 
target height. 
Table 3. General characteristics of the study population in the university hospital (n=398) 
and the general hospital (n=144)
University 
hospital
General 
hospital
Difference between 2 
hospitals (p-value)
Gender Male: n (%) 219 (55%) 65 (45%) 0.04
Ethnicity
N (%)
Dutch/European 291  (73.1%) 127 (88.2%)
0.01
Turkish 31 (7.8%) 6 (4.2%)
Moroccan 11 (2.8%) 1 (0.7%)
Others: 54 (13.6%) 10 (6.9%)
Unknown 11 (2.8%) 0 (0%)
Age at time of referral (yrs): mean (SD) 9.1 (4.0) 8.4 (4.7) 0.2
HSDS at time of referral: mean (SD) -2.3 (0.8) -1.9 (0.9) <0.01
THSDS: mean (SD) -0.7 (1.0) -0.2 (0.9) <0.01
HSDS - THSDS at time of referral: mean (SD) -1.6 (0.8) -1.7 (1.0) 0.7
Delta HSDS in last year before referral: mean (SD) -0.08 (0.3) -0.10 (0.3) 0.5
Dysmorphic features: n (%) 22 (5.5%) 2 (1.4%) 0.1
Disproportion: n (%) 15 (3.8%) 2 (1.4%) 0.08
HSDS= height standard deviation score; THSDS= target height standard deviation score
Referral criteria
Table 4 shows how many children in the correctly referred group complied with the 7 
different referral criteria mentioned in the DCG (although longitudinal data were used 
Table 4. Auxological criteria applicable to the correctly referred (CR) group of children > 
3years old in both the university hospital (n=284) and 
the general hospital (n=85) (multiple criteria per patient are possible).
Description rule Rule 
nr.
University hospital General hospital Difference between 2 
hospitals (p-value)n      (%) n    (%)
Absolute height 1. 173 (60.9) 34  (40.0) 0.01
Clinical symptoms 2. 23   (8.1) 3    (3.5) 0.1
Persistent short stature after born SGA 3. 55   (19.4) 13  (15.3) 0.3
Short for target 
height and 
population 
(HSDScorr)
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
4. 210 (73.9) 75  (88.2)
0.04
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
5. 9     (3.2) 0    (0)
Height 
deflection
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
6. 58   (20.4) 18  (21.1)
0.9
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
7. 0     (0) 0    (0)
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for the analyses a child could only meet a specific referral criterion once). There was 
a significant difference in referral pattern between the two hospitals with respect to 
absolute height and “short for target height and population” (HSDScorr). In both hospitals 
HSDScorr is the criterion most complied with, followed by absolute height and height 
deflection. 
Diagnostic work-up after referral (Table 5)
In 43 % of the correctly referred patients in the university hospital and 32% in the general 
hospital, no routine laboratory examination was done at all. In 52% and 49%, respectively, 
only some of the categories mentioned in the laboratory screening of the 
Table 5. Diagnostic work up in correctly  (CR) and not correctly referred (NCR) children > 
3 years old. Percentages of patients with 
complete/partial evaluation are given (several test categories per patient).
University hospital General hospital Difference in 
categories between 
2 hospitals
(p-value)
CR  
(n=284) (%)
NCR  
(n=63) (%)
CR  
(n=85) (%)
NCR  
(n=24) (%)
Routine laboratory investigations
Anemia / infections 0.4 / 39.8 0.0 / 25.4 1.2 / 57.6 4.2 / 37.5 < 0.01
Liver diseases 22.5 / 4.2 2.8 / 0.0 14.1 / 21.2 8.3 / 25.0 0.03
Renal diseases (blood) 1.4 / 27.3 0.0 / 17.5 0.0 / 38.8 0.0 / 33.3 0.5
Celiac disease 21.1 / 15.8 11.1  / 3.2 49.4 / 4.7 25.0 / 4.2 <0.01
Hypothyroidism 37.0 / 3.2 2.5 / 0.0 45.9 / 3.5 29.2 / 8.3 0.02
Growth hormone deficiency 35.2 9.5 45.9 25 0.02
Turner syndrome * 17.2 6.5 14.0 18.1 1.0
Renal diseases (urine) 0.0 / 19.4 0.0 / 19.0 0.0 / 40.0 0.0 / 29.2 <0.01
Combined categories (at least one 
test category)
4.9 / 52.1 1.6 / 39.7 18.8 / 49.4 33.3 / 16.7 <0.01
Further and specific diagnostics
Special 
investigations
Chromosomal 
analyses for Turner 
syndrome*
26.2 6.5 26.0 0.0 0.9
Biopsy** 2.1 0.0 5.9 0.0 0.03
Zinc-determination 0.4 0.0 0.0 0.0 0.6
Further, more 
specific tests
GH-tests 16.2 3.2 12.9 0.0 0.3
Other tests*** 8.8 3.2 28.2 25.0 <0.01
CR = Correctly referred; NCR = Not correctly referred
*  These categories are only applicable to girls. The percentages are therefore calculated 
only on the female population. 
**  biopsy to rule out celiac disease.
***  other tests, like stool examinations, X-rays of the skeleton, ultrasounds of abdomen, 
hart, kidneys and thyroids, serum levels of steroids, genetic analyses, immunologic 
tests and allergic tests
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DCG were covered and in only 5% and 19% respectively, all categories were covered. 
In none of the children a complete detailed routine diagnostic work up was performed.  
There was a significantly different approach towards the diagnostic workup between the 
two hospitals. In the general hospital more tests were performed, with less distinction 
between the correctly referred group and the non-correctly referred group. This difference 
was significant for all categories in the routine laboratory investigations except for the 
investigations for renal diseases in blood and screening for Turner syndrome. Significantly 
more biopsies to rule out celiac disease and other, more specific tests were done in 
the regional hospital. Less than a quarter of the girls was screened on FSH for Turner 
syndrome in the correctly referred group and in approximately 26% chromosomal analysis 
for Turner syndrome was performed. When the age rules recommended by paediatric 
endocrinologists (plasma FSH only <2 years and > 9 years, see material and methods) 
were applied the figures hardly changed. The determination of zinc was used only once in 
the diagnostic work up. 
Outcome
In 80 children (14.8%) the diagnosis of persistent short stature after born SGA could be 
made on the basis of recorded birth size, although only 17 children (3.3%) were classified 
as such by the physicians. Pathologic causes of short stature were found in 27 children 
(5%) (see table 6). A large share of these were due to Turner, GHD, and celiac disease. 
Other pathological causes were: syndromes (n=2: Noonan syndrome, Leri Weill syndrome), 
anaemia (n=3), skeletal diseases (n=4) and emotional deprivation (n=1). Three children 
born SGA had also a pathologic cause for short stature (celiac disease, Turner syndrome 
and GHD). These three were classified under their pathologic cause and not under SGA in 
table 6.
Table 6. Diagnoses after diagnostic workup of short stature.
University hospital General hospital
Total
Children 
< 3 years
Children > 3 years Children 
< 3 years
Children > 3 years
CR NCR NC CR NCR NC
n = 30 n = 284 n = 63 n = 21 n = 29 n = 85 n = 24 n = 6
n   (%) n    (%) n    (%) n   (%) n   (%) n   (%) n   (%) n   (%) n = 542 (%)
GHD 1   6    0   0  0   0  0  0 7     
CD 0   1     0   0   3  2   0  1 7     
Turner 0   2     0   0   0  1   0  0  3    
Other 
pathology
4   5     1   0   0  0   0  0  10  
Total 
pathology
5   (16.7) 14   (5.2) 1   (5.7) 0   (0) 3   (10.3) 3   (3.4) 0   (0.0) 1  (16.7) 27   (5.0)
SGA only 4   (13.3) 54   (20.1) 3   (3.5) 4   (18.2) 1   (3.4) 13 (14.9) 0   (0.0) 1  (16.7) 80   (14.8)
Idiopathic 21 (70) 216 (74.7) 59 (90.8) 17 (81.8) 25 (86.2) 69 (81.6) 24 (92.1) 4  (66.8) 435 (80.2)
CR = Correctly referred; NCR = Not correctly referred; NC= Not classifiable (information 
to confirm CR was lacking); 
SGA = Small for gestational age (with persistent short stature after two years); GHD = 
Growth hormone deficiency; CD = Celiac disease
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Of all 27 children with pathologic outcome, seven were referred for other reasons (anaemia 
(2), coughing (2), delayed closure of fontanel (1), health check after adoption (1), poor 
weight gain (1) and poor food intake (1)) in addition to their short stature. Five children 
had dysmorphic features at the time of referral (2 children with Turner syndrome, 1 child 
with Noonan, 1 child with achondroplasia and 1 child with partial GHD) and 3 children 
were disproportionate (2 children with achondroplasia and 1 child with Leri- Weill 
syndrome). Six children had already been seen by a specialist before referral: 2 for short 
stature (they were referred for a second opinion), 1 for hydrocephalus, 1 for exostoses, 1 
for neurofibromatosis and glioma of the medulla oblongata and 1 for ASD, but none of the 
children were previously investigated for short stature.  For none of the children the family 
or medical history was helpful in determining the cause. Most of the correctly referred 
children with pathology complied with a deviant HSDScorr (83.4%), followed by absolute 
height (see table 7). The only child with a pathologic cause that was incorrectly referred, 
had a height SDS of –1.7 SDS at time of referral and was referred because of its short 
stature in combination with an undefined anaemia. The child turned out to have a beta-
thalassemia.
Table 7. Auxological criteria applicable to children with pathology < 3 yrs (n=8, excluding 
SGA only) and correctly referred (CR) children with 
pathology >3 yrs (n=17, excluding SGA only) (multiple criteria per patient are possible).
Description rule Rule 
nr.
<3 yrs
n (%)
>3 yrs
n (%)
Absolute height 1. 7 (87.5) 11  (64.7)
Clinical symptoms 2. 2 (25.0) 5  (29.4)
Persistent short stature after born SGA 3. 0 (0.0) 3  (17.6)
Short for target height 
and population 
(HSDScorr)
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
4.
6 (75.0) 15  (88.2)
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
5.
Height deflection
?: < 10 yr and  > 13.4 yr; 
/: < 9 yr and  > 12.3 yr 
6.
2 (25.0) 3  (17.6)
?: 10 – 13.4 yr; 
/: 9 – 12.3 yr
7.
Discussion
This study was designed to evaluate consensus guidelines on poor growth in secondary 
health care and their outcome in terms of pathology. According to the referral criteria 
mentioned in the DCG 76.4% (284 in the university and 85 in the general hospital) of 
the children older than 3 years were correctly referred. In both hospitals “short for target 
height and population (HSDScorr)” appears to be the criterion most complied with, 
followed by absolute height and height deflection. The approach towards the diagnostic 
workup was significantly different between the two hospitals, but  in none of the children 
a complete detailed routine diagnostic work up was performed. Pathologic causes for short 
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stature were found in 27 children (5%) and in 80 children (14.8%) the short stature was 
classified as persistent short stature after born SGA.
The Netherlands has a health care system based on referral, in which outpatient clinics of 
general paediatric departments mainly provide secondary health care to referred patients 
from the well organised national primary health care system. Consequently we believe that 
by identifying all children referred for short stature to outpatient clinics most children 
with short stature from the two geographical areas were gathered.  The majority of the 
children older than 3 years were referred correctly according to the DCG. However, if 
the DCG had been followed strictly, more than 38% of the normal population of children 
would have been referred as van Buuren et al pointed out in their study.27
The 5 % of pathology found in our study concurs with previous reports.4, 6, 28 In the 
Wessex growth study 8 children (4.4%) were identified as having an organic disease 
among the 180 children, whose height on screening at school entry was below the 3rd 
percentile.6 In the Oxford study Ahmed et al reported 7 newly recognized children (3.0%) 
with organic disease among the 260 children whose height was below - 2 SDS, measured 
at the ages of  3 and 4.5 years.4 In the Utah growth study29 twenty-five out of 555 children  
(4.5%) were newly discovered as having GHD, hypothyroidism or Turner syndrome and 
another 53 children (9.5%) had other medical reasons for their poor growth (height below 
the 3rd percentile and/or growth rate below 5 cm/yr). In contrast to these population based 
studies Grimberg et al and Green et al found a higher percentage of newly diagnosed 
children with organic causes for their poor growth (23.7% (66 out of 278 children and 
40% (79 out of 198), respectively).20, 29 The children included in these studies were 
however referred to specialised growth centres because of short stature, without specific 
choices of anthropometric indicators or criteria for abnormality.
 
In both hospitals most children with pathology older than three years complied with the 
HSDScorr rule, followed by the absolute height rule and height deflection rule. This result 
is contrary to most findings in literature, where absolute height is referred to as the most 
important criterion for abnormal growth.1, 2 It concurs however with the observation by 
Van Buuren et al that the best decision rule to detect children with Turner syndrome, 
one of the major causes of short stature, is the distance between height SDS and target 
height.30 In the 8 children with pathology referred before the age of 3 years (CD (n=3), 
GHD (n=1), anaemia (n=2), skeletal diseases (n=2) and emotional deprivation (n=1)) 
both HSDScorr and absolute height seemed important criteria. According to the English 
consensus these children would however not have been diagnosed at this point, as it 
recommends a single measurement at the age of 5 years old.2 As these children did not 
reach the age of 5 years in our study we are not able to evaluate whether they would have 
been picked up in the English system, but we can surely say that there would have been 
a delay. Especially in the children with GHD and celiac disease early diagnosis and 
treatment is important for its prognosis. In order to improve the referral criteria for growth 
monitoring with optimal cut-off points, we believe that more studies, similar to the recent 
report on Turner syndrome are required, with specific attention for children under the age 
of 3 years.
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As far as we know, the DCG is the only published guideline on the general diagnostic 
work-up for short stature in secondary health care. Despite the fact that this consensus 
was well known in both hospitals participating in this study, in none of the children a 
complete detailed routine diagnostic work up as proposed in the DCG was performed 
and in 43 % of the patients in the university hospital and 32% in the general hospital 
no routine laboratory examination was done at all. The heterogeneity of tests used in 
the diagnostic work up, resulting in many missing data for the individual tests in this 
study, does unfortunately not allow us to construct an evidence-based decision rule for 
the general diagnostic work-up in children with short stature. We know however from a 
previous study that testing on celiac disease should be part of this work up, especially 
when there is no specific indication of another cause for short stature 31. Likewise the 
diagnosis of Turner syndrome should be considered in any girl with unexplained short 
stature 32,33. In contrast, the prior-probability of CF in infants or children with a low 
weight or length for age is very low and therefore a sweat test is not necessary in all 
children with short stature (Grote et al, submitted). Whether an acid-base equilibrium is 
necessary in every child with short stature to rule out renal acidosis will be addressed in a 
later study.  In the meantime, the available evidence so far can be used to construct a new 
guideline with an expected acceptable efficacy and efficiency.
Conclusion
For the identification of children with abnormal growth accurate and well-defined referral 
criteria and a diagnostic work up are important. The current study shows that with the 
DCG, though only partially adhered to, at least 5 % pathologic growth failure could be 
detected. In a substantial part of these children (30%) there would at least have been 
a delay in diagnosis if the English consensus guideline would have been used.  From 
previous studies it is known on the other hand that the DCG leads to too many referrals 
27. Therefore new guidelines are needed with a better sensitivity and specificity, in which 
target height should play a more prominent role and the implementation process receives 
more attention.  Concerning the general diagnostic work up for short stature we emphasise 
the importance of testing for celiac disease in all children and for Turner syndrome in 
girls. 
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Abstract
Objectives: To evaluate the performance of growth monitoring in detecting diseases. 
Turner Syndrome (TS) is taken as the target disease.
Design: Case-control simulation study. Three archetypal screening rules are applied to 
longitudinal growth data comparing a group with TS versus a reference group from birth to 
the age of 10 years.
Setting: Primary child health care.
Participants: Girls with diagnosed TS and a reference cohort.
Main outcome measures: Sensitivity, specificity and median referral age.
Results: Clear differences in performance of the rules were found. The best rule takes 
parental height into account. Combining rules could improve diagnostic accuracy.
Conclusion: Growth monitoring is useful to screen for TS. A combined rule that takes 
absolute height SDS, parental height and deflection in height velocity into account is the 
best way to do this. Similar research is needed for other diseases, populations and ages, 
and the results should be synthesised into evidence based referral criteria.
Grote_opm_H1_H8_v4.indd   102 22-01-2007   14:04:49
103
Towards Evidence Based Referral Criteria for Growth Monitoring
Introduction
Monitoring child growth and development is a routine part of child health care in many 
countries. In a typical scenario, the health care worker plots heights and weights on a 
reference diagram, and assesses whether the growth pattern of the child deviates from 
that of the reference population. If so, closer examination of the child might be needed. 
An important goal is to identify diseases and conditions that manifest themselves through 
abnormal growth. Examples include Turner Syndrome (TS), growth hormone deficiency, 
celiac disease, malnutrition, as well as many rare diseases. 
In contrast to its widespread use, current knowledge about the diagnostic performance 
of growth monitoring is incomplete.1, 2 Growth diagrams define the specificity of a single 
height measurement. The sensitivity of a single height measurement is unknown for even 
the most frequent diseases. Also, the sensitivity and specificity of measures involving two 
or more repeated observations, like height gain, are unknown. The current state of affairs 
unfortunately precludes an informed discussion about referral criteria. Referral criteria 
have been evaluated,3, 4, 5, 6, 7 but these studies have not prevented the appearance of 
widely different guidelines. For example, the recent UK guideline is based on just one 
universal height measurement at age five.8 In contrast, the Dutch consensus guidelines 
consist of multiple referral criteria covering infancy, childhood and adolescence.9 
All in all, current practice differs among practitioners, and practices are not founded on 
evidence.
In order to make progress, we propose that all applications of growth monitoring should be 
judged along the conventional Wilson-Jungner criteria for screening tests.10 Measures of 
diagnostic performance include sensitivity, specificity and median referral time. The latter 
measure is essential to account for the temporal aspect of the problem.
Of all diseases that might be detected by monitoring growth, TS is one of the most 
frequent, occurring in 1:2500 female live births. Only 20-40% of the affected individuals, 
usually the ones with typical clinical features and somatic abnormalities, are diagnosed 
in the newborn period.11, 12 Diagnosis of the remaining patients is made during childhood 
(usually because of growth retardation) or later (because of lack of pubertal development 
12). This makes growth retardation the most important referral criterion in the screening 
process of TS. The average adult height of untreated women is about 20 cm lower than the 
mean of the population.13 Early detection of TS permits the clinician to counsel the family 
about the consequences of TS, such as an increased risk for cardiac, renal, thyroid and 
auditory abnormalities associated with TS. Early detection also allows for the initiation of 
treatment with growth hormone, which increases final height substantially if started at a 
young age.14,15 However, the diagnosis is often made too late,11, 16 so that the results of 
growth hormone treatment are less favourable. Some work has been done to identify girls 
with TS earlier using height velocity,17 but the diagnostic value appeared limited. The 
goal of the present study is to gain insight into the diagnostic performance of a broader set 
of referral criteria for auxological screening for TS in the open population. 
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Method
Table 1:  Three archetypal screening rules for growth monitoring with their definition, 
scenario parameters, interpretation, default parameter values according to the Dutch 
consensus guidelines,7 and the parameter values used in the simulation.
Screening 
rule
Definition Para- 
meter
Interpretation Default value* Simulation values
Absolute 
height SDS
For ages 0 to p years, 
refer if SDS < a. 
a SDS referral level before 
age p
-2.5
-1.5, -2, -2.5, -3, 
-3.5, -4
For ages p to 10 years, 
refer if SDS < b.
b SDS referral level after 
age p
-2.5 -1, -1.5, -2, -2.5, -3
p Age (in years) at which 
the referral level changes
Unspecified 1, 2, 3
Parental 
height 
corrected
For ages q to 10 years, 
refer if
c
SDS cut off level below 
which SDS must lie
-1.3 -1, -1.3, -1.5, -2, -2.5
SDS < c, AND
d Difference between target 
height SDS and SDS
-1.3 -1, -1.3, -1.5, -2, -2.5
SDS - THSDS < d.
q Age (in years) after which 
the rule is effective
0, 3** 1, 2, 3
Deflection For any pair SDS1 and 
SDS2 measured at ages 
X1 and X2 (in years), 
refer if
r ≤ X1 < X2 < 10, AND
e Minimal interval (in years) 
between X1 and X2
1*** 1, 2, 3
X2 – X1 ≥ e, AND
f SDS cut off level below 
which SDS2 must lie
Unspecified 10, 0, -1, -2, -2.5
SDS2 < f, AND
g Height velocity change in 
SDS per year
-0.25
-0.20, -0.25,-0.33, 
-0.50
(SDS2 – SDS1)/ 
(X2-X1) < g
r Age (in years) after which 
the rule is effective
0, 3** 3
* According to Dutch consensus guidelines
** The Dutch consensus guidelines are ambiguous
***  The Dutch consensus guidelines require that three measurements should have been 
taken, each at least one half a year apart
Screening rules
We investigated screening rules that are suitable for application within the setting of the 
child health care system. A child that is “screened in” will be referred to a physician 
for further investigation, eventually leading to the diagnosis of TS. We formulated three 
archetypal screening rules: an absolute height standard deviation score rule (HSDS), a 
parental height corrected rule, and a deflection rule (∆HSDS). Based on the absolute 
HSDS rule a child is referred if HSDS is lower than some criterion value. The parental 
height corrected rule takes genetic height potential into account by comparing the HSDS 
of the child to its target height SDS. The target height (TH) is the expected adult height 
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given the heights of the biological parents and corrected for secular trend. For Dutch 
girls, the relevant formulas are TH = (maternal height + paternal height - 13)/2 + 4.5 and 
THSDS = (TH-170.6)/6.5.18 The deflection rule signals whether an abnormal deflection in 
height occurs in terms of a change in HSDS per year. Table 1 gives the precise definition 
of each rule, the description of the free parameters, and default values of the parameters 
as used in the Dutch guidelines.9 
Each screening rule was implemented in a computer program written in S-Plus,19 and 
each rule was applied to longitudinal height data of children with and without TS. For 
each screening rule, we computed the sensitivity, specificity and median referral age for 
specific scenarios. A scenario is a combination of parameters. We defined scenarios by all 
possible parameter combinations. We first studied the properties of each screening rule 
separately. Given these results, we defined scenarios that combined the most promising 
elements of the separate rules, and computed the outcomes for combined scenarios.
Material 
Longitudinal height curves from 777 girls with TS were collected from three sources. 
The National Registry of Growth Hormone Treatment in Children of the Dutch Growth 
Foundation contains data of all children in the Netherlands receiving growth hormone 
(GH) treatment. From this registry, 316 girls with TS, born between 1968 and 1996 were 
selected. In addition, data from 87 girls with TS, born between 1973 and 1988 from the 
Sophia Children’s Hospital and the data of 374 Dutch girls described by Rongen et al. 
[13] were used. The first two sources contain data of girls that were treated with GH and 
other growth promoting treatment. For this analysis we used only height measurements 
before treatment. Karyotype, date of diagnosis TS, the presence of congenital anomalies 
and/or dysmorphic features and parental height were collected when available. The 
average numbers of measurements per year per child during the first 10 years were 2.2, 
0.7, 0.6, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5 and 0.5, respectively.
A reference sample of longitudinal height data was retrospectively obtained for a cohort of 
all girls (n=489) born in 1989 and 1990 in the municipality of Landgraaf, located in the 
south of the Netherlands. Data were collected from the records of the local child health 
care centre. These are routinely collected data, and they thus include all measurement 
errors that are being made in practice. The modal number of observations per girl was 17. 
Data were collected in 2001, so the oldest girls were about 11 years. The average numbers 
of visits per year per child during the first 10 years were 8.1, 2.2, 0.8, 0.8, 0.7, 0.7, 0.2, 
0.1, 0.1 and 0.8. Table 2 contains additional information about the samples.
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Table 2: Summary statistics for the Turner and reference samples. 
Turner Reference
Count/Mean S.D. Count/Mean S.D.
Total sample size (n) 777 489
Total number of measurements 9660 7319
Mean number of measurements per girl 12.4 15.0
Mean height for age SDS (ages 0-10 year) -2.44 1.13 -0.31 1.05
Mean weight for age SDS (ages 0-10 year) -1.74 1.28 -0.12 1.05
Mean weight for height SDS (ages 0-10 year) -0.06 1.29 0.12 1.04
Mean BMI for age SDS (ages 0-10 year) -0.19 1.27 0.11 1.04
Height of both father and mother known 357 203
Height of only one parent known 3 10
Height of both parents unknown 417 276
Mean father’s height (cm) 179.4 7.50 178.4 7.57
Mean mother’s height (cm) 166.4 6.29 166.7 7.38
Target height (cm) 169.7 5.89 170.6 5.70
Target height SDS 0.06 0.82 0.01 0.88
Gestational age (weeks) 38.9 2.07 39.7 1.61
Dysmorphic features (%) (N=145)  
  Cubitus valgus 31
  Large inter-nipple distance 29
  Low hair implantation 21
  Webbed neck 19
Karyotype (%)   (N=327)
  45,X 62
  46,X,iX or 46,X,idic(X) 5
  45,X and 46,XX 5
  45,X and (46,X,iX or 46,X,idic(X)) 12
  Other 16
Median age of diagnosis of TS (years)  (N=46)
  45,X   (N=27) 6.9 4.94
  Other  (N=19) 10.4 4.81
Statistical analysis
HSDS was calculated with respect to the Dutch height reference data.20 Parental heights 
were frequently missing (55% of the Turner group, 58% in the reference group). Deleting 
incomplete records would not only be wasteful, but would also lead to a selective 
subsample. Mean HSDS of girls with TS was –3.24 for the subsample with missing 
parental heights, compared to –2.53 for the subsample with known parental heights, 
but no such differences were found in the reference group. We imputed these data 
under the assumption that the data are missing at random21 using mice.22 The method 
created multivariate imputations by applying sequential linear regressions, where each 
incomplete variable was imputed conditional on all other variables in an iterative fashion. 
The imputation model consisted of the last known HSDS, weight SDS, weight/height 
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SDS, BMI SDS, age, and the height of the other parent. The number of iterations was 
set to 15. Predictive mean matching was used to create parental heights imputations. 
The imputation method possesses important properties: it includes parameter uncertainty, 
preserves the multivariate structure in the data and has good coverage properties.23 
Figure 1 plots father’s height against mother’s height separately for the real and artificial 
data. It shows that the distribution is similar in both groups.
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Figure 1: Father’s height plotted against mother’s height in the reference sample. The 
upper figure plots observed data from group in which both parental heights are known 
(n=203). The lower figure plots the imputed (artificial) data for cases where at least 
one parental height missing (n=286). The reference line indicates the location of equal 
parental heights.
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We assumed that a child is referred the first time the growth pattern meets the criteria 
of a given screening rule. Multiple referrals by different rules were treated depending on 
the type of scenario under investigation. As long as we dealt with separate rules, the same 
child could be referred according to each rule, i.e., as if the screening rules operated 
in isolation, but in any combined scenario, multiple referrals were counted as one. 
The screening age of children that were not referred before the age of 10 years was taken 
as 10 years. TS girls with a referral age of 10 under a given scenario are missed, so the 
proportion of such girls is the false negative rate (1-sensitivity). The age of 10 years was 
chosen because treatment of TS, if indicated, could best be started before that age.
Finally, we synthesised our results by fitting linear regression models to the main outcome 
variables. These models can be used to predict sensitivity, specificity and median referral 
age (MRA) in intermediate cases that were not part of the simulation design.
Results
Sensitivity and specificity
Figure 2a is the ROC-plot of scenarios under the absolute HSDS rule. Only scenarios with 
a true positive rate (sensitivity) of at least 40%, a false positive rate (1-specificity) of at 
most 15%, and with cut off age p = 3 are plotted. Under the default scenario “(-2.5, -2.5)” 
children are referred that have a HSDS < -2.5 (a = -2.5, b = -2.5, p = 3). Scenario “(-2.5, 
-2.5)” has a sensitivity of 70.2% and a specificity of 93.1%. Scenarios (-3, -2), (-3.5, -2) 
and (-4, -2) have better sensitivity and specificity for detecting TS. Specificity is, however, 
still on the low side for screening purposes (95 - 97%), thus these scenarios might lead 
to substantial numbers of false positives. Scenarios (-3.5, -2.5) and (-4, -2.5) cut down 
the number of false positives, at the expense of a loss of sensitivity. The influence of p on 
sensitivity and specificity was limited. 
Performance of the parental height corrected rule was generally better (Figure 2b). 
The current Dutch guideline (-1.3, -1.3) pairs a high sensitivity of 93.5% with a 
specificity of 95.9%. Rules using more stringent cut off points reduce the number of 
false positive referrals at the expense of sensitivity. Examples of interesting scenarios 
are (-1.5, -1.5), (-2, -2) and (-2.5, -2.5). Note that for these cases c=d. The difference 
with the absolute SDS rule is the extra requirement that THSDS > (c-d), i.e., THSDS > 
0 or taller than average parents. 
Screening based on the deflection of the growth curve has low sensitivity for rules with 
a specificity of at least 85% (c.f. Figure 2c). Though not very sensitive, some deflection 
rules are highly specific. For example, the rule with e=3, f=-2 and g=-0.25 (not in Figure 
2c) pairs a sensitivity of 23% with the maximal specificity of 100. It can be efficient to use 
such rules in conjunction with more sensitive rules. 
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Median referral age
Median referral age in the Turner group 
generally did not exceed 6 years under 
the absolute HSDS or the parental height 
corrected rule. Median referral age tends 
to be lower for higher sensitivity and 
lower specificity. Thus, more cases imply 
younger cases. This is especially true 
under scenarios that correct for parental 
height. The absolute HSDS rule provides 
the fastest detection of TS, primarily due 
to the fact that this is the only rule that 
takes measurements during infancy into 
account. Earlier detection of TS is possible 
at the expense of specificity, especially if 
done through the parental height rule.
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Figure 2: ROC plot of different scenarios 
under three archetypal rules. Each 
scenario is labeled by its parameter values 
according to Table 1. For example, the 
label “(-3, -2)” in the left plot indicates 
the scenario with a = -3 and b = -2. Only 
scenarios with p = q = r = 3 (c.f. Table 1) 
are plotted.
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Figure 3: Median referral age of girls with TS as a function of sensitivity and specificity 
under each rule. Every dot corresponds to a scenario. 
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Predicting sensitivity, specificity and median referral age
Table 3 contains a synthesis of the results. It gives estimated coefficients of the linear 
regression for all outcomes. As the proportion of explained variance is generally high, the 
regression equations can be used to generate fairly accurate predictions for intermediate 
scenarios not listed in the table. As an example, the estimated sensitivity for scenario 
(-3, -2) for the absolute HSDS rule is equal to 97.5 – 3.62a – 0.60b – 6.04ab = 73.3%. 
The observed values vary between 74.2% (for p=3) and 76.5% (for p=1). In this case, 
the differences between these observed and predicted values fall within one standard 
deviation of the residual variation (4.97%). 
Table 3: Regression equations for predicting sensitivity, specificity and median referral 
age of the absolute HSDS (sds), parental height corrected (phc) and deflection (def) 
screening rules, the residual standard error, and the proportion of explained variance (r2).
Rule Outcome Predictive equation Resid s.e. r2
sds Sensitivity 97.5 – 3.62a – 0.60b – 6.04ab 4.97 0.89
Specificity 58.4 – 3.55a – 2.32b + 1.20p + 2.00ab 4.56 0.79
Median referral age 1.45 + 0.33a + 1.13b – 0.04p + 0.59ab – 0.32ap + 0.20bp 0.38 0.94
phc Sensitivity 145 + 21.6c + 26.8d + 5.95cd 3.66 0.91
Specificity 67.0 –11.0c - 11.3d +4.82q – 3.41cd + 1.06cq – 1.15dq 0.68 0.95
Median referral age – 1.09 – 1.76c –1.92d + 1.26q – 0.62cd + 0.26cq + 0.32dq + 
0.11cdq
0.10 0.98
def Sensitivity 89.9 – 8.59e + 0.40f + 145g 7.46 0.86
Specificity 82.9 + 3.48e –1.05f – 21.1g 5.47 0.57
Median referral age 5.63 + 0.82e – 0.02f + 2.28g 0.28 0.87
Combining rules
A child will be referred if she meets any of the rules. Sensitivity of a combined rule will 
be higher than that of its components, while its specificity will be lower. 24 Thus in order 
to create highly specific combinations, the component rules must have high specificity to 
start with. 
Table 4 shows the diagnostic properties of two combinations. Combining the parental 
height corrected rule (-2, -2) with the absolute height corrected rule (-3.5, -3) increases 
sensitivity from 76.9% to 82.4%, decreases specificity from 99.4% to 97.5%, and lowers 
median referral age to 4.7 years. Observe that this combined rule is inferior to the parental 
height corrected rule (-2,-1.5) in terms of sensitivity and specificity. The story is different 
for the combination of the absolute rule with the deflection rule (3,-2,-0.25), which refers 
children with a HSDS below –2 and a deflection of at least 0.25 SDS per year during at 
least three years. While this rule detects only 23% of the TS group, there is not a single 
child in the reference group with this growth pattern. The rule picks up a few new cases. 
Sensitivity increases from 76.9% to 79.2%, whereas specificity remains at 99.4%. This 
combined rule is better than comparable parental height corrected rules. 
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Table 4: Combining rules using a high specificity strategy. Rows 1-3 list a parental height 
corrected (phc), an absolute sds (sds) and their combined (phc-sds) rule. Rows 4-6 list 
a parental height corrected (phc), a deflection (def) and their combined (phc-rule) rule. 
Row 7 is a single parental height corrected rule that is better than row 3 but not preferable 
to row 6. MRA = Median Referral Age. 
Row Rule Scenario parameters Sensitivity Specificity MRA
a b c d e f g (*100) (*100)
1 phc -2.0 -2.0 76.9 99.4 5.2
2 sds -3.5 -3.0 41.4 98.1 4.8
3 phc-sds -3.5 -3.0 -2.0 -2.0 82.4 97.5 4.7
4 phc -2.0 -2.0 76.9 99.4 5.2
5 def 3 -2.0 -0.25 23.3 100.0 7.7
6 phc-def -2.0 -2.0 3 -2.0 -0.25 79.2 99.4 5.3
7 phc -2.0 -1.5 84.9 98.8 5.1
Discussion
Growth monitoring is important for detecting TS, but until now no evidence has been 
available about the diagnostic quality of possible screening procedures. We estimated 
sensitivity, specificity and median referral age of TS for three screening rules, and 
for combinations of these rules. We found that these rules had different performance 
in discriminating TS. Rules that correct for parental height could identify TS better 
than rules using the absolute HSDS or rules based on the deflection of growth curves. 
Combining rules improved performance in particular cases. 
The children in our control sample live in the southern part of the Netherlands, and are 
shorter on average (-0.31 HSDS) than the Dutch reference population. This means that the 
specificity for the Dutch reference population might be more favourable than estimates 
based on the shorter population. The equations in Table 3 can be used to estimate the size 
of the effect. For example, setting a=-2, b=-2.5 and p=1 yields a predicted specificity 
of 82.5%. Had the group been -0.31 shorter, then substituting a= -1.69, b= -2.19 and 
p=1 predicts a specificity of 78.1% for that group. So the actual specificity for a group 
that is 0.31 HSDS shorter is here 4.4% lower. In order to eliminate such biases, we 
added 0.31 HSDS to the measurements of the reference group. The existence of regional 
height differences implies that the actual false-positive rates can vary across the country. 
The parental height corrected rule and the deflection rule are less sensitive to such 
differences. Using the equations in Table 3, it is straightforward to compute the effect of 
regional differences on sensitivity and specificity. Region-specific screening rules can be 
created if the effect is substantial. Similar considerations apply to ethnic minority groups.
Diagnosis of TS is often unnecessarily delayed. Excluding the 20-40% of the patients 
identified in infancy, the median age of diagnosis is somewhere between 10 and 12 years 
11, 16 Including 30% of the early cases into the calculation would lower the median age of 
diagnoses to the range of 7 to 8.4 years. By the time of diagnosis, patients were extremely 
short (mean –3.0 HSDS). We found that the median referral age of most screening rules 
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studied here is between 4 and 6 years. Some rules even identify 50% or more of the cases 
within the first year. The current policy in the Netherlands is that GH-Treatment in girls with 
TS is applied if HSDS < -1.5 and if the child is older than 6 years, but preferably younger 
than 9. Before the age of 6 years treatment is only started if HSDS < -2.5. Our results suggest 
that systematic growth monitoring is able to find the large majority of cases in time. 
The occurrence of missing parental heights complicated the analysis. It is inappropriate 
to simply ignore the records with incomplete parental heights because the shorter TS 
girls drop out more frequently. This leads to sensitivity estimates that are too low. The 
effect is substantial. For example, using just the complete cases in scenario c=d=-1.3 and 
q=3 results in a sensitivity estimate of 88.7%, compared to 93.5% based on the imputed 
sample. As it would be unfair to exclude the incomplete cases only for the parental 
height rule, sensitivity estimates for other rules would also be affected. Imputation yields 
unbiased estimates for the TS group as a whole. The precision of these estimates is lower 
than found in the hypothetical case in which we would have had complete data, but it is 
higher than obtained in the inappropriate complete-case analysis just discussed.
Our results enable informed decisions about specific choices in screening rules for 
identifying TS. Although growth charts are also used to detect other anomalies, like growth 
hormone deficiency or celiac disease, growth monitoring should at least be able to detect 
TS. If monitoring cannot pick up TS, then it almost certainly will fail in more complicated 
cases where the effects on growth are less pronounced. It is likely that repeating our study 
for other diseases will lead to different estimates for sensitivity and specificity. Additional 
complexities will surface, for example, the lack of a gold standard for diagnosis of growth 
hormone deficiency. However, such studies would probably not lead to a different ranking 
among the three rules. We expect that rules that take parental height into account are 
generally preferable to rules that do not. 
The findings appear to be only partially in harmony with published guidelines and 
proposals.7, 9 As anticipated,17, 25 we found that centile crossing has low sensitivity 
and specificity, and in this sense, the Dutch guidelines may need re-evaluation. Marked 
differences occur with respect to the correction for parental height. Hall dismissed a 
correction for parental target height on practical grounds,8 whereas we found that it 
represents a substantial improvement, in line with earlier observations by Massa et al..16
We conclude that growth monitoring is useful to screen for TS. The parental height 
corrected rule will refer 60-77% of the girls with TS before the age of 10 at tolerable 
levels of false positives, i.e., at a maximum of 1%. We recommend the use of the combined 
rule “phc-def” listed in Table 4. This rule refers children older than age three if HSDS is 
below –2 and if either HSDS is more than 2 SD below the target HSDS, or HSDS shows 
a deflection of 0.25 SDS per year or more during a period of at least three years. This 
rule picks up almost 80% of the girls with TS, while it refers only 0.6% of the non-TS 
population. We also recommend that similar research should be done for other diseases, 
populations and ages. The results should be synthesised into general evidence based 
referral criteria.
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Abstract
Objective: To study the diagnostic efficiency of several auxological criteria for the 
detection of children with celiac disease (CD).
Design: We studied various criteria concerning length and weight.
Patients: Longitudinal length and weight measurements up to 2.5 years of age from 3 
groups of CD patients (two groups with clinical manifestations, one group diagnosed by 
screening) (n=134) and a reference group obtained from the Social Medical Survey of 
Children Attending Child Health Clinics (SMOCC) cohort (n=2,151) in The Netherlands.
Main outcome measures: Sensitivity, specificity and positive predictive value (PPV) for 
each criterion.
Results: The auxological criteria hardly discriminate between the screened CD group 
and the reference group. Criteria based on a decrease of body mass index (BMI) or weight 
standard deviation score (SDS) performed best for the groups with clinical manifestations. 
Thirty-four percent of the CD children and 2% of the reference children have a deflection 
in BMI SDS of at least -2.5 per year and a BMI SDS below -1.3 from the age of 0.5 year
Conclusion: Although the efficacy of growth monitoring for the detection of CD is modest, 
testing for CD deserves a place in the diagnostic work-up in young children with failure to 
thrive.
Keywords: growth monitoring, celiac disease 
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Introduction
Growth assessment is worldwide accepted and in many countries regularly integrated 
in a child health care system, despite the insufficient evidence to support this activity.1 
One of the most important goals of growth monitoring in developed countries is the 
detection of undiagnosed illnesses. There is nevertheless little consensus on referral 
criteria for children with growth retardation and the diagnostic performance of growth 
monitoring among countries.2 Only recently, we reported on the predictive value of various 
auxological criteria for the detection of Turner’s syndrome.3 Since short stature is the main 
common physical characteristic of Turner’s syndrome, we focused in that study on short 
stature and poor height gain. Growth retardation however does also imply failure to thrive 
in terms of poor weight gain.
Celiac disease (CD) is an illness in which both length (or height) deficit and poor weight 
gain might be the earliest signs of the disease. It is a gluten-sensitive enteropathy, 
characterized by subtotal villous atrophy of the small intestine and might be clinically 
diagnosed at an early age, when diarrhoea, belly distension and/or failure to thrive is 
present. In the Netherlands in 1994 the incidence of clinically diagnosed CD was 0.54 
per 1000 live births.4 However CD remains frequently unrecognized. Screening studies by 
means of detection of anti-endomysium antibodies have shown a much higher prevalence 
(1:300 to 1:100). The ratio clinically diagnosed versus screening detected CD is between 
1:7 and 1:14.5 A reduction in adult height, a higher prevalence of malignancies, adverse 
pregnancy outcome, neurological problems and osteomalacia are associated with CD. 
Early detection and treatment of CD may prevent these problems.
Mass screening for CD through specific antibodies in the general population probably 
will not be performed in the forthcoming years because of the uncertainty about the cost-
benefit ratio. As there is a high incidence of CD (1.7 to 8.3%) in children with growth 
retardation without gastrointestinal symptoms and even higher (up to 59.1%) when other 
(endocrine) causes for short stature are excluded,6 one could expect that a substantial 
proportion of infants and children with CD might be detected through growth monitoring.
In the Netherlands, nearly every child is monitored for height and weight from birth till 
the age of 16-18 years. Children with abnormal growth are referred to secondary health 
care according to certain criteria.7 As in most of them no pathologic causes for short 
stature can be detected, in a current project the referral criteria are evaluated and adapted 
to minimize unnecessary referrals, without missing important diseases like CD, Turner’s 
syndrome and endocrine diseases. This should result in evidence-based guidelines for 
growth monitoring. This project aims at determining optimal auxological referral criteria 
for detecting CD.
Method
Material
The longitudinal length and weight data of the patients with CD included in this study 
were collected from three different studies. The first study was a screening study on 
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unrecognised CD in children aged 2-4 years, visiting the Community Child Health Care 
Centres in the Dutch province of Zuid-Holland.5 In this study 32 children with CD 
between May 1997 and June 1998 were detected. The second study was a retrospective 
study on catch up growth in patients with CD.8 A written questionnaire including their 
symptomatology, duration of complaints before diagnosis, age at diagnosis, associated 
diseases in the past and parental heights was sent to all members of the Dutch Celiac 
Society in the early eighties. Growth data were collected from 74 children younger than 16 
years. The third study was a prospective study on catch up growth.9 All newly diagnosed 
childhood CD patients at two departments of paediatrics were included between April 
1994 and September 1995 (n=28). We used all growth data before and at the start of the 
gluten-free diet and till the age of 2.5 years. The data was gathered retrospectively from 
child welfare clinics, paediatricians and general practitioners.
A reference sample was obtained from the Social Medical Survey of Children Attending 
Child Health Clinics (SMOCC) cohort, a nationally representative cohort of 2,151 children 
born in the Netherlands in 1988-1989.10 This cohort consists of longitudinal data of 
length and weight of children up to the age of 2.5 years. Length and weight from birth to 
two years were previously described by Herngreen et al.11
Screening rules
For this study we formulated nine auxological rules for screening that could serve as 
criteria for referral to specialist care. We started with three archetypal rules of which the 
diagnostic performance to detect Turner’s syndrome was reported by Van Buuren et al.3 
The first rule was the absolute Height Standard Deviation Score (HSDS) rule, which 
would lead to referral of a child if HSDS is lower than some simulation value. The second 
rule took genetic height potential into account by comparing the HSDS of the child to its 
target height SDS in combination with a HSDS below some simulation value (parental 
height corrected rule). The third rule signalled whether an abnormal deflection in height 
occurs in terms of change in HSDS per year in combination with a HSDS below some 
simulation value (deflection rule).
The present study expands these screening rules with analogical absolute SDS rules 
for weight, BMI and weight for length (i.e. refer when weight, BMI, weight for length, 
respectively, is lower than some simulation value), an analogical deflection rule for weight 
and BMI (i.e. refer when a change in weight or BMI SDS per year occurs and weight or 
BMI SDS is below some simulation value) and six other rules. The first of these other rules 
is a deflection rule that detects a child with a deflection in length, weight or BMI SDS/year 
without the restriction of having an SDS below some value (unrestricted deflection rule). 
The second rule refers if an absolute change in SDS occurs (delta rule). The third rule 
signals whether a deflection moves away from the child’s target height (parental height 
deflection rule). The fourth rule is the combined weight and length deflection rule 
in which a deflection in length occurs after a deflection in weight. The fifth rule refers 
if the conditional weight gain SDS (SDSgain)
13 is below some value and weight SDS is 
below a simulation value (conditional weight gain rule). The sixth rule is similar to the 
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conditional weight gain rule without the restriction of having a weight SDS below some 
value (unrestricted conditional weight gain rule). Table 1a/b shows the definitions, 
parameters, interpretations and simulation values of the rules. It should be noticed that 
some parameters select a subset of the data and/or assume 2 or 3 measurements. The rules 
are only tested on children that comply with these assumptions.
Each screening rule was implemented using S-Plus version 7.0, and was applied to 
the longitudinal data of children. For the deflection, delta and conditional weight gain 
rules, all possible pairs of weights for each infant were used. We calculated sensitivity, 
specificity and positive predictive value (PPV) of different scenarios (a combination 
of parameters). The rules were ordered according to their sensitivity at high levels of 
specificity. A 
higher sensitivity at the same level 
of specificity, results in a better performance. Receiver Operating Characteristic (ROC) 
curves were constructed for the three best screening rules. Scenarios of rules with 
approximately 2% false-positive rate will be presented in detail as we assume that a 
false-positive rate of more than 2% would lead to too many referrals. PPV was calculated, 
assuming that the average incidence of CD is 0.54 per 1000 live births in the Caucasian 
population.4
Statistical analysis
Length, weight, BMI and weight for length were expressed as SDS, using the Dutch 
reference growth data.13, 14 In preterm infants (gestational age < 37 weeks) length and 
weight SDS were corrected for gestational age. The intrauterine growth curve of the 
Swedish reference population was used to express SDS till the age corresponding with 40 
weeks of gestation.15 Between 40 and 42 weeks an interpolation between the growth curve 
of the Swedish reference population and that of the Dutch reference population was used. 
From 42 weeks of gestation till the age of 2 years, SDS was calculated on ages corrected 
for gestation, using the Dutch reference growth data.
We assume that a child is referred if the growth pattern meets the criteria of a given 
screening rule for the first time. All rules were dealt with separately, meaning that the 
same child could be referred according to each separate rule. Because of the difference 
in presentation at diagnosis (screening versus symptomatic), the analyses were performed 
separately for CD-patients from group 1 (screened) and patients from group 2 and 3 
(symptomatic).
Results
From the 134 children with CD, 12 were excluded from the analyses because of missing 
data (see figure 1). Table 2 contains general characteristics of the unscreened and 
screened CD groups. In the unscreened group mean SDS for weight was compromised 
most, followed by BMI SDS.
Grote_opm_H9_etc_v4.indd   121 22-01-2007   14:06:58
122
Chapter 9
Ta
bl
e 
1a
 A
ux
ol
og
ic
al
 c
ri
te
ri
a 
w
ith
 th
ei
r 
de
fin
iti
on
s,
 s
ce
na
ri
o 
pa
ra
m
et
er
s,
 in
te
rp
re
ta
tio
ns
 a
nd
 s
im
ul
at
io
n 
va
lu
es
 (p
ar
t 1
).
Sc
re
en
in
g 
ru
le
D
efi
ni
tio
n
Pa
ra
m
et
er
In
te
rp
re
ta
tio
n
Si
m
ul
at
io
n 
va
lu
es
A
bs
ol
ut
e 
SD
S 
ru
le
▲
Fo
r 
ag
es
 0
 to
 p
 y
ea
rs
, r
ef
er
 if
 S
D
S 
< 
a,
 A
N
D
a
SD
S 
re
fe
rr
al
 le
ve
l b
ef
or
e 
ag
e 
p
-1
,-
1.
3,
 -
1.
5,
 -
2,
 -
2.
5,
 -
3,
 -
3.
5
Fo
r 
ag
es
 p
 to
 2
.5
 y
ea
rs
, r
ef
er
 if
 S
D
S 
< 
b
b
SD
S 
re
fe
rr
al
 le
ve
l a
fte
r 
ag
e 
p
-1
, -
1.
3,
 -
1.
5,
 -
2,
 -
2.
5,
 -
3
p
A
ge
 (i
n 
ye
ar
s)
 a
t w
hi
ch
 th
e 
re
fe
rr
al
 le
ve
l c
ha
ng
es
0,
 0
.5
, 1
Pa
re
nt
al
 h
ei
gh
t 
co
rr
ec
te
d 
ru
le
Fo
r 
ag
es
 x
 to
 2
.5
 y
ea
rs
, r
ef
er
 if
 
x
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
Le
ng
th
 S
D
S 
< 
c,
 A
N
D
c
C
ut
 o
ff 
le
ve
l b
el
ow
 w
hi
ch
 le
ng
th
 S
D
S 
m
us
t l
ie
-1
, -
1.
3,
 -
1.
5,
 -
2,
 -
2.
5
Le
ng
th
 S
D
S 
– 
TH
 S
D
S 
< 
d
d
D
iff
er
en
ce
 b
et
w
ee
n 
le
ng
th
 S
D
S 
an
d 
ta
rg
et
 h
ei
gh
t S
D
S
-1
, -
1.
3,
 -
1.
5,
 -
2,
 -
2.
5
D
efl
ec
tio
n-
ru
le
 ‡
Fo
r 
ag
es
 e
1 
to
 2
.5
 y
ea
rs
, A
N
D
 
e 1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
– 
X
1 
≥ 
1/
12
 r
ef
er
 if
M
in
im
al
 o
ne
 m
on
th
 in
te
rv
al
 b
et
w
ee
n 
ag
es
 X
1 
an
d 
X
2
SD
S 2
< 
f, 
A
N
D
f
SD
S 
cu
t o
ff 
le
ve
l b
el
ow
 w
hi
ch
 S
D
S 2
 m
us
t l
ie
-1
,-
1.
3,
 -
1.
5,
-2
, -
2.
5
(S
D
S 2
- 
SD
S 1
)/(
X
2-
X
1)
 <
 g
1
g 1
C
ha
ng
e 
in
 S
D
S 
pe
r 
ye
ar
-0
.5
,-
1,
-1
.5
,-
2,
-2
.5
U
nr
es
tr
ic
te
d 
de
fle
ct
io
n-
ru
le
 ‡
Fo
r 
ag
es
 e
2 
 to
 2
.5
 y
ea
rs
, A
N
D
 
e 2
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
– 
X
1 
≥ 
1/
12
 r
ef
er
 if
M
in
im
al
 o
ne
 m
on
th
 in
te
rv
al
 b
et
w
ee
n 
ag
es
 X
1 
an
d 
X
2
(S
D
S 2
 –
 S
D
S 1
)/(
X
2-
X
1)
 <
 g
2
g 2
C
ha
ng
e 
in
 S
D
S 
pe
r 
ye
ar
-1
.5
,-
2,
-2
.5
,-
3,
-3
.5
,-
4,
-4
.5
,-
5,
-5
.5
D
el
ta
-r
ul
e 
▲
Fo
r 
ag
es
 e
3 
 to
 2
.5
 y
ea
rs
, A
N
D
 
e 3
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
(S
D
S 2
 –
 S
D
S 1
) <
 w
w
C
ha
ng
e 
in
 S
D
S
-0
.5
,-
1,
-1
.5
,-
2,
-2
.5
,-
3
Pa
re
nt
al
 h
ei
gh
t 
de
fle
ct
io
n 
ru
le
Fo
r 
ag
es
 k
1 
 to
 2
.5
 y
ea
rs
, A
N
D
k 1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
(L
en
gt
h 
SD
S 2
 –
 L
en
gt
h 
SD
S 1
) <
 n
1,
 A
N
D
n 1
C
ha
ng
e 
in
  l
en
gt
h 
SD
S 
-0
.5
,-
1,
-1
.5
,-
2,
-2
.5
,-
3
| L
en
gt
h 
SD
S 2
 –
 T
H
 S
D
S 
| >
| L
en
gt
h 
SD
S 1
 –
 T
H
 S
D
S 
| 
Le
ng
th
 S
D
S 
at
 a
ge
 X
1 
is
 c
lo
se
r 
to
 it
’s 
ta
rg
et
 h
ei
gh
t t
ha
n 
Le
ng
th
 S
D
S 
at
 a
ge
 X
2
C
om
bi
ne
d 
w
ei
gh
t 
an
d 
le
ng
th
 d
efl
ec
tio
n 
ru
le
Fo
r 
ag
es
 k
2 
 to
 2
.5
 y
ea
rs
, A
N
D
k 2
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
3 
>  
X
2 
> 
X
1,
 A
N
D
A
ge
 X
3 
af
te
r 
X
2 
, X
2 
af
te
r 
X
1 
(a
ge
s 
fo
r 
w
ei
gh
t)
Y
3 
>  
Y
2 
> 
Y
1,
 r
ef
er
 if
A
ge
 Y
3 
af
te
r 
Y
2 
, Y
2 
af
te
r 
Y
1 
(a
ge
s 
fo
r 
le
ng
th
)
(W
ei
gh
t S
D
S 2
 –
 W
ei
gh
t S
D
S 1
)<
 n
2,
 A
N
D
n 2
W
ei
gh
t v
el
oc
ity
 c
ha
ng
e 
in
 W
ei
gh
t S
D
S 
-0
.2
5,
-0
.5
,-
1,
-1
.5
,-
2
(L
en
gt
h 
SD
S 2
 –
 L
en
gt
h 
SD
S 1
) <
 n
3,
 A
N
D
n 3
Le
ng
th
 v
el
oc
ity
 c
ha
ng
e 
in
 L
en
gt
h 
SD
S 
-0
.2
5,
-0
.5
,-
1,
-1
.5
,-
2
Y
1 
> 
X
1 
St
ar
tin
g 
po
in
t l
en
gt
h 
de
fle
ct
io
n 
af
te
r 
st
ar
tin
g 
po
in
t w
ei
gh
t 
de
fle
ct
io
n
▲
 T
hi
s 
ru
le
 is
 c
al
cu
la
te
d 
fo
r 
le
ng
th
, w
ei
gh
t, 
B
M
I 
an
d 
w
ei
gh
t f
or
 le
ng
th
 S
D
S.
‡  
Th
is
 d
efl
ec
tio
n 
ru
le
 is
 c
al
cu
la
te
d 
fo
r 
le
ng
th
, w
ei
gh
t a
nd
 B
M
I 
SD
S.
 
Grote_opm_H9_etc_v4.indd   122 22-01-2007   14:06:59
123
Which auxological characteristics are useful for the detection of Celiac disease?
Ta
bl
e 
1b
 A
ux
ol
og
ic
al
 c
ri
te
ri
a 
w
ith
 th
ei
r 
de
fin
iti
on
s,
 s
ce
na
ri
o 
pa
ra
m
et
er
s,
 in
te
rp
re
ta
tio
ns
 a
nd
 s
im
ul
at
io
n 
va
lu
es
 (p
ar
t 2
).
Sc
re
en
in
g 
ru
le
D
efi
ni
tio
n
Pa
ra
m
et
er
In
te
rp
re
ta
tio
n
Si
m
ul
at
io
n 
va
lu
es
C
on
di
tio
na
l w
ei
gh
t g
ai
n 
ru
le
†  
$
Fo
r 
ag
es
 h
1 
to
 2
.5
 y
ea
rs
, A
N
D
h 1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
SD
Sg
ai
n=
(S
D
S 2
 –
 r
 S
D
S 1
)/(
√1
-r
²) 
< 
h2
, A
N
D
h 2
C
ha
ng
e 
in
 S
D
S
-0
.5
,-
1,
-1
.5
,-
2,
-2
.5
 
SD
S 2
< 
h 3
h 3
SD
S 
cu
t o
ff 
le
ve
l b
el
ow
 w
hi
ch
 S
D
S2
 m
us
t l
ie
-1
,-
1.
3,
 -
1.
5,
-2
, -
2.
5
w
ith
 r
=(
ex
p(
2z
)-
1)
/(e
xp
(2
z)
+1
) a
nd
 
z=
2.
98
-1
.6
7l
og
(g
ap
)+
0.
25
1l
og
(m
ea
n 
ag
e)
lo
g(
ga
p)
-2
.0
6/
ga
p+
0.
59
0l
og
(m
ea
n 
ag
e)
-
0.
10
4 
(lo
g(
m
ea
n 
ag
e)
 ²)
U
nr
es
tr
ic
te
d 
co
nd
iti
on
al
 w
ei
gh
t 
ga
in
 r
ul
e†
 $
Fo
r 
ag
es
 m
1 
 to
 2
.5
 y
ea
rs
, A
N
D
m
1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 0
.5
, 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
SD
Sg
ai
n=
(S
D
S 2
 –
 r
 S
D
S 1
)/(
√1
-r
²) 
< 
m
2,
 A
N
D
m
2
C
ha
ng
e 
in
 S
D
S
-1
.5
,-
2,
-2
.5
,-
3,
-3
.5
,-
4,
-4
.5
,-
5,
-5
.5
w
ith
 r
=(
ex
p(
2z
)-
1)
/(e
xp
(2
z)
+1
) a
nd
 
z=
2.
98
-1
.6
7l
og
(g
ap
)+
0.
25
1l
og
(m
ea
n 
ag
e)
lo
g(
ga
p)
-2
.0
6/
ga
p+
0.
59
0l
og
(m
ea
n 
ag
e)
-
0.
10
4 
(lo
g(
m
ea
n 
ag
e)
 ²)
†  
 Th
is
 r
ul
e 
is
 c
al
cu
la
te
d 
fo
r 
w
ei
gh
t S
D
S.
$  
 SD
S g
ai
n 
su
m
m
ar
is
es
 th
e 
ch
ild
’s 
w
ei
gh
t g
ai
n 
ov
er
 a
 p
er
io
d 
of
 ti
m
e 
co
m
pa
re
d 
w
ith
 th
e 
ga
in
 e
xp
ec
te
d 
in
 a
n 
av
er
ag
e 
ch
ild
 o
f t
he
 s
am
e 
in
iti
al
 
w
ei
gh
t, 
m
ea
su
re
d 
at
 th
e 
sa
m
e 
tw
o 
ag
es
.
Grote_opm_H9_etc_v4.indd   123 22-01-2007   14:07:00
124
Chapter 9
n=134
n=124
n=122
n=26 screened
children
n=10 
Unknown date of starting diet
n=96  children with
clinical manifestation
n=2 
No measurement before age
2.5 years
Figure 1 Flow chart of children with CD used in the study.
Table 2 General characteristics of the CD-population.
Characteristic Screened (n=26) Unscreened (n=96)
Gender (M) 50% 35%
Ethnicity Dutch 92% 98%
Others 8% 2%
Median (range) age in years at start diet 3.96 (2.94-6.06) 1.43 (0.41-20.7)
Mean (SD) length SDS*∞ -0.26 (0.98) -0.89 (1.30)
Mean (SD) weight SDS*∞ -0.06 (0.81) -1.54 (1.15)
Mean (SD) BMI SDS*∞ 0.28 (0.57) -1.28 (1.15)
Mean (SD) weight for length SDS*∞ 0.14 (0.65) -1.23 (1.13)
Mean (SD) target height SDS 0.41 (0.92) 0.00 (0.75)
*  For the children in the screened group figures at diagnosis are given (also when 
diagnosis is after 2.5 years of age). For the unscreened children figures at the start of 
diet are given.
∞  Based on children with at least one measurement between 6 months before or 3 months 
after diet or diagnosis. 
We tested the performance of all rules in distinguishing between the CD groups from the 
reference group. Sensitivity was almost similar to 1-specificity (the false-positive rate) for 
the group of CD children detected by screening. This indicates that the growth pattern 
of these patients does not differ much from the reference population. Figure 2 shows the 
ROC plots for the three best rules of the clinically suspected children with CD (groups 
2 and 3). Only scenarios with a false-positive rate of less than 10% are plotted. The line 
for which sensitivity is equal to 1-specificity is given in the plot. Seventeen percent of 
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the CD children and almost none of the reference children have a change in BMI SDS of 
at least -1.5 from the age of 1 year. Thirty-seven percent of the CD children and 3.3% of 
the reference children have a deflection of at least -2.5 BMI SDS per year and a BMI SDS 
below -1 after the age of 0.5 year.
1-specificity (%)
se
ns
it
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it
y 
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)
0 2 4 6 8 10
0
20
40
60
80
100
BMI deflection rule
BMI delta rule
weight deflection rule
Figure 2 ROC plots of the three best auxological screening rules for the detection of CD 
in the unscreened groups (group 2 and 3). The rules are a deflection in BMI or weight 
SDS/year in combination with a BMI or weight SDS below some simulation value, and an 
absolute change in BMI SDS.
The properties of the three best rules for group 2 and 3, in terms of sensitivity and PPV 
at approximately 98% specificity, are presented in table 3. Thirty-four percent of the 
CD children and 2% of the reference children have a deflection in BMI SDS of at least 
-2.5 per year and a BMI SDS below -1.3 from the age of 0.5 year. In children with such 
deflection in BMI SDS the prior-probability of CD is 0.86%. After 0.5 year of age, 27% 
of the CD children versus 2% of the reference children have a BMI SDS change of -1.5. 
The weight deflection rule results in a sensitivity of 20% at a specificity level of 98%, and 
this result is similar for the conditional weight gain rule. For a higher specificity level, the 
weight deflection rule is slightly better than the conditional weight gain rule (18% versus 
16% for 98.5% specificity).
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Table 3 Properties of the best scenarios with approximately 2% false-positives 
(=98% specificity).
(unscreened) CD Simulation values Sensitivity 1-Specificity PPV
BMI deflection rule e1=0.5 f =-1.3 g1=-2.5 33.9% 2.1% 0.86%
BMI delta rule e3=0.5 w=-1.5 27.0% 1.9% 0.76%
weight deflection rule e1=0.5 f =-2.5 g1=-0.5 to -1 19.7% 1.9% 0.56%
Discussion
This study shows that the overall performance of detecting CD with auxological criteria is 
modest. The auxological criteria hardly discriminate between the screened CD group and 
the reference group. In the patients with clinical suspicion of CD, rules that consider a 
change or deflection in BMI or weight SDS show the best performance.
The conditional weight gain rule is based on the concept of regression to the mean. The 
amount of regression to the mean depends on how highly correlated the weights are at the 
ages.12 The correlations of the weights we used in this study are based on the UK 1990 
weight reference.20 To validate if these correlations can also be applied to Dutch children, 
we calculated if SDSgain has a mean of zero and a SD of 1, and if it is uncorrelated with 
the first weight SDS. For the reference group of Dutch children, the mean (SD) SDSgain 
is -0.05 (1.38) and its correlation with the first weight SDS is -0.22. As both SD and 
correlation are quite high, the conditional weight gain rule might perform better when 
using Dutch correlations of weights. However, at the moment these correlations are not 
available.
The CD data in our study were gathered retrospectively meaning that there was no fixed 
schedule of measurements in the CD-patients, resulting in a wide variation in the number 
of measurements between the individual patients. We tried to minimize the problem 
by gathering extra information about growth from school doctors in the Regional health 
centres, where nearly every child in the Netherlands is monitored for height and weight 
from birth till the age of 16-18 years.
As Csizmadia et al. reported earlier, the children with CD detected by screening had a 
normal weight and length at time of diagnosis.5 We have now shown that all children in 
this group indeed had a normal growth pattern before diagnosis, which corresponds with 
the asymptomatic character of this silent form of CD. Therefore auxology seems not useful 
for the detection of silent CD.
Most of the patients in our study were females, as was reported in several other studies.16 
Bardella et al. hypothesized that males escape diagnosis, but that the two sexes are 
equally affected. This hypothesis is supported by the absence of differences in gender in 
the screening study (see table 2).
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CD is often atypical or clinically silent and many children remain undiagnosed. 
However, since the widespread use of serologic testing and the increased awareness of 
CD in the late 1990s there has been an increase in incidence and a change in clinical 
presentation.17, 18 Classical symptoms, like malabsorption and poor weight gain tend to 
start between the ages of 6-24 months and do no longer dominate the clinical picture. 
Instead, there is an increase of non-classical symptoms such as unusual intestinal 
complaints or extra-intestinal symptoms like short stature, involving older children.20 
Since our non-screened population was diagnosed before 1995, we were not able to study 
the effect of this change in clinical presentation on the performance of the auxological 
criteria. One may however assume that in the age-group studied in the present study the 
performance of the auxological criteria is similar for the present CD-population, since it 
is especially the delayed onset of the disease (the non-classical form) that has increased 
during the recent years, suggesting that the growth impairment becomes apparent much 
later.
In conclusion, the efficacy of growth monitoring for the detection of CD is modest in the 
first 2.5 years. As there is a high incidence of CD in children with growth retardation, the 
clinician may however consider testing for CD in a diagnostic work-up in young children 
with failure to thrive. The most sensitive auxological parameter is the deflection in BMI 
SDS.
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What is already known on this topic?
CD is a gluten-sensitive enteropathy, characterized by subtotal villous atrophy of the small 
intestine. In the Netherlands, the incidence of clinically diagnosed CD was 0.54 per 1000 
live births. Length (or height) deficit and poor weight gain may be the earliest signs of the 
disease.
What this study adds
As far as we know, this is the first large evidence-based investigation on various types of 
auxological referral criteria for detecting children with CD.
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Abstract
Aim: To study the diagnostic efficiency of several auxological criteria for the detection of 
Cystic fibrosis (CF).
Method: We studied the performance of various criteria concerning length, weight and 
body mass index (BMI), using longitudinal length and weight measurements up to 2.5 
years of age from CF patients visiting three major CF clinics (n=216) and a reference 
group obtained from the Social Medical Survey of Children Attending Child Health 
Clinics (SMOCC) cohort (n=2,151) in The Netherlands.
Results:  Within the first year weight is a better auxological tool for detecting CF than 
length.. At a false positive rate of 3 percent,  45% of children diagnosed within 1 year can 
be detected by weight Standard Deviation Score (SDS) deflection of -0.20 to -0.50 per year 
combined with a weight SDS below -2.5 (Positive predicted value (PPV)= 0.6%). Similarly 
28% of children diagnosed after 1 year can be detected by BMI SDS deflection of –1 
disregarding the time interval (PPV = 0.4%).
Conclusion: In the absence of a newborn screening program for CF, weight SDS deflection 
of -0.2 to -0.5 per year combined with weight SDS below -2.5 has the highest PPV for 
infants and BMI SDS decrease of -1 for older children.
 
Keywords: growth retardation, failure to thrive, Cystic Fibrosis, screening, early childhood
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Introduction
Cystic fibrosis (CF) is one of the most common life-threatening autosomal recessive 
diseases in the Caucasian population, and early diagnosis is of great importance. Mostly 
symptoms start at an early age and include failure to thrive, persistent bronchopulmonary 
infections and exocrine pancreas insufficiency with malabsorption as a result.1 The 
estimated incidence varies worldwide from 0.25 to 5 per 10.000 life births.2 In Caucasian 
European newborns the incidence is 1:2000-3000 whereas in Caucasian North American 
newborns it is about 1:3500.3 Although symptoms start at an early age, CF is not always 
timely diagnosed, because its presentation is variable.4 In several countries Newborn 
screening (NBS) programs for CF have been introduced. In areas where there is no NBS 
program the diagnosis is made at an average age of 2 years.1 In these countries growth 
monitoring is assumed to be instrumental in the early detection of at least part of the CF-
population, since most of the CF-patients have presenting symptoms like failure to thrive 
and some even have failure to thrive as the only symptom.1, 5-9
Growth assessment is accepted worldwide and generally implemented in child health care 
systems although sufficient data to support this activity are lacking.10 A diversity in the 
growth monitoring process and the diagnostic work-up of growth disorders is noticeable in 
industrialised countries.11 Only a few guidelines have been published on referral criteria 
and diagnostic work-up for children with impaired growth.12, 13 These guidelines emphasize 
height more than weight and are based on consensus meetings rather than on experimental 
evidence. Even for failure to thrive, often used in infancy and early childhood to describe 
growth impairment, consensus on the choice of anthropometric indicators or their criteria 
for abnormality is lacking.14 Recently, Van Buuren et al reported on the predictive value of 
various auxological criteria for the detection of Turner syndrome.15 The present study aims 
to explore the diagnostic efficiency of several auxological criteria (including both weight and 
length) for the detection of children with CF.
Method
Material
Longitudinal length- and weight measurements were collected retrospectively from 
CF patients visiting three major CF clinics in The Netherlands: Erasmus MC - Sophia 
Children’s Hospital in Rotterdam (n=166), University Hospital Maastricht (n=30) and 
Juliana Children’s Hospital in The Hague (n=20). The data were collected from existing 
patient data files. Additional data were obtained, with permission from the patient or his or 
her parents, from the school doctors in the regional health centres.
The following information was obtained: date of birth, date of diagnosis, gender, ethnicity, 
perinatal information (birth weight, length, gestation), date of diagnosis of CF, DNA-
mutation and height of biological parents. If the ethnicity was not recorded, it was 
assessed based on the patient’s first and family name according to an algorithm reported 
earlier.16
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A reference sample was obtained from the Social Medical Survey of Children Attending 
Child Health Clinics (SMOCC) cohort, a nationally representative cohort of 2,151 children 
born in the Netherlands in 1988-1989.17 This cohort consists of longitudinal data of 
length and weight up to the age of 2.5 years. Length and weight from birth to two years 
were previously described by Herngreen et al.18
Screening rules
For this study we formulated seven auxological rules for screening, that could serve as 
criteria for referral to specialist care. We started with the three archetypal rules of which 
the diagnostic performance to detect Turner’s syndrome was reported by Van Buuren 
et al.15  The first rule was the absolute Height Standard Deviation Score (HSDS) 
rule, which would lead to referral of a child if HSDS is lower than some simulation 
value. The second rule took genetic height potential into account by comparing the 
HSDS of the child to its target height in combination with a HSDS below some simulation 
value (parental height corrected rule). The third rule signalled whether an abnormal 
deflection in height occurs in terms of change in HSDS per year in combination with a 
HSDS below some simulation value (deflection rule).
The present study expands these screening rules with analogical absolute SDS rules 
for weight, BMI and weight for length (i.e. refer when weight, BMI, weight for length 
respectively is lower than some simulation value), an analogical deflection rule for weight 
(i.e. refer when a change in weight SDS per year occurs and weight SDS is below some 
simulation value) and four other rules. The first of these other rules is a deflection rule 
that detects a child with a deflection in length or weight SDS/year without the restriction 
of having an SDS below some value (deflection rule 2). The second rule refers if a 
change in SDS occurs disregarding time (delta rule). The third rule signals whether a 
deflection moves away from the child’s target height (parental height deflection rule). 
The fourth rule is the combined weight and length deflection rule in which a deflection 
in length occurs after a deflection in weight. Table 1 shows the definitions, parameters, 
interpretations and simulation values of the rules.
Each screening rule was implemented using S-Plus version 7.0, and was applied to the 
longitudinal data of children. We calculated sensitivity, specificity and positive predictive 
value (PPV) of different scenarios (a combination of parameters). The rules were ordered 
according to their sensitivity at high levels of specificity. A higher sensitivity at the same 
level of specificity, results in a better performance. Receiver Operating Characteristic 
(ROC) curves were constructed for the four best screening rules. Scenarios of rules with 
approximately 3% false-positive rate will be presented in detail as we assume that a 
false-positive rate of more than 3% would lead to too many referrals. PPV was calculated 
assuming that the average incidence of CF is 1:3000 in the Caucasian population.3
Statistical analysis
Length, weight, target height, body mass index (BMI) and weight for length were expressed 
as SDS, using the Dutch reference growth data.19, 20 In preterm infants (gestational age < 
37 weeks) length and weight SDS were corrected for gestational age. The intrauterine 
Grote_opm_H9_etc_v4.indd   134 22-01-2007   14:07:10
135
The value of auxological screening for Cystic Fibrosis
Ta
bl
e 
1 
A
ux
ol
og
ic
al
 c
ri
te
ri
a 
w
ith
 th
ei
r 
de
fin
iti
on
s,
 s
ce
na
ri
o 
pa
ra
m
et
er
s,
 in
te
rp
re
ta
tio
ns
 a
nd
 s
im
ul
at
io
n 
va
lu
es
Sc
re
en
in
g 
ru
le
D
efi
ni
tio
n
Pa
ra
m
et
er
In
te
rp
re
ta
tio
n
Si
m
ul
at
io
n 
va
lu
es
A
bs
ol
ut
e 
SD
S 
ru
le
▲
Fo
r 
ag
es
 0
 to
 p
 y
ea
rs
, r
ef
er
 if
 S
D
S 
< 
a,
 A
N
D
a
SD
S 
re
fe
rr
al
 le
ve
l b
ef
or
e 
ag
e 
p
-1
,-
1.
3,
 -
1.
5,
 -
2,
 -
2.
5,
 -
3,
 -
3.
5
Fo
r 
ag
es
 p
 to
 2
.5
 y
ea
rs
, r
ef
er
 if
 S
D
S 
< 
b
b
SD
S 
re
fe
rr
al
 le
ve
l a
fte
r 
ag
e 
p
-1
, -
1.
3,
  -
1.
5,
 -
2,
 -
2.
5,
 -
3
p
A
ge
 (i
n 
ye
ar
s)
 a
t w
hi
ch
 th
e 
re
fe
rr
al
 le
ve
l c
ha
ng
es
0,
 1
Pa
re
nt
al
 h
ei
gh
t 
co
rr
ec
te
d 
ru
le
Fo
r 
ag
es
 x
 to
 2
.5
 y
ea
rs
, r
ef
er
 if
 
x
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
Le
ng
th
 S
D
S 
< 
c,
 A
N
D
c
C
ut
 o
ff 
le
ve
l b
el
ow
 w
hi
ch
 le
ng
th
 S
D
S 
m
us
t l
ie
-1
, -
1.
3,
 -
1.
5,
 -
2,
 -
2.
5
Le
ng
th
 S
D
S 
– 
TH
 S
D
S 
< 
d
d
D
iff
er
en
ce
 b
et
w
ee
n 
le
ng
th
 S
D
S 
an
d 
ta
rg
et
 h
ei
gh
t S
D
S
-1
, -
1.
3,
 -
1.
5,
 -
2,
 -
2.
5
de
fle
ct
io
n-
ru
le
 1
‡
Fo
r 
ag
es
 e
1 
to
 2
.5
 y
ea
rs
, A
N
D
 
e 1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
X
2 
– 
X
1 
≥ 
1/
12
 r
ef
er
 if
M
in
im
al
 o
ne
 m
on
th
 in
te
rv
al
 b
et
w
ee
n 
ag
es
 X
1 
an
d 
X
2
SD
S 2
< 
f, 
A
N
D
f
SD
S 
cu
t o
ff 
le
ve
l b
el
ow
 w
hi
ch
 S
D
S 2
 m
us
t l
ie
-1
,-
1.
3,
 -
1.
5,
-2
, -
2.
5
(S
D
S 2
- 
SD
S 1
)/(
X
2-
X
1)
 <
 g
1
g 1
C
ha
ng
e 
in
 S
D
S 
pe
r 
ye
ar
-0
.2
0,
-0
.2
5,
-0
.3
3,
 -
0.
50
,-
1,
-1
.5
,-
2,
-2
.5
de
fle
ct
io
n-
ru
le
 2
‡
Fo
r 
ag
es
 e
2 
 to
 2
.5
 y
ea
rs
, A
N
D
 
e 2
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
X
2 
– 
X
1 
≥ 
1/
12
 r
ef
er
 if
M
in
im
al
 o
ne
 m
on
th
 in
te
rv
al
 b
et
w
ee
n 
ag
es
 X
1 
an
d 
X
2
(S
D
S 2
 –
 S
D
S 1
)/(
X
2-
X
1)
 <
 g
2
g 2
C
ha
ng
e 
in
 S
D
S 
pe
r 
ye
ar
-0
.2
0,
-0
.2
5,
-0
.3
3,
 -
0.
50
,-
1,
-1
.5
,-
2,
-2
.5
de
lta
-r
ul
e▲
Fo
r 
ag
es
 e
3 
 to
 2
.5
 y
ea
rs
, A
N
D
 
e 3
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
(S
D
S 2
 –
 S
D
S 1
) <
 w
w
A
bs
ol
ut
e 
ch
an
ge
 in
 S
D
S
-0
.5
0,
-1
,-
1.
5,
-2
,-
2.
5,
-3
Pa
re
nt
al
 h
ei
gh
t 
de
fle
ct
io
n 
ru
le
Fo
r 
ag
es
 k
1 
 to
 2
.5
 y
ea
rs
, A
N
D
k 1
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
X
2 
> 
X
1 
 r
ef
er
 if
A
ge
 X
2 
 a
fte
r 
X
1
(L
en
gt
h 
SD
S 2
 –
 L
en
gt
h 
SD
S 1
) <
 n
1,
 A
N
D
n 1
Le
ng
th
 v
el
oc
ity
 c
ha
ng
e 
in
 H
SD
S 
-0
.5
0,
-1
,-
1.
5,
-2
,-
2.
5,
-3
| L
en
gt
h 
SD
S 2
 –
 T
H
 S
D
S 
| >
| L
en
gt
h 
SD
S 1
 –
 T
H
 S
D
S 
| 
Le
ng
th
 S
D
S 
at
 a
ge
 X
1 
is
 c
lo
se
r 
to
 it
’s 
ta
rg
et
 h
ei
gh
t t
ha
n 
Le
ng
th
 S
D
S 
at
 a
ge
 X
2
C
om
bi
ne
d 
w
ei
gh
t a
nd
 
le
ng
th
 d
efl
ec
tio
n 
ru
le
Fo
r 
ag
es
 k
2 
 to
 2
.5
 y
ea
rs
, A
N
D
k 2
A
ge
 (i
n 
ye
ar
s)
 a
fte
r 
w
hi
ch
 th
e 
ru
le
 is
 e
ffe
ct
iv
e
0,
 1
X
3 
>  
X
2 
> 
X
1,
 A
N
D
A
ge
 X
3 
af
te
r 
X
2 
, X
2 
af
te
r 
X
1 
(a
ge
s 
fo
r 
w
ei
gh
t)
Y
3 
>  
Y
2 
> 
Y
1,
 r
ef
er
 if
A
ge
 Y
3 
af
te
r 
Y
2 
, Y
2 
af
te
r 
Y
1 
(a
ge
s 
fo
r 
le
ng
th
)
(W
ei
gh
t S
D
S 2
 –
 W
ei
gh
t S
D
S 1
)<
 n
2,
 A
N
D
n 2
A
bs
ol
ut
e 
w
ei
gh
t c
ha
ng
e 
in
 W
ei
gh
t S
D
S 
-0
.1
,-
0.
25
,-
0.
5,
-1
,-
1.
5,
-2
(L
en
gt
h 
SD
S 2
 –
 L
en
gt
h 
SD
S 1
) <
 n
3,
 A
N
D
n 3
A
bs
ol
ut
e 
le
ng
th
 c
ha
ng
e 
in
 L
en
gt
h 
SD
S 
-0
.1
,-
0.
25
,-
0.
5,
-1
,-
1.
5,
-2
Y
1 
> 
X
1 
St
ar
tin
g 
po
in
t l
en
gt
h 
de
fle
ct
io
n 
af
te
r 
st
ar
tin
g 
po
in
t 
w
ei
gh
t d
efl
ec
tio
n
▲
 T
he
 r
ul
e 
is
 th
e 
ca
lc
ul
at
ed
 fo
r 
le
ng
th
, w
ei
gh
t, 
B
M
I 
an
d 
w
ei
gh
t f
or
 le
ng
th
 S
D
S.
‡  
 T
he
se
 d
efl
ec
tio
n 
ru
le
s 
w
er
e 
ca
lc
ul
at
ed
 fo
r 
le
ng
th
 a
nd
 w
ei
gh
t S
D
S.
Grote_opm_H9_etc_v4.indd   135 22-01-2007   14:07:12
136
Chapter 10
growth curve of the Swedish reference population.21 was used to express SDS till the age 
corresponding with 40 weeks of gestation. Between 40 and 42 weeks an interpolation 
between the growth curve of the Swedish reference population and that of the Dutch 
reference population was used. From 42 weeks of gestation till the age of 2 years, SDS was 
calculated on ages corrected for gestation, using the Dutch reference growth data.
Parental height was missing in 31% of the CF-patients. We imputed these data under 
the assumption that the data were missing at random using Multivariate Imputation by 
Chained Equations (MICE).22 The method created multivariate imputations by applying 
sequential linear regressions, where each incomplete variable was imputed conditionally 
on all variables in an iterative fashion. The imputation model consisted of the height 
SDS at the age of 5 years (or closest to the age of 5 years), weight SDS, weight for height 
SDS, BMI SDS, age, age at diagnosis, gender,  the height of the other parent and hospital. 
Height SDS at the age of 5 was chosen for the imputation model, because in most children 
the catch-up growth has resulted in a normal height at this age.23 The number of iterations 
was set to 15. Predictive mean matching was used to create parental height imputations. 
The imputation method includes parameter uncertainty, preserves the multivariate 
structure in the data and has good coverage properties.24
We divided the CF-population into a group diagnosed within 1 year and a group diagnosed 
after 1 year and compared this with two different datasets from the reference group (one 
with data up to 1 year of age and one with data up to 2.5 years of age). This was done to 
minimize the variation in number of measurements between CF children caused by the 
variability in age at diagnosis.
Calculations were based on the assumption that a child is referred if the growth pattern 
meets the criteria of a given screening rule for the first time. All rules were dealt with 
separately, meaning that the same child could be referred according to each separate 
rule. The analyses were done separately for children, who were diagnosed before the age 
of 1 year and for children who were diagnosed after the age of 1 year. Children diagnosed 
before the age of 1 year were compared with the reference sample with measurements up 
to 1 year of age.
Results
From the 216 children with CF, 93 were excluded from the analyses because of missing 
data (see figure 1). Almost 80% of the children are diagnosed within 2.5 years of age. 
Table 2 contains general characteristics of the CF group. Mean SDS for weight was 
compromised most, followed by an index of weight for length (weight-for-length or Body 
Mass Index (BMI)) and length SDS.
We tested the performance of all rules in distinguishing between the CF group and the 
reference group. ROC plots of scenarios under the four best rules (according to their 
sensitivity and specificity) are shown in figure 2. Only scenarios with a false-positive rate 
of less than 10% are plotted. The line for which sensitivity is equal to 1-specificity 
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n=216
n=208
n=132
n=123
n=8 
Unknown date of diagnosis
n=76 
No measurement before 
or at diagnosis
n=9 
No measurement before 
2.5 years
Figure 1 Flow chart of children with CF used in the study.
Table 2 General characteristics of the CF-population.
Characteristic
Gender (M) 51%
Ethnicity Dutch/European 91%
Turkish 2%
Moroccan 1%
Others 4%
Unknown 2%
Median (range) age in years at time of diagnosis   0.59 (0-15)
Mean (SD) length SDS at time of diagnosis∞ -1.08 (1.13)
Mean (SD) weight SDS at time of diagnosis∞ -1.60 (1.35)
Mean (SD) BMI SDS at time of diagnosis∞ -1.13 (1.79)
Mean (SD) weight for length SDS at time of diagnosis∞ -1.31 (1.74)
Mean (SD) target height SDS 0.21 (0.64)
DNA Homozygous for dF508 47.2%
Heterozygous for dF508* 20.3%
Others* 3.3 %
Unknown 29.3%
*  mutations other than dF508 were: ‘A455E’, ‘G542X’, ‘N1303K’, ‘R1162X’, ‘R553X’, 
‘1717-1G>A’  ‘IVS17bTA’, ‘Q552P’, ’R1066C’,  ‘S1251N’, ‘G542x’, ‘1677d’, ‘G178R’, 
‘Q493X’ and ‘3659delC’.
∞  Based on children with at least one measurement between 6 months before or 3 months 
after diagnosis.
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is given in the plots. The ROC curves show that the performance of the rules of children 
with CF diagnosed within 1 year (Figure 2A) is better than that of children diagnosed 
after 1 year (Figure 2B). The length deflection rule, BMI delta rule and absolute weight 
SDS rule result in a sensitivity of 18-26% at a specificity level of 99% for the CF group 
diagnosed within 1 year. For the CF group diagnosed after 1 year, the BMI delta rule and 
the absolute BMI SDS rule show a sensitivity of 23% at a specificity of 98.3%.
1-specificity (%)
0 2 4 6 8 10
weight deflection rule 1
length deflection rule 1
BMI delta rule
absolute weight SDS rule
1-specificity (%)
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length deflection rule 1
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Figure 2 ROC plots of the four best auxological screening rules for the detection of CF.  
A. Optimal ROC curves for CF diagnosed < 1 year. The rules are a deflection in weight or 
length SDS per year in combination with a weight or length SDS below some simulation 
value, an absolute change in BMI SDS, and a weight SDS below a value.
B. Optimal ROC curves for CF diagnosed >= 1 year. The rules are an absolute change in 
BMI SDS, a deflection in length SDS per year in combination with length SDS below some 
simulation value, and a BMI or weight SDS below a value.
The properties of the four best rules, in terms of sensitivity and PPV at approximately 
97% specificity, are presented in table 3. The upper part shows the results of the children 
with CF diagnosed within 1 year and a reference group with measurements until the age of 
1 year. Almost 45% of the CF children diagnosed within 1 year and 2.6% of the reference 
children have a weight SDS below -2.5 and a change in weight SDS per year between 
0.2 and 0.5 (weight deflection rule 1:  e1=0, f=-2.5 and g1=-0.2 to -0.5). In children with 
such change in weight SDS the prior-probability of CF is 0.57%. When this rule would be 
applied, median referral age would be 0.19 years, which is on average 1.3 months earlier 
than the real age of diagnosis.
The lower part of table 3 shows the results of the rules of children with CF diagnosed after 
the age of one year and all measurements of the reference children. Almost 28% of the 
CF children diagnosed after the age of one year and approximately 2.5% of the reference 
children have a change in BMI SDS of at least -1 between 1 and 2.5 years (BMI delta rule: 
e3=1,w=-1), resulting in a PPV of 0.37%. Median referral age would then be 2.0 years, 
which is 21 months earlier than the observed age at diagnosis. The length deflection rule 
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and the absolute BMI and weight SDS rule result in a sensitivity between 28 to 30% at a 
specificity level between 96.4 and 96.9%.
Table 3 Properties of the best scenarios with approximately 3% false-positives (=97% 
specificity).
CF diagnosed < 1 year Simulation values Sensitivity Specificity PPV
Weight deflection rule 1 e1=0 f=-2.5 g1= -0.20 to -0.50 44.8% 97.4% 0.57%
Length deflection rule 1 e1=0 f=-2 g1= -2 33.3% 97.5% 0.44%
BMI delta rule e3=0 w=-2.5 37.5% 96.6% 0.37%
Absolute weight SDS rule a=all b=-2.5 p=0 31.6% 97.0% 0.35%
CF diagnosed >= 1 year Simulation values Sensitivity Specificity PPV
BMI delta rule e3=1 w=-1 27.6% 97.5% 0.37%
Length deflection rule 1 e1=0 f=-2 g1= -2.5 28.9% 96.9% 0.31%
Absolute BMI SDS rule a=-3 b=-2 p=1 27.9% 96.9% 0.30%
Absolute weight SDS rule x=-2.5 c=-3 d=1 29.8% 96.4% 0.28%
Discussion
We studied if auxological criteria can be of practical value for the detection of cystic 
fibrosis (CF) and showed that the overall performance of detecting CF with such 
parameters is moderate. Especially in the first year of life, weight seems to be a better 
auxological tool for the detection of CF than length and deflection is more important 
than a single measurement. Almost 45% of the CF children diagnosed within 1 year 
would be detected by a certain weight deflection (PPV = 0.57%) and almost 28% of the 
CF children diagnosed after 1 year by an absolute change in BMI SDS (PPV = 0.37%). 
The performance of the rules of children with CF diagnosed within the first year of life is 
better than that of children diagnosed later. The better performance of the rules in infants 
than in older children may be associated with the higher likelihood of being diagnosed 
sooner when the disease is more severe.
Growth status at the time of diagnosis of CF, as well as methods to classify failure to thrive 
have previously been described, but results vary widely, partially due to the diversity in 
criteria used.25-27 In agreement with other studies we found an abnormal mean absolute 
length and weight at time of diagnosis.7, 28-32 Based on these studies we estimated that the 
predictive value of such criteria is limited.33 By gathering longitudinal growth data of CF-
patients before diagnosis, we were able to study not only growth status at certain moments 
but also the deflection of the growth curve.
The CF data in our study were collected retrospectively, which implies that there was 
no fixed schedule of measurements in the CF-patients, resulting in a wide variation in 
the number of measurements between the individual patients. We tried to minimize the 
problem by gathering additional information about growth from school doctors in the 
“Regional health centres”, where nearly every child in the Netherlands is monitored 
for height and weight from birth till the age of 16-18 years. The data can therefore be 
considered as representative of the situation in daily practice.
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Newborn screening has shown beneficial effects on the prognosis of CF and has been 
implemented in several countries.34-36 In the absence of a newborn screening program, 
however, the clinician may consider to test for CF in a diagnostic work-up in children 
with failure to thrive, since CF is a severe disease representing itself sometimes with 
monosymptomatic FTT and still up to 45% of the children can be detected within the first 
year using auxology. In this case the observation of weight impairment is more useful than 
length impairment and deflection of the growth curve is a relevant parameter.
A weight SDS deflection of -0.20 to -0.50 per year in combination with a weight SDS 
below -2.5 has the highest PPV for children under the age of one year and a BMI SDS 
decrease of -1 for older children. These screening rules can form the basis for future 
computer algorithms in child welfare clinics.
Acknowledgements
We acknowledge Wendelien Planten for her great contribution to the study,  
all the members of the CF team of the ErasmusMC - Sophia Children’s Hospital,  
with Dr. H.A.W.M. Tiddens as coordinator, for gathering the information, Dorien Holtslag 
for her help gathering all information in Maastricht. This publication was supported by an 
educational grant from Pfizer.
Grote_opm_H9_etc_v4.indd   140 22-01-2007   14:07:16
141
The value of auxological screening for Cystic Fibrosis
References
1.  Giglio L, Candusso M, D’Orazio C, Mastella G, Faraguna D. Failure to thrive: the earli-
est feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr 
1997;86:1162-5.
2.  Lewis PA. The epidemiology of cystic fibrosis. In Hodson ME, Geddis DM, eds. Cystic fibro-
sis, pp 1-13. London: Chapman & Hall, 1995.
3.  Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of 
CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 
2002;19:575-606.
4.  Kharrazi M,.Kharrazi LD. Delayed diagnosis of cystic fibrosis and the family perspective. J 
Pediatr 2005;147:S21-S25.
5.  Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respi-
ratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 
1995;310:1571-2.
6.  Oliveira MC, Reis FJ, Chagas AJ, Brasileiro FG, Bahia M, Silva LD, Penna FJ. [Study of 
intestinal malabsorption diseases as cause of monosymptomatic short stature]. J Pediatr (Rio J 
) 1998;74:213-6.
7.  Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S, Castle R, Dinwiddie R, Hoo 
AF, Lum S, Price J, Stroobant J, Wallis C. The evolution of airway function in early childhood 
following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2004;169:928-33.
8.  Tepper RS, Hiatt P, Eigen H, Scott P, Grosfeld J, Cohen M. Infants with cystic fibrosis: pulmo-
nary function at diagnosis. Pediatr Pulmonol 1988;5:15-8.
9.  Wesley AW, Horne AM, Elliott RB. Problems in diagnosis of cystic fibrosis. N Z Med J 
1984;97:773-5.
10.  Garner P, Panpanich R, Logan S. Is routine growth monitoring effective? A systematic review 
of trials. Arch Dis Child 2000;82:197-201.
11.  Grote FK, Oostdijk W, de Muinck Keizer-Schrama SMPF, Dekker FW, Verkerk PH, Wit JM. 
Growth monitoring and diagnostic work-up of short stature: an international inventorisation. J 
Pediatr Endocrinol Metab 2005;18:1031-8.
12.  Hall DM. Growth monitoring. Arch Dis Child 2000;82:10-5.
13.  de Muinck Keizer-Schrama SM. [Consensus ‘diagnosis of short stature in children.’ National 
Organization for Quality Assurance in Hospitals]. Ned Tijdschr Geneeskd 1998;142:2519-25.
14.  Wilcox WD, Nieburg P, Miller DS. Failure to thrive. A continuing problem of definition. Clin 
Pediatr (Phila) 1989;28:391-4.
15.  van Buuren S, van Dommelen P, Zandwijken GR, Grote FK, Wit JM, Verkerk PH. Towards 
evidence based referral criteria for growth monitoring. Arch Dis Child 2004;89:336-41.
16.  Landsmeer-Beker EA, Bouwmeester-Landweer MBR, Korbee-Haverhoek HD, Kousemaker 
NPJ, Baartman HEM, Wit JM, Dekker FW. Non-response on a postal questionnaire adressing 
risk factors for child maltreatment. In: Bouwmeester-Landweer MBR.  Early home visitation 
in families at risk for maltreatment. Thesis, Leiden University Medical Center, 2006
17.  Herngreen WP, Reerink JD, van Noord-Zaadstra B.M., Verloove-Vanhorick SP, Ruys JH. The 
SMOCC-study: Design of a representative cohort of live-born infants in the Netherlands. Eur J 
Public Health 1992;2:117-22.
18.  Herngreen WP, van Buuren S, van Wieringen JC, Reerink JD, Verloove-Vanhorick SP, Ruys 
JH. Growth in length and weight from birth to 2 years of a representative sample of Neth-
erlands children (born in 1988-89) related to socioeconomic status and other background 
characteristics. Ann Hum Biol 1994;21:449-63.
19.  Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede 
MJ, Verloove-Vanhorick SP, Wit JM. Continuing positive secular growth change in The Neth-
erlands 1955-1997. Pediatr Res 2000;47:316-23.
Grote_opm_H9_etc_v4.indd   141 22-01-2007   14:07:17
142
Chapter 10
20.  Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index measurements in 
1996-7 compared with 1980. Arch Dis Child 2000;82:107-12.
21.  Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the 
Swedish reference standards for weight, length and head circumference at birth for given 
gestational age (1977-1981). Acta Paediatr Scand 1991;80:756-62.
22.  van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure 
covariates in survival analysis. Stat Med 1999;18:681-94.
23.  Karlberg J, Kjellmer I, Kristiansson B. Linear growth in children with cystic fibrosis. I. Birth 
to 8 years of age. Acta Paediatr Scand 1991;80:508-14.
24.  Brand J, van Buuren S, van Mulligen EM, Timmers T, Gelsema E. Multiple imputation as a 
missing data machine. Proc Annu Symp Comput Appl Med Care 1994;303-6.
25.  Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, Shen G, Walker S, 
Farrell PM. Growth status in children with cystic fibrosis based on the National Cystic Fibro-
sis Patient Registry data: evaluation of various criteria used to identify malnutrition. J Pediatr 
1998;132:478-85.
26.  Raynor P,.Rudolf MC. Anthropometric indices of failure to thrive. Arch Dis Child 
2000;82:364-5.
27.  Wright JA, Ashenburg CA, Whitaker RC. Comparison of methods to categorize undernutrition 
in children. J Pediatr 1994;124:944-6.
28.  Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, 
Splaingard ML. Early diagnosis of cystic fibrosis through neonatal screening prevents severe 
malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening 
Study Group. Pediatrics 2001;107:1-13.
29.  Haeusler G, Frisch H, Waldhor T, Gotz M. Perspectives of longitudinal growth in cystic fibro-
sis from birth to adult age. Eur J Pediatr 1994;153:158-63.
30.  Kraemer R, Aebi C, Casaulta AC, Gallati S. Early detection of lung disease and its associa-
tion with the nutritional status, genetic background and life events in patients with cystic 
fibrosis. Respiration 2000;67:477-90.
31.  Waters DL, Wilcken B, Irwing L, Van Asperen P, Mellis C, Simpson JM, Brown J, Gaskin KJ. 
Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 
1999;80:F1-F7.
32.  Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in 
infants with cystic fibrosis. J Pediatr 2005;147:S37-S41.
33.  Grote F.K., Planten W.A., Oostdijk, W., Dekker, F. W., and Wit, J. M. The probability of Cystic 
Fibrosis in infants and children with failure to thrive. Arch Dis Child . 2006.  In Press
34.  Lai HJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fibrosis diagnosed 
through neonatal screening: evidence from the United States Cystic Fibrosis Foundation 
registry data. J Pediatr 2005;147:S57-S63.
35.  Sims EJ, McCormick J, Mehta G, Mehta A. Neonatal screening for cystic fibrosis is beneficial 
even in the context of modern treatment. J Pediatr 2005;147:S42-S46.
36.  Dankert-Roelse JE,.Merelle ME. Review of outcomes of neonatal screening for cystic fibrosis 
versus non-screening in Europe. J Pediatr 2005;147:S15-S20.
Grote_opm_H9_etc_v4.indd   142 22-01-2007   14:07:17
143
The value of auxological screening for Cystic Fibrosis
Grote_opm_H9_etc_v4.indd   143 22-01-2007   14:07:18
Grote_opm_H9_etc_v4.indd   144 22-01-2007   14:07:18
Part E
Radiographic evaluation
Grote_opm_H9_etc_v4.indd   145 22-01-2007   14:07:23
Grote_opm_H9_etc_v4.indd   146 22-01-2007   14:07:23
Radiographic evaluation of children with 
growth disorders
S.G. Kant1, F. Grote2, M.H. de Ru1,2, W. Oostdijk2, H.M. Zonderland3, M.H. Breuning1, J.M. Wit2
1 Center for Human and Clinical Genetics, Department of Clinical Genetics
2 Department of Pediatrics
3 Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Submitted
Chapter 11
Grote_opm_H9_etc_v4.indd   147 22-01-2007   14:07:27
148
Chapter 11
Abstract
Short stature as well as tall stature can have a wide variety of causes. Tall stature is 
usually experienced as a less important problem than short stature, but for both clinical 
presentations it is important to make a correct diagnosis as to etiology. The identification 
of the diagnosis frequently relies on radiological criteria. However, no international 
uniformity exists with respect to the radiographic evaluation of children with growth 
problems. We recommend that in patients with a possible diagnosis of a skeletal dysplasia 
a skeletal survey must be performed. In patients with a proportionate stature radiographic 
analysis of the hand and wrist will be sufficient in most cases. However, whenever 
there are clinical abnormalities with a possible underlying bone anomaly, a modified 
skeletal survey is appropriate. The combination of clinical and biochemical features and 
an appropriate skeletal survey can often make the correct diagnosis and/or guide the 
subsequent molecular analysis.
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Introduction
Growth disorders are a major concern for parents and their children, and it can be the 
first sign of a pathologic condition. A height more than 2.0 standard deviations (SD) 
below or above the mean, corrected for sex and age, is considered as short stature and tall 
stature respectively, but these limits are arbitrary. Tall stature is frequently associated 
with positive qualities of character and high social status, and is generally seen as a 
less serious problem than short stature, although tall girl often face social problems. 
Nevertheless, for both clinical presentations it is important to search for the cause of the 
growth problem, in order to know the therapeutical options and the natural course of the 
disorder, and for genetic counseling.
Many causes of growth disorders are known, and are usually classified as primary growth 
disorders, secondary growth disorders and idiopathic short or tall stature.1, 2 Whenever a 
child has a growth disorder, it is important to measure body proportions. Body proportions 
can best be described as the ratio between sitting height and total height. This ratio 
is dependent on the age of the child. Several age references have been published.3-6 
Relating arm span to heigth can also be considered, but one has to keep in mind that in a 
patient with short limbs total height is affected by the shortened legs. The ratio between 
arm span and height can therefore be normal, while clinically there is clear disproportion. 
Disproportion is usually defined as an abnormal ratio between the length of the trunk and 
the length of the limbs. When the child has a disproportionate short stature there is a high 
suspicion of a skeletal dysplasia. In most cases this means relatively short legs compared 
to the trunk, but a disproportion can also consist of a normal or short trunk with relatively 
long legs and/or arms.
In order to differentiate familial or constitutional growth problems from pathologic 
growth disorders, the patient’s history, the family history and parental heights, physical 
examination and reviewing of growth charts is needed. Further examinations generally 
consist of a radiograph of the left hand and wrist to define bone age. When there is still 
no indication for a particular disorder laboratory measurements in blood are performed 
to search for infectious diseases, anemia, systemic disorders or gastrointestinal and 
endocrine abnormalities.7 
More specialized examinations, like chromosome analysis or growth hormone stimulation 
tests, are needed if a specific disorder is suspected. Whenever there is a suspicion of a 
skeletal dysplasia, radiographic analysis (especially worthwhile in the growing child) is 
important to get to a more precise diagnosis, or to narrow down the number of possibilities. 
The aim of this review is to make an inventory of what is known about the skeletal survey 
that is needed with respect to the different growth problems: short or tall stature, with 
or without disproportion. For this purpose, we searched for relevant literature in the 
biomedical literature databases PubMed and Embase, and in standard texts, in order 
to come up with advice on this subject for physicians dealing with children with growth 
disorders.
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Radiographic evaluation in children with short stature
Radiographic evaluation in children with short stature is usually meant to confirm a 
suspected  skeletal dysplasia, and to help differentiate between the many types that are 
known. Various guidelines for radiographic analysis of disproportionate short stature 
(table 1) are available.8-13 
Table 1 Reported guidelines for skeletal survey in children with disproportionate short 
stature
ESDN  
(2003) [8]
ISDR  
(2004) [9]
ACR  
(2001) [10]
Lachman 
(1998) [11]
Mortier 
(2001) [12]
Offiah 
(2003) [13]
Skull - AP
 - lateral
-
-
+
+
+
+
+d
+
+
+
+
+
Spine - AP
 - lateral
+
+
+b
+
+
+
+
+e
+
+
+g
+
Thorax - AP (ribtechnique) + + +c + + +
Pelvis (including hips) - AP + + + + + +
Upper limb - AP - + +, bi + + +
Hand/wrist (left) - AP or PA + +, bi +, bi +, bi + +
Lower limb - AP +a, bi + +, bi + +f +
Foot - AP - +, bi +, bi +, bi - -
ESDN = European Skeletal Dysplasia Network
ISDR = International Skeletal Dysplasia Registry (of the Cedars-Sinai Medical Center)
ACR = American College of Radiology 
bi = bilateral
a only a view of the knee recommended, AP and lateral 
b from the cervical spine only a lateral view recommended
c also a lateral view of the thorax recommended
d  also a Towne’s projection recommended to ascertain the size of the foramen magnum 
and the base of the skull
e  separate flexion-extension views of the cervical spine recommended to evaluate the 
odontoid and C1-C2 dislocation
f lateral view of the knee recommended to view the patella
g only a view of the thoracolumbar spine recommended
The significance of the radiographs of different parts of the skeleton has been commented 
on in many reports.11, 13-19 and is summarized below. 
Skull
A radiograph of the skull can provide supplementary information that supports the 
diagnosis. Clinical features like microcephaly or macrocephaly, or craniosynostosis can be 
confirmed with a radiograph. The size of the fontanels is important to record, because it is 
known that these can be rather large with delayed closure in cleidocranial dysplasia.
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Spine and ribs
Radiographs of the whole spine, including the cervical region, are made for a good view 
of the position of the spine, to define a possible scoliosis, kyphosis or pronounced lumbar 
lordosis. Besides, the width of the spinal canal is measured. Progressive caudal narrowing 
of the interpedicular distance and stenosis of the lumbar spinal canal might be an 
indication for achondroplasia or hypochondroplasia. Finally, the shape and size of all the 
vertebra is observed. For instance, platyspondyly (flattening of the vertebra) is typical for 
osteogenesis imperfecta or spondyloepiphyseal dysplasia. 
A frontal view of the thorax is useful when abnormalities of the ribs are suspected. 
Besides, the scapulae and clavicles can be viewed in such a radiograph.
Pelvis
The pelvis is often abnormal in skeletal dysplasias, especially the size and shape of the 
iliac wings and the ossification pattern. In most neonatal chondrodystrophies delayed 
ossification of the pubic bones is seen.
Long bones
Radiographs of the long bones are made to enable the measurements of the different bone 
lengths, in order to differentiate between rhizomelic (proximal segment or upper arm/leg), 
mesomelic (middle segment or under arm/leg) or acromelic (distal segment or hand/foot) 
shortening. Besides, it can be established whether the problem is located in the epiphysis, 
metaphysis or diaphysis.
Hands and feet
A radiograph of the left hand and wrist is generally made to establish bone age. It is 
assumed that the shape and development of the phalanges and metacarpals on this 
radiograph reflect the development of those bones that define total body height (vertebra 
and long bones in the legs). However, a radiograph of the hand and wrist is also important 
when looking for morphologic abnormalities, for instance a trident hand as an indication 
for achondroplasia. Furthermore, one should look for fusion of the phalanges, oligodactyly 
or polydactyly. For example, syndactyly can occur in Holt-Oram syndrome.
Radiographs of the feet rarely contribute to the diagnostic process in short stature, 
because mostly the same abnormalities are seen in the hands and and many more 
variations of normal ossification occur in the feet.
According to some of the reported guidelines radiographic evaluation of the long bones 
can be restricted to one side of the body, unless the child has body asymmetry.12, 13 Others 
are less explicit on this subject 8, 9, 11 and the ACR guideline 10 advise radiographs of 
both upper limbs and both lower limbs for complete evaluation. The evaluation can be 
repeated, mostly with an interval of two years, because some features become clearer 
when a child grows older.13, 20
In the fetus or newborn frontal and lateral views of the total body (“babygrams”) often 
suffice for most diagnoses, but carefully positioned separate films are preferred, or as an 
adjunct at least separate films of the hands.11, 13, 16
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In patients with proportionate short stature a radiograph of the left hand and wrist, in 
order to define skeletal maturation (bone age), will usually be sufficient.11,19 An extensive 
skeletal survey is not considered useful in these patients, because abnormalities of the 
skeleton are not expected. In order to define bone age the different bones in the hand are 
compared to reference radiographs.21, 22 In this way it is also possible to make a rough 
estimation of the expected final height.22, 23 This will be most reliable from the age of 6-8 
years, depending on the method used.24
Short stature with normal proportions is usually not related to a skeletal dysplasia, but 
there are several exceptions. This means that in a child with short stature and normal 
body proportions, it is still important to look for dysmorphic features and/or congenital 
anomalies. A cleft palate can be part of Stickler syndrome, specific toe abnormalities can 
indicate Otopalatodigital syndrome, while the Madelung deformity is a strong indication 
for Leri-Weill dyschondrosteosis. Such abnormal findings can warrant targeted extension 
of radiographic analysis.
In some instances a radiograph of the hand is used for metacarpophalangeal pattern 
profile (MCPP) analysis. Determining the MCPP is a method to standardize the length of 
the phalangeal and metacarpal bones in the form of a Z-score. This score is defined by 
the difference in length between one of the hand bones and a reference length for this 
bone, corrected for sex and age, divided by the standard deviation of the used reference 
length.25, 26 These Z-scores for the 19 hand bones are plotted in graphics, which shows 
that different syndromes have different patterns. Specific MCPP’s have, among others, 
been published for achondroplasia, Robinow syndrome, Noonan syndrome, Turner 
syndrome and Leri-Weill dyschondrosteosis.27-31 In most cases an MCPP analysis is used 
to help support a certain diagnosis, especially when molecular analysis to confirm the 
diagnosis is not possible.
Radiographic evaluation in children with tall stature
No guidelines exist for radiographic analysis of tall stature. Generally, a skeletal survey 
is not necessary, because the suspicion of a skeletal dysplasia in the case of tall stature 
is low. Whenever children with tall stature have clinical abnormalities suggesting 
skeletal abnormalities, the accompanying clinical features lead to a targeted radiographic 
analysis, instead of a routine skeletal survey. For instance in sclerosteosis 32 radiographs 
of the skull and hands will be sufficient, while a more extended series of radiographs is 
needed in the case of one specific form of spondyloepiphyseal dysplasia.33 This policy is 
comparable to that for children with proportionate short stature who have accompanying 
abnormalities.
The most important radiograph in children with tall stature is an X-ray of the left hand and 
wrist, in order to define skeletal maturation (bone age) 21, 22 and predict final height.22, 
23 Children with tall stature often have an advanced skeletal maturation. This is seen in 
constitutional or familial tall stature, but also in some endocrine disorders (precocious 
puberty, adrenal hyperplasia) and in several overgrowth syndromes (Sotos syndrome, 
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Weaver syndrome). A delayed skeletal maturation is rarely seen in patients with tall 
stature, but does exist for example in cases of hypogonadism.34 
A radiograph of the hand can also be used to notice possible osteoporosis in patients with 
tall stature based on a sex chromosome abnormality, like Klinefelter syndrome (47,XXY). 
Androgen deficiency in boys and men with Klinefelter syndrome is an important risk 
factor for osteoporosis. Treatment with testosterone supplements increases the bone 
mineral density, and should be started preferably at the beginning of puberty.35 However, 
a radiograph of the hand and wrist may only provide an indication of osteoporosis. Bone 
mineral density is best measured by bone densitometry.
MCPP’s with a specific pattern have also been published for some syndromes with tall 
stature, like Sotos syndrome and Marfan syndrome.36, 37 Since molecular analysis is 
possible for both syndromes in respectively the NSD1 and FBN1 gene, the clinical 
relevance is not very high. However, not in all clinically distinct cases of Sotos or Marfan 
syndrome can a gene abnormality be identified. In these patients an MCPP is useful to 
support the clinical diagnosis.
To define arachnodactyly the metacarpal index (MCI) can be used. This index represents 
the ratio of the mean length to the mean width of the second to fifth metacarpal bones. 
In arachnodactyly the index is more than 8.5, while normally the index is less than 
7.9. Arachnodactyly is a typical feature in Marfan syndrome, but is also reported in 
homocystinuria, osteogenesis imperfecta, dystrophia myotonica, Ehlers-Danlos syndrome, 
contractural arachnodactyly (Beals syndrome), and constitutional tall stature.38, 39
Discussion
Owing to the fast development and implementation of molecular genetics in recent 
years, it is nowadays possible to diagnose various growth disorders by DNA analysis. 
Because of the high costs that go with molecular investigations, it is advisable to ask for 
a targeted gene analysis. This is why radiographic analysis is still of eminent importance 
in the analysis of growth disorders. Results of radiographic analysis can guide molecular 
analysis, and therefore can contribute to an efficient approach to diagnosing growth 
disorders.40 
Recommendations for conventional radiographic analysis are different for children with 
short and tall stature. Particularly in children with disproportionate short stature a 
series of radiographs known collectively as a skeletal survey is indicated.11, 13, 19 Various 
skeletal surveys with different contents have been suggested (table 1).8-13 Guidelines for 
pediatricians in The Netherlands were published in 1998.41 These guidelines were based 
on consensus and consisted of a radiograph of the left hand and wrist, a radiograph of the 
lumbar spine, humerus and femur. In our experience these series of radiographs have 
turned out to be too limited in clinical practice. Other, more extended guidelines that are 
recommended also lack scientific evidence. Most of these are based on clinical experience 
and the philosophy that visualization of both the axial skeleton and the long and short 
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tubular bones enables a reliable differentiation between the different skeletal disorders.2, 
12, 13, 16, 17 
Uniformity in its application will enable research to define sensitivity and specificity 
of the different radiographs in the future. Looking at the overlap between the different 
skeletal surveys in table 1, and taking into account the reported relevance of each 
radiograph , we recommend to use a series of radiographs as noted in table 2. This skeletal 
survey matches almost completely with the ones recommended by Mortier 12 and Offiah.13 
Further research is needed to collect scientific evidence for the usefulness of this series of 
radiographs.
Table 2. Recommendations for radiographic analysis in children with growth disorders
Short stature Tall stature
Disproportionate Proportionate Disproportionate/proportionate
Skull (PA and lateral)
Spine (AP and lateral)
Thorax (AP)
Pelvis (AP)
Upper limb (AP)
Left hand and wrist (PA)
Lower limb (AP)
Left hand/wrist (PA)
Further films dictated by clinical 
features 
Left hand/wrist (PA)
Further films dictated by clinical 
features
PA = posteroanterior view  AP = anteroposterior view lateral = lateral view
In children with a proportionate stature, whether short or tall, a radiograph of the left 
hand and wrist is often sufficient, to define skeletal maturity and predict final height. 
A modified skeletal survey is appropriate only whenever clinical abnormalities suggest 
skeletal anomalies. In children with disproportionate tall stature radiographic analysis 
is also defined by the clinical abnormalities observed.
One has to keep in mind that the methods used to define skeletal maturation are based 
on data from normal children, and are not demonstrated to be accurate in children with 
growth abnormalities. Besides, the normal rate of skeletal maturation differs between 
males and females, and between different ethnic groups.42 Even though the data on 
which skeletal maturation is based originate from the 1930’s, they are still applicable 
nowadays.43
In children, of course, radiation dose must be kept as low as possible. The skeletal survey 
we propose consists of conventional radiographs, of which the radiation dose in the course 
of years has diminished, as a result of progressive modernizing of equipment. Radiation 
dose in this series of radiographs can therefore be considered as low.44 By choosing 
a systematic approach, the number of radiographs can be reduced to a minimum and 
irrational radiographs of several parts of the skeleton are avoided. In this way conventional 
radiographs are a safe and valuable contribution to the diagnosis of growth disorders.
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Abstract
Objective: To establish evidence-based guidelines for growth monitoring on a population 
basis.
Study design: Several auxological referral criteria were formulated and applied to 
longitudinal growth data of four different patient groups, as well as three samples from the 
general population. 
Results:  Almost 30 % of pathology can be detected by height standard deviation score 
(HSDS)  below -3 or at least two observations of HSDS below -2.5 at a low false-positive 
rate (<1%) in 0-3 year old infants. For 3-10 year olds, a rule concerning distance to 
target height of >2 SD in combination with HSDS < -2.0 has the best predictive value. 
In combination with a rule concerning severe short stature (<-2.5 SDS) and a minor 
contribution of a rule concerning height deflection, 85.7% of children with Turner’s 
syndrome and 76.5% of short children due to various disorders are detected at a false-
positive rate of 1.5-2%. 
Conclusion: The proposed guidelines for growth monitoring show a good sensitivity at an 
acceptably low false-positive rate in 3-10 year old children. Distance to target height is 
the most important criterion. Below the age of 3 years the sensitivity is considerably lower. 
The resulting algorithm appears suitable for industrialized countries, but requires further 
testing in other populations.
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Introduction
Growth monitoring in infancy and childhood has been part of preventive child health 
programs since more than a century, and short stature or growth retardation is regarded 
as a relatively early sign of poor health. Despite this longstanding and wide acceptance 
of growth monitoring, there is little evidence for its effectiveness and efficiency.1 In 
developing countries, growth monitoring is primarily aimed at detecting malnutrition. 
In industrialized countries, where malnutrition is rare, the major purpose of growth 
monitoring is early detection of growth disorders, such as Turner’s syndrome (TS), Growth 
Hormone deficiency (GHD) and celiac disease (CD). 
For early identification of children with abnormal growth one needs good growth 
monitoring systems as part of preventive child health programs; well-defined and 
accurate referral criteria; and good diagnostic work-ups after referral. Although most 
industrialized countries have a child health program including regular growth monitoring, 
there is a wide diversity in protocols used for growth monitoring and diagnostic work-
up of growth disorders, and a virtual absence of experimental studies on the efficacy of 
these screening and diagnostic procedures.2 Only few guidelines have been published 
on referral criteria and diagnostic work-up for children with impaired growth and these 
are based on consensus meetings rather than on experimental evidence.3, 4 In the few 
experimental studies on growth monitoring various referral criteria have been used.5-7 
For failure to thrive, a common term for growth impairment in infants, the situation is even 
more complicated as there is considerable confusion about the definition and choice of 
anthropometric indicators.8
For a rational approach of growth monitoring, one has first to determine cut-off points of 
auxological criteria to be used in the decision whether growth-retarded children should be 
referred for further investigations. In the Netherlands, a consensus meeting was held in 
the mid nineteen nineties to establish such referral criteria.3 Three auxological parameters 
were chosen: height standard deviation score (HSDS), change in HSDS (HSDS deflection), 
and distance between height and target height SDS. Additional criteria included clinical 
signs (disproportion or dysmorphism), specific symptoms (as those associated with 
emotional deprivation), or previous history of low birth weight and/or length (small for 
gestational age, SGA). Thereafter, however, it was shown that applying the criteria would 
lead to far too many referrals.9
Consequently we started a project aimed at producing evidence-based guidelines for 
growth monitoring, with high positive predictive values (PPV’s) at acceptable false-
positive rates. The first step in this process was to study the predictive value of various 
auxological criteria for the detection of TS.10 We then studied the auxological parameters 
of patients with various causes of growth failure referred to the paediatric clinic in two 
hospitals (Chapter 7). Subsequently, we analysed the percentage of infants and children 
in three random samples from the general population that would comply with the various 
screening rules. In the present report we describe the performance of the best auxological 
parameters in terms of sensitivity and specificity in four groups of patients with growth 
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disorders and in three supposedly normal population samples, and propose that these can 
be used in growth monitoring protocols. 
Method
Material
For the analysis longitudinal height and weight data from four different patient groups 
were included, as well as three samples from the general population. Each group was 
analysed separately.  For the patient groups only measurements before or at age of 
diagnosis or start diet (CD-population) were taken into account. 
The first group of patients consisted of 777 girls with TS, collected from three sources 
and previously described by van Buuren et al.10 The second group was a group of new 
patients referred for short stature to the outpatient clinics of the general paediatric 
departments of two hospitals (Erasmus MC - Sophia Children’s Hospital, Rotterdam 
and Spaarne Hospital, Haarlem) between January 1998 and December 2002 (Chapter 
7). Out of 542 children referred to the clinic, 27 children with pathology were found: 7 
with GHD, 7 with CD, 3 with TS and 10 with other pathological causes (syndromes (n=2: 
Noonan’s syndrome, M. Leri-Weill), anaemia (n=3), skeletal diseases (n=4) and emotional 
deprivation (n=1)). Only these 27 children were included in the analyses. The third 
group consisted of CF patients collected from three major CF clinics in The Netherlands: 
Erasmus MC - Sophia Children’s Hospital in Rotterdam (n=166), University Hospital 
Maastricht (n=30) and Juliana Children’s Hospital in The Hague (n=20) (Chapter 10).
The last group was a group of CD-patients consisting of two separate subgroups: 1) a 
retrospective study described by Damen et al., in which they studied the catch up growth 
in patients with celiac disease,11 and 2) a prospective study on catch up growth by B. 
Boersma et al.12 
The relevance for testing the new guidelines varied between the groups. TS is particularly 
relevant for determining the sensitivity of screening rules as TS is one of the main medical 
conditions detectable only by growth monitoring. Moreover, it can be well defined (by 
chromosomal analysis) and growth data from a relatively large group were at our disposal. 
Another group that was relevant to test the sensitivity was the mixed pathology group 
(n=27). We observed that growth monitoring is less successful in detecting CF and CD 
(Chapter 9 and 10). Also, these conditions could be screened and diagnosed in other ways 
than growth only.  Therefore, the proposed guideline was particularly aimed at detecting a 
high percentage of pathology in the first two patient groups.
For the determination of the specificity of the proposed guidelines, three different 
reference populations were used. The first reference sample was obtained from the 
Social Medical Survey of Children Attending Child Health Clinics (SMOCC) cohort, a 
nationally representative cohort of 2,151 children born in the Netherlands in 1988-1989, 
consisting of longitudinal data of length and weight up to the age of 2.5 years.13 The 
second reference population is a cohort of all children born in the years 1989 and 1990 in 
Landgraaf and Kerkrade, located in the southern part of The Netherlands (“LIMBURG”, 
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n = 970).9 The third population is a random sample of children born between 01-01-1985 
and 31-12-1988, attending school doctors between 1998 and 2000 in Leiden and Alphen 
aan den Rijn, the Netherlands (“ZHN”, n = 400) (Grote et al, in preparation). 
Screening rules
By combining evidence found in previous studies, three auxological referral criteria were 
formulated. Only criteria of practical value for child health programs were considered.  
The first rule takes genetic height potential into account by comparing the HSDS of the 
child to its target height in combination with a HSDS below a certain cut-off. In our earlier 
study on TS 10 as well as in a study on a mixed population of short children (Grote et 
al, in preparation) we found that this combination offers the best predictive value.  We 
calculated the test characteristics for a distance between HSDS and target height of 
more than 2 SDS with cut-off points for height SDS of -2, –1.5, or –1.0 SDS.  This rule is 
labelled “short for target height and population” (further called “short for target 
height”). In TS the combination of distance to target height SDS of >2 and HSDS<-2 led 
to the best sensitivity (76.9%) and specificity (99.4%).10
The second rule concerns HSDS for the appropriate reference population. HSDS is 
generally considered as one of the most important referral criteria, especially when 
parental height is not available.2, 4 In order to keep the percentage of false-positives 
low, we chose a cut-off of -2.5 (~ 0.4th percentile). This cut-off was chosen for historical 
and pragmatic reasons, as it is the lowest line on the Dutch and various other growth 
charts. If this rule would be applied irrespective of age and of ethnic origin, it would 
lead to approximately 6% of referrals,9 but if only applied to children older than three 
years using the ethnically appropriate growth charts the referrals decline considerably to 
approximately 2% (Grote et al, in preparation). This rule is labelled “very short”.  
The third rule applies to deviation of the individual growth curves from the expected 
growth channels, either expressed as height velocity (cm/year or SDS for age) or as a 
change of HSDS. The HSDS change is thought to be more suitable, because it better 
reflects the deviation from canalisation of the growth curve, and because height velocity 
depends not only on age but also on HSDS position. A low growth velocity has long 
been considered as the most important growth parameter, and many clinicians can show 
examples of cases where deflection of growth curve is the only indication of a growth 
disorder, e.g. an acquired form like GH deficiency caused by a brain tumour or primary 
hypothyroidism by Hashimoto disease. However, its usefulness for growth screening 
appears limited. Voss et al found that height velocity did not distinguish short stature 
due to pathology from normal short stature.7 We have shown this earlier for children with 
growth hormone deficiency.14 Van Buuren et al found that a height deflection of more 
than 0.25 SDS would lead to a large number of false-positives.9 The predictive value 
of deflection can be improved if one demands a continuous deflection over 3 years (e.g. 
0.25 SDS/yr during at least 3 years),10, 14 a larger deflection over an undefined time 
interval (e.g.  a deflection of >1.0 SDS), or in combination with an absolute HSDS<-2. 
In the present analysis we combined various expressions of height deflection (per year 
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or cumulative) with various cut-off points for HSDS (<-2.0, <-1.5 or <-1.0). This decision 
rule is labelled “height deflection and short for population” (further called “height 
deflection”).  We decided that deflection with a cut-off of 1.0 SDS over an undetermined 
time interval would be most practical, as this should detect both a slow and fast bend of the 
growth curve, and most growth reference diagrams include lines with a distance of 1 SDS.15
Analytic procedure  
Length, height, weight, target height, body mass index (BMI) and weight for length or 
height were expressed as SDS, using recent Dutch, Turkish and Moroccan reference 
data.16-19 All criteria were first analysed for all age-groups. As growth curves in the first 
three years can cross SDS lines when birth length SDS is far from target height SDS, and 
length measurements are less accurate, specificity of the various rules is expected to be 
lower than in later years, leading to too many referrals.9 We therefore performed separate 
analyses in two age groups (0-3 and 3-10 years), and calculated test characteristics 
for different cut-off values (HSDS -3.0, -2.5, -2.0, -1.5 and -1.0) and other additive 
parameters.
Parental height was frequently (4-58%) missing in the various data sets. We imputed 
these data under the assumption that data were missing at random using Multivariate 
Imputation by Chained Equations (MICE).20 The method created multivariate imputations 
by applying sequential linear regressions, where each incomplete variable was imputed 
conditionally on all variables in an iterative fashion. The imputation model consisted of 
the last known HSDS (except for the CF-population where we chose the HSDS closest to 
the age of 5 years instead), HSDS, weight SDS, weight for height SDS, BMI SDS, gender 
(except for the TS group as these are all girls), HSDS of the father and/or HSDS of the 
mother (if available), ethnicity (except for the TS and Limburg cohort) and for CF and CD 
age at diagnosis or start diet. For CF HSDS at the age of 5 was chosen for the imputation 
model instead of the last known height, because in most children catch-up growth 
has resulted in a normal height at this age.21 The number of iterations was set to 15. 
Predictive mean matching was used to create parental height imputations. The imputation 
method includes parameter uncertainty, preserves the multivariate structure in the data 
and has good coverage properties.22
Calculations were based on the assumption that a child is referred if the growth pattern 
meets the criteria of a given screening rule for the first time. All rules were analysed 
separately as well as in combination with the others. A false-positive rate of <1% for the 
separate rules and < 2% for the combined rules was assumed to be acceptable from the 
perspective of preventive child health care. 
Results
As the data were gathered retrospectively, there was no fixed schedule of measurements, 
resulting in a varying number of measurements per individual child. Table 1 shows the 
number of children per age group and the mean number of measurements.
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Table 1. Number of children (N) and mean number of measurements (n) per child in each 
group
Limburg
N=970
ZHN
N=400
SMOCC
N= 2151
Turner’s 
syndrome
N= 777*
Short stature 
due to 
pathology
N= 27
Cystic 
Fibrosis
N=216
Celiac 
disease
N=120
Age 
group
Number of 
measurements
N (n) N (n) N (n) N (n) N (n) N (n) N (n)
0-3
≥1 AND at least 1 
weight measurement 
before 0.1 years† 
931 (11) 341 (11) 1942 (8) 353 (4) 23 (6) 89 (5) 86 (7)
≥2 with 0.5-1 year 
interval AND at least 
1 weight measurement 
before 0.1 years† 
810 (12) 321 (14) 1835 (9) 158 (8) 15 (9) 32 (10) 66 (12)
3-10
≥1 958 (3) 361 (4) 0 524 (5) 17 (3) 25 (2) 22 (4)
≥2 893 (4) 339 (4) 0 472 (6) 13 (3) 14 (3) 16 (5)
* 492 children had measurements under the age of 3 years.
†  At least 1 weight measurement before 0.1 years is necessary  to be able to exclude 
children with a birth weight < 2500 grams or a first measurement within 0.1 year (5 
weeks) with weight SDS<  -2 if no birth weight available, and gestational age <37 weeks 
(or not available) (see table 2)
Applying the three auxological criteria to all age groups resulted in a high number of 
referrals in the general population (presumably false positives) (data not shown). This 
was primarily due to referrals in the 0-3 year group: the height deflection and short for 
target height rules would produce a high false-positive rate. By adding extra criteria 
under the age of 3 years and varying the cut-off points, the performance of the different 
rules were then tested in the two age groups. Scenarios with the best test performance 
are shown in table 2 and the yield of these best scenarios in terms of sensitivity (true-
positives) and 1-specificity (false-positives) are shown in tables 3 and 4, respectively.
Table 2. Referral criteria with the best test characteristics
A.
0-3 years Criteria Rule nr.
Repeatedly very short
HSDS_1 < -2.5 and HSDS_2 < -2.5 AND 0.5≤Age_2-Age_1<1 year  AND
[birth weight >=2500 grams or if no birth weight available than first 
measurement within 0.1 year (5 weeks) with weight SDS≥  -2, and gestational 
age ≥37 weeks (or not available)]
1.
Extremely short   
HSDS < -3 AND
[birth weight ≥2500 grams or if no birth weight available than first 
measurement within 0.1 year (5 weeks) with weight SDS ≥ -2, and gestational 
age ≥37 weeks (or not available)]
2.
Combination of rule 1+2 3.
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B.
3-10 years Criteria Rule nr.
Short for target height and population HSDS-THSDS < -2 AND HSDS < -2 1.
Very short HSDS < -2.5 2.
Height deflection (and short for population) Delta HSDS < -1 AND HSDS < -2 3.
Combination of  rule 1+2+3 4.
Table 3. Sensitivity (%) of several auxological rules for four different patient-groups (true-
positives)
Turner’s 
syndrome
Short stature due to 
pathology
Cystic 
Fibrosis
Celiac 
disease 
0-3 years 
Repeatedly very short* 7.1% 14.8% 0.0% 1.2%
Extremely short 13.0% 26.1% 6.7% 4.7%
Combination 14.7% 26.1% 6.7% 4.7%
3-10 years
Short for target height and population 76.9% 58.8% 8.0% 27.3%
Very short 74.0% 58.8% 4.0% 18.2%
Height deflection (and short for population)** 13.4% 17.6% 0.0% 18.2%
Combination 85.7% 76.5% 8.0% 27.3%
Note: if a child has only 1 measurement, the child cannot be referred according to the 
repeatedly very short rule and the absolute height deflection rule. 
* In the subgroup with ≥2 measurements the percentage of  referrals would be 15.8% for 
Turner’s syndrome, 26.7% for mixed pathology, and 1.5% for celiac disease
**  In the subgroup with J 2 measurements the percentage of referrals would be 14.8% for 
Turner’s syndrome, 23.1% for mixed pathology, and 25.0% for celiac disease.  
Table 4. Estimated percentages of referrals in three reference populations (false-positives)
Limburg ZHN SMOCC
0-3 years
Repeatedly very short* 0.2% 0.0% 0.4%
Extremely short 0.2% 0.6% 0.7%
Combination 0.3%^ 0.6% 0.9%^
3-10 years
Short for target height and population 0.7% 1.1% NA
Very short 0.9% 0.8% NA
Height deflection (and short for population)** 0.1% 0.8% NA
Combination 1.5%# 1.9%# NA
NA=not available
Note: if a child has only 1 measurement, the child cannot be referred according to the 
repeatedly very short rule and the absolute height deflection rule. 
*  Based on subgroup with ≥2 measurements percentage referrals is 0.2% Limburg and 
0.4% SMOCC
** Based on subgroup with ≥2 measurements percentage referrals is 0.1% Limburg and 
0.9% ZHN
^  No significant difference between Limburg and SMOCC for the combined rule 0-3 years 
(χ2 (1)=2.79, p=0.10)
#  No significant difference between Limburg and ZHN for the combined rule 3-10 years 
significant (χ2 (1)=0.38, p=0.54)
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For children under the age of three years the true positive rate for pathology is modest, 
if the false-positive rate has to be kept low. The best rule consists of an HSDS <-2.5 at 
least twice within 1 year (very short repeated) or an HSDS <-3 (extremely short) rule, 
confined to infants born at or after 37 weeks of gestational age (or when information on 
gestational age is not available) and born with a weight >= 2500 g (if birth weight was not 
available, the first measurement within 0.1 year (5 weeks) with a weight SDS >= -2 was 
used).  With this rule 14.7% of the children with TS can be detected, at a false positive 
rate of <1%. This is probably an underestimation, because the percentage of 7.1% for a 
repeated HSDS <-2.5 increased to 15.8% by assessing only the subgroup of children with 
more than 2 measurements. The short for target height rule did not result in acceptable 
test characteristics.
Above the age of 3 years a total of 85.7% of children with TS and 76.5% of the children 
with mixed pathology can be detected by the combination of the short for target height 
rule, the very short rule and the height deflection rule.  
If a stepwise approach would be taken for 3-10 year old children, the very short rule 
would add  42 patients (7.7%) to the 76.9% of the girls with Turner syndrome who 
complied with the short for target height  rule.  For the group of children with short 
stature due to mixed pathology 3 persons (17.7 %) would be added to the 58.8% of 
children who complied with the short for target height  rule.  The addition of this rule 
would increase the false-positive rate by 0.3 % (1 child) in the ZHN cohort and 0.7% (7 
children) in the Limburg cohort. Applying the height deflection rule after the two other 
rules would only add few extra patients (4 patients (0.8%) for TS, none for the children 
with mixed pathology), while the false-positive rate would increase by 0.6% (2 children).     
Discussion
In an effort to establish evidence-based guidelines for growth monitoring on a population 
basis, we studied the performance of a set of decision rules in four groups of patients and 
three samples from the general population, aiming at a combination of a high sensitivity 
with an acceptably low false-positive rate. In 0-3 year old infants, after exclusion of 
babies born preterm and with a low birth weight, we found that a HSDS <-3 or at least 
two observations of a HSDS <-2.5 within 1 year, has the best performance at a low false-
positive rate (<1%). However, only 14.7% of the children with TS and 26.1% of children 
with other growth disorders can be detected with these rules. For 3-10 year old children 
the short for target height  rule in combination with the very short rule and a minor 
contribution of the height deflection rule detects 85.7% of children with TS and 76.5% 
of short children due to various disorders, at a false-positive rate of 1.5-2%. A graphical 
representation of the algorithm is shown in fig 1. 
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Fig 1. Flowdiagram of proposed criteria for referral of children with growth disorders.
HSDS= Height Standard Deviation
THSDS= Target Height Standard Deviation
The low efficacy and efficiency of growth monitoring between 0-3 years, particularly of 
rules involving target height and length deflection, is probably mainly caused by the well-
established fact that correlation between length and midparental height is low at birth, and 
rapidly increases during the first 3 years of life.23 Crossing SDS lines in this age period 
is therefore not unusual. This is in line with our observation that referral based on a low 
length velocity or a large distance to target height would lead to too many referrals in this 
age group, and confirms our earlier data.9 For this age group the only useful referral rule 
was based on an extremely low or repeatedly low HSDS. Still, only 15-26% of the growth 
disorders studied were detected, and even less infants with CF or celiac disease. This is in 
concurrence with our previous studies on CF and CD, in which we found that weight is a 
better auxological tool than length at this young age. 
In concurrence with our earlier observations in TS,10 we found that also in a mixed set of 
growth disorders diagnosed in a pediatric clinic the best decision rule to detect children 
with pathology older than three years is the short for target height  rule. This result 
contrasts with earlier speculations that this parameter might be too inaccurate because of 
the uncertainty of parental height.4 From a preventive health care perspective the height 
deflection rule is of little use. Still, we propose to keep this rule in the algorithm, as it is 
important that the rare cases with growth deflection due to acquired growth disorders are 
detected timely. In order to keep the false-positive rate low, we combined HSDS deflection 
with a HSDS<-2.0, but a severe deflection irrespective of the HSDS reached should be 
considered as an alarming signal.
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There are a number of methodological issues that can be discussed. First, as our data 
were gathered retrospectively, there was no fixed schedule of measurements, resulting 
in a variation in the number of measurements between the individual children. In some 
children only one measurement was available. The deflection could therefore not be 
calculated or used as a potential referral rule. We assumed for our analyses that these 
children did not meet the criteria concerning deflection or repetition. This may have led 
to an underestimation of the suitability of the deflection rule. However, since for the vast 
majority of the children more than one measurement was available, this underestimation is 
probably small. 
For the algorithm not only auxologic rules are important, but also a number of clinical 
symptoms and signs. If medical history reveals that birth weight and/or length was low, 
and HSDS is <-2.0 from the age of approximately 3 years, the diagnosis of persistent short 
stature after SGA can be made. It is known that approximately 10% of these children 
do indeed remain short, and do not achieve normal adult height.24 Referral to a growth 
clinic is needed for further diagnostic tests and for the decision on growth hormone 
treatment. As catch-up can emerge within the first 2 years but sometimes between the 
age of two and three, we set the age limit for catch-up at three years. An important, 
but fortunately rare, issue in the medical history is to check for symptoms of emotional 
deprivation (psychosocial short stature).25-27 Obviously, a thorough physical examination 
should be carried out, and special attention should be given to body proportions and 
dysmorphic features. Abnormal body proportions are important signs of skeletal dysplasia 
and dysmorphic features can direct the attention to various primary growth disorders 
(“syndromes”).  We propose that combining a HSDS<-2.0 with any of these clinical 
symptoms and signs is sufficient reason for referral.  
In conclusion, the proposed guidelines for growth monitoring show a good sensitivity at 
an acceptably low false-positive rate in 3-10 year old children. Distance to target height 
is the most important criterion. Below the age of 3 years the guidelines can only detect a 
small percentage of pathology at an acceptably low false-positive rate, and are therefore 
of limited use, even if the rules are restricted to children born at term with a normal birth 
size. The auxological part of the flow diagram can be included into a computer program to 
assist medical personnel. Besides auxological rules, clinical issues taken form the medical 
history and physical examination can offer important guidance in taking the decision to 
refer patients for further tests. The resulting algorithm appears suitable for industrialized 
countries, but requires further testing in other populations. Finally, no algorithm can fully 
replace clinical judgement of the physicians, and in case of an unusual growth pattern 
even if it would not comply with the rules for referral, physicians should still be free to 
follow their clinical judgement. 
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General discussion
The aim of this thesis was to collect evidence for establishing new guidelines for the 
assessment of short stature in children. In this assessment one can distinguish two parts: 
1) auxological screening in the general population; and 2) diagnostic work up in children 
referred to the specialist. In this chapter we will first discuss the new evidence-based 
guideline for the auxological part of the assessment of short children, based on the 
evidence that was collected in the various parts of this project. Thereafter we will discuss 
the assembled evidence for the diagnostic work up in children with short stature and offer 
suggestions for a new guideline. Finally, we will discuss the plans for the implementation 
process of the new guideline in the Netherlands and present proposals for future research.
Auxological screening
As mentioned earlier in this thesis, little experimental evidence can be found in the 
literature on which schemes for growth monitoring and auxological screening can be 
based. Various auxological criteria have been used for growth failure in experimental 
studies, and also in the few consensus-guidelines that have been published on growth 
monitoring different criteria were proposed for referral of short children.1-5
As a first step in this project aimed at establishing evidence based-guidelines we 
made enquiries among paediatric endocrinologists in Europe and other industrialised 
countries, as well as among general practitioners and Primary Health Care physicians in 
the Netherlands, about the referral criteria used for growth monitoring (see part B of this 
thesis). Height for age, either expressed as centile position or as standard deviation score, 
was mostly used in industrialized countries with referral protocols for children with short 
stature, followed by the deviation of height, either expressed as height velocity or delta 
height SDS. The distance to target height appeared to be used less frequently. Primary 
Health Care physicians in the Netherlands reported that the distance to target height, as 
well as height for age, were the most relevant criteria. They thought that clinical signs and 
symptoms (e.g. disproportion or dysmorphic features) and extreme short stature were the 
most important referral criteria. They further thought that height deflection would lead to 
too many referrals. This is in partial agreement with the arguments given by Hall et al in 
their Consensus statement, i.e. that absolute height is the best referral criterion, and that 
deflection and the distance to target height are often unreliable.4
Subsequently we evaluated the auxological rules of the existing guidelines in practice 
(Chapter 6) in part C. We confirmed the results of Van Buuren et al 6 that the current 
Dutch Consensus Guideline would lead to too many referrals (approximately 80%), 
mainly due to the deflection of length during the first 3 years of life. This is, however, in 
sharp contrast to the much lower number of referrals for deflection that was expected at 
the time of the consensus meeting (175 children each year).7 The discrepancy between 
the expected and observed specificity can be explained by various factors. First, in this 
context measurement error is a relevant issue, which for example can become visible as a 
single low value in between normal measurements. Voss et al reported that in the Wessex 
study imprecision in auxological assessment was not uncommon and that especially 
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height velocity over a short period of time is prone to this phenomenon.8 Second, ethnic 
variety is an important factor, given the considerable differences in mean height between 
different ethnic groups. In the original consensus guideline and the study of Van Buuren 
one population reference was used, while it is now well documented that the “original” 
Dutch population is considerably longer/taller than for example Moroccan, Turkish 
and Asian children), and that the growth charts for children with these origins have to 
be used.9, 10 Third, the inclusion of growth data from early infancy, where a low length 
shortly after birth will rapidly increase/decrease into the direction of target height SDS, 
has presumably a negative effect on specificity. The correlation between length and 
midparental height is low at birth, and rapidly increases during the first 3 years of life.11 
Crossing SDS lines in this age period is therefore not unusual. 
We additionally found that the UK Consensus Guideline leads to far less referrals, but is 
expected to be relatively insensitive to several clinically relevant growth disorders, as it 
disregards target height, whereas we found that especially that criterion was most complied 
with by children with pathology in our evaluation study in secondary health care (chapter 7).
 
To improve the referral pattern of children with short stature we chose in part D three 
patient groups to determine cut-off points of auxological criteria to be used in the decision 
whether growth-retarded children should be referred for further investigations. While a 
great diversity of congenital or acquired conditions can cause short stature, only Turner 
syndrome (TS), cystic fibrosis (CF) and celiac disease (CD) were taken into account as 
these are the biggest and most important groups to be detected next to Growth Hormone 
Deficiency. As Growth Hormone Deficiency is heterogeneous in its clinical presentation 
and diagnosed partially on the basis of growth pattern, while no gold standard test is 
available, we did not consider this group suitable for the determination of appropriate 
auxological screening criteria for short stature.12
We found that  growth monitoring is useful to screen for TS. The best decision rule to detect 
children with TS is the distance between height SDS and target height (the so-called parental 
height corrected rule). Application of this rule would lead to the referral of 60-77% of girls 
with TS before the age of 10 years, at acceptable levels of false positives. We recommended 
the use of a combined rule, i.e. to refer children older than 3 years if HSDS is below –2 and 
if either HSDS is more than 2 SD below the target HSDS, or HSDS shows a deflection of 0.25 
SDS per year or more during a period of at least three years. This rule picks up almost 80% 
of the girls with TS, while it refers only 0.6% of the non-TS population. 
In contrast, the overall performance of detecting CD or CF with auxological criteria is 
modest. Nevertheless, testing for CD deserves a place in the diagnostic work-up in young 
children (within the first 2.5 years ) with failure to thrive, since it is especially the delayed 
onset of the disease (the non-classical form) that has increased during the recent years, 
suggesting that the growth impairment becomes apparent later than previously.  Likewise 
the clinician may consider to test for CF in a diagnostic work-up in children with failure 
to thrive in the absence of a newborn screening program, since CF is a severe disease 
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representing itself sometimes with monosymptomatic failure to thrive  and up to 45% of 
the children can be detected within the first year using auxology. Evidently, a much better 
tool to detect CF at an early age is newborn screening, which has shown beneficial effects 
on the prognosis of CF and has now been implemented in several countries.13-15 For the 
detection of both disorders (CF and CD) rules that consider a deflection of BMI or weight 
SDS show the best performance and can form the basis for future computer algorithms in 
child welfare clinics. 
Finally, we established a new guideline in part F, by working out the performance of 
the best auxological parameters in terms of sensitivity and specificity in four groups of 
patients with growth disorders and in three supposedly normal population samples. The 
low efficacy and efficiency of growth monitoring between 0-3 years, particularly of rules 
involving target height and length deflection, led to the only useful referral rule that 
was based on an extremely low or repeatedly very low HSDS. Still, only 15-26% of the 
growth disorders studied were detected, and even less infants with CF or CD. This is in 
concurrence with our previous studies on CF and CD, in which we found that weight is a 
better auxological tool than length at this young age (part D). 
Like in our study in TS, we found that also in a mixed set of growth disorders diagnosed in 
a pediatric clinic the best decision rule to detect children with pathology older than three 
years is the rule that takes target height into account. We derived that the distance should 
be more than 2.0 SD, instead of the –1.3 cut-off used in the 1996 Consensus guideline,7 
and combined it with a HSDS <-2.0 in order to limit the number of false positive results. 
This combined rule resulted also in one of the best combinations of sensitivity and 
specificity for the detection of TS (chapter 8). 
Height SDS (HSDS) for age is still considered as one of the most important referral 
criteria, especially when parental height is not available.4, 16 A HSDS of -2.5 SD (~ 0.4th 
percentile) was chosen as cut-off since this leads to an acceptable false-positive rate, 
while it is the lowest line on most growth charts and therefore suitable for practical use. 
Although British investigators have shown that growth velocity over a period of 1 year is of 
little use as a screening tool,3 and despite our observations that the change in HSDS per year 
leads to too many referrals (chapter 6), we propose to keep a parameter of growth deflection 
rule in the algorithm, as it is important that (rare) acquired growth disorders which present 
primarily with growth deflection are detected timely. By putting the cut-off point at 1 SDS 
and by omitting the time-limit, we created a practical deflection rule, which detects both a 
slowly deviating growth curve (for example in girls with Turner syndrome) and a rapid growth 
retardation, such as seen for example in children with a malignant brain tumor or other 
acquired growth disorders. Still, in order to keep the false-positive rate low, we combined 
HSDS deflection with a HSDS<-2.0 for screening purposes, but a severe deflection 
irrespective of the HSDS attained should also be considered as an alarming signal.
Besides auxological rules, a number of clinical symptoms and signs are important for the 
algorithm for the referral of children with short stature. As it is known that approximately 
10% of children born with a low birth weight and/or length (small for gestational age, 
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SGA) remain short, and do not achieve normal adult height,17  the diagnosis of persistent 
short stature after SGA can be made, if medical history reveals that birth weight and/or 
length was low, and HSDS is <-2.0 from the age of approximately 3 years. As catch-up 
usually occurs within the first 2 years but sometimes continues in the third year of life, we 
set the age limit for catch-up at three years. Likewise the medical history should be checked 
for symptoms of emotional deprivation (psychosocial short stature). [18-20] Finally, abnormal 
body proportions are important signs of skeletal dysplasia and dysmorphic features can 
direct the attention to various primary growth disorders (“syndromes”).  We propose that 
combining a HSDS<-2.0 with any of these clinical symptoms and signs is sufficient reason 
for referral. The resulting algorithm is presented in fig 1.
Diagnostic work up by the medical specialist 
A proper auxological screening for short stature should be followed by an evidence-based 
diagnostic work-up in secondary health care. However, we could not find experimental 
evidence supporting the use of a certain diagnostic procedure. The only information in 
the literature on this issue comes from expert opinion papers on specific guidelines for 
the diagnosis of growth hormone deficiency in childhood and adolescence,7, 21, 22 and 
from the Dutch Consensus Guideline.7 In addition, we have shown in part C, chapter 
4 that while there is agreement among paediatricians in Europe,that some biochemical, 
radiological and genetic tests have to be used, there is no full consensus on which tests 
should be preferred. For the presentation of our new recommendations for the diagnostic 
work up based on the evidence found in our project, we shall follow the various steps 
suggested by the Dutch Consensus Guideline.
 
Table 1. Laboratory investigations in the diagnostic work up according the DCG
Laboratory investigations  In order to diagnose Category
Blood   
Hb, Ht, Leukocytes, Cell indices, leukocyte differentiation, 
ESR, (Ferritin) 
Anemia / infections (and celiac disease 
and cystic fibrosis)
I
ALAT, ASAT, γ GT Liver diseases II
Albumin, Creatinine, Sodium, Potassium, Calcium, 
Phosphate, Alkaline phosphatase, acid-base equilibrium
Renal diseases III
IgA-anti endomysium, IgA- antigliadin, Anti-tissue 
glutaminase*, Total IgA
Celiac disease IV
TSH, FT4 Hypothyroidism V
IGF-I Growth hormone deficiency VI
FSH** Turner syndrome VII
Urine   
pH, glucose, protein, blood and sedimentation Renal diseases VIII
*At the moment the consensus meeting took place, anti-tissue glutaminase as a diagnostic 
tool for celiac disease was not yet introduced nation wide.
**Only in girls. 
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When there are no signs or symptoms leading to the suspicion of a certain disease, the Dutch 
Consensus Guideline proposes a list of laboratory investigations for screening of several 
pathological conditions (table 1). Dependent on the abnormalities in the screening laboratory 
investigations further, more specific tests, like a sweat test for Cystic Fibrosis, can be 
performed to establish the final diagnosis. However, if no indication of a certain disease is 
present after the preceding procedures, the three following tests should still be considered 
according to the Dutch Consensus Guideline: chromosomal analysis for Turner syndrome 
in girls, a biopsy to prove or rule out celiac disease and the determination of zinc levels in 
plasma or hairs to investigate zinc deficiency in children with failure to thrive.23 
We found that although this consensus guideline was not well followed in the two 
hospitals in which we performed the study, at least 5 % pathologic growth failure could be 
detected.. This concurs with previous reports.1, 3, 24 In the Wessex growth study 8 children 
(4.4%) were identified as having an organic disease among the 180 children, whose height 
on screening at school entry was below the 3rd percentile.3 In the Oxford study Ahmed 
et al reported 7 newly recognized children (3.0%) with organic disease among the 260 
children whose height was below - 2 SDS, measured at the ages of  3 and 4.5 years.1 In the 
Utah growth study twenty-five out of 555 children (4.5%) were newly discovered as having 
growth hormone deficiency (GHD), hypothyroidism or Turner syndrome and another 53 
children (9.5%) had other medical reasons for their poor growth (height below the 3rd 
percentile and/or growth rate below 5 cm/yr). 29 In contrast to these population based 
studies Grimberg et al and Green et al found a higher percentage of newly diagnosed 
children with organic causes for their poor growth (23.7% (66 out of 278 children and 
40% (79 out of 198), respectively).25, 26 The children included in these studies were, 
however, referred to specialized growth centers because of short stature, without specific 
choices of anthropometric indicators or criteria for abnormality. 
Laboratory investigations in the diagnostic work up
There was considerable heterogeneity in the amount of diagnostic work up carried out in 
our evaluation study. In none of the children referred for short stature a complete detailed 
routine diagnostic work up as proposed in the Dutch Consensus Guideline was performed 
and in 43 % of the patients in the university hospital and 32% in the general hospital no 
routine laboratory examination was done at all (part C, chapter 7), resulting in many 
missing data for the individual tests. Therefore, these results did unfortunately not allow 
us to construct an evidence-based decision rule for the general diagnostic work-up in 
children with short stature. New recommendations will therefore depend on a combination 
of various factors: the prevalence of the disease; the frequency in which the disorder 
presents itself with growth retardation only; the sensitivity and specificity of the test; the 
costs of the test; and the implications for the patients. In the remainder of this paragraph 
we will suggest new recommendations based on the evidence found in this thesis, 
following the categories of the consensus guideline (see table 2).
The first laboratory category exists of hematological parameters, cell indices, leukocyte 
differentiation and erythrocyte sedimentation rate (ESR). Its main aim is to detect or 
Grote_opm_H9_etc_v4.indd   181 22-01-2007   14:07:52
182
Chapter 13
exclude anemia and infectious or inflammatory diseases. Our international inquiry showed 
that these tests were recommended in most countries with guidelines for diagnostic work 
up (chapter 4). We did not perform a thorough literature search on the prevalence of 
short stature in combination with anemia, but the available literature shows that there is a 
strong relationship between thalassemia, sickle cell disease and growth retardation.27-30 
Likewise, Stephenson et al showed evidence of the association between infectious diseases 
in general and linear growth.31 Anemia and infection can also be the first signs of other 
growth related disorders like inflammatory bowel diseases (IBD), celiac disease (CD) or 
cystic fibrosis (CF). Also the ESR is an important parameter in detecting IBD. In chapter 
2 we concluded that all children with short stature should be evaluated for CD. However, 
this category of laboratory investigations is not very specific for the detection of CD in 
contrast to category IV, which will be discussed later. 
In chapter 3 we found that the prior probability of CF in infants or children with a low 
weight or length for age is too low for a reliable result of a sweat test. The same conclusion 
might be drawn for  the infectious parameters, but experimental data are lacking. 
However, as anemia and infectious parameters are important for the detection of other 
growth related disorders, and as they are noninvasive for the patient and relatively cheap, 
we recommend these parameters to be kept in the routine diagnostic work up of short 
children.
The second category of the routine diagnostic work up exists of parameters to exclude 
liver diseases. Especially ASAT and ALAT were recommended in more than 50% of 
the countries with an existing guideline for the assessment of short stature (chapter 4), 
but yGT was usually considered optional. Although Sokol et al concluded that growth 
retardation is common in children with chronic liver disease,32  not any asymptomatic 
short child in whom liver function tests revealed a liver disorder, is encountered in more 
than 30 years of experience. Therefore we believe that it is extremely unlikely that the 
sole presenting sign of a liver disorder is growth retardation. However, we have not been 
able to perform an extensive literature search on the prevalence of monosymptomatic 
short stature at diagnosis in children with liver disorders and further research has to be 
performed to collect experimental evidence on the issue. At present, we considere  it 
justified to remove these parameters from the routine diagnostic work up of short stature.
The third category, in combination with the parameters in the urine-sample mentioned 
in category VIII (see table 1), is aimed at detecting renal diseases, calcium/phosphate 
disorders and malabsorption. More than 50% of the countries with a guideline for a 
diagnostic work up in children with short stature recommended to evaluate electrolytes, 
albumin and creatinine (chapter 4). This concurs with the literature that shows that 
several renal diseases are in fact associated with short stature and that growth retardation 
is often present at diagnosis while other clinical symptoms are still absent.33-35.  An acid 
base equilibrium measurement, an easy and cheap test to screen for kidney diseases such 
as renal acidosis, was only recommended in 32% of the countries with guidelines and was 
seldom done in the hospitals familiar with the Dutch Consensus Guideline (chapters 4 
and 5). Probably the main reason for skipping this test was that an extra capillary blood 
sample is necessary, besides the routine venous blood sample to rule out other diseases. 
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Currently we are still working on a study that addresses this issue and we hope to provide 
stronger evidence for the value of this parameter in the diagnostic work-up of children 
with short stature. Preliminarily, we can already say that, in accordance with previously 
published data, several patients with distal renal tubular acidosis show failure to thrive as 
the first and main symptom.36-40 Therefore, for the time being we recommend to keep this 
test in the diagnostic work-up, besides the other parameters mentioned in category III and 
VII.
Category IV is a specific category to rule out CD. Although less than 50% of the children 
with short stature were screened for CD in secondary health care (chapter 5), we 
concluded in chapter 2 that children with short stature should be evaluated for CD, as 
in 2% to 8% of the children with short stature and no gastrointestinal symptoms, CD may 
be the underlying cause, and the risk increases to 19% to 59% if other causes for short 
stature are excluded.  At the time of the consensus meeting in the Netherlands, IgA-anti 
endomysium, IgA- antigliadin, and total IgA were used for screening for CD. However, at 
present screening with anti-tissue transglutamase antibodies or anti-endomysium is the 
best way to identify patients at risk.41 For a proper interpretation of the results of these 
tests total IgA remains important, as 7-10% of the CD patients have IgA-deficiency.42
There seems to be international consensus on testing TSH and FT4 to diagnose or rule 
out hypothyroidism in the diagnostic work up in children with short stature (chapter 4). 
Nevertheless, not every child was screened for hypothyroidism in our evaluation study in 
secondary health care. Although a systematic literature search was not performed, clinical 
experience combined with the prevalence of hypothyroidism is in favour of including these 
tests in the work-up.43 
As growth hormone deficiency is one of the most important conditions to be detected by 
auxological screening, it is obvious that IGF-I should be kept in the diagnostic work-up. 
This opinion is shared by most of the countries with current guidelines (chapter 4).
FSH is only recommended as screening tool for Turner syndrome in the diagnostic 
work up for short stature in 50% of the countries with guidelines. In our study, FSH 
was determined in less than a quarter of the girls in the correctly referred group of 
children to secondary health care (chapter 5). When the age rules recommended by 
pediatric endocrinologists (to measure plasma FSH only in girls <2 years and > 9 years) 
were applied, the figures hardly changed. From the literature, as well as from clinical 
experience, we know that the diagnosis of Turner syndrome should be considered in any 
girl with unexplained short stature.44, 45 Therefore, we believe that irrespective of the 
FSH result, a chromosomal analysis should be carried out in each girl in whom the initial 
laboratory screening has not shown an abnormality. 
More specific tests in the diagnostic work up
Although anti-tissue transglutamase and anti-endomysium antibodies have a relatively 
good sensitivity and specificity, the gold standard for the definite diagnosis of CD remains 
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an intestinal biopsy. As children with short stature should be evaluated for CD, this test 
should always be considered if no indication of a certain disease is present after the 
routine diagnostic work up, especially in children with an IgA deficiency and in children 
younger than 2 years in whom the sensitivity of the serologic screening tests is relatively 
low. This is even more indicated, if haematological investigations provide additional 
support for CD.
As we pointed out earlier, the diagnosis of Turner syndrome should be considered in 
any girl with unexplained short stature. Nevertheless chromosomal analysis for Turner 
syndrome was only performed in approximately 26% of the correct referred population in 
our evaluation study, and only 50% of the countries with guidelines recommend it for the 
diagnostic work up. As stated above, we believe that in any girl with unexplained short 
stature a karyotype has to be performed.
The determination of zinc was used only once in the diagnostic work up of the children 
referred for short stature to secondary health care (chapter 5), in contrast to the 
guideline. Reasons to consider zinc (Zn) deficiency as cause of short stature are that Zn 
is essential for somatic growth in children and that even in developed countries marginal 
to moderate Zn deficiency is not unusual.23 Therefore, there are certainly arguments in 
favour of testing children with unexplained short stature for Zn deficiency. On the other 
hand, the prevalence of Zn deficiency in western countries is unknown. Furthermore, there 
are no data on sensitivity and specificity of the various tests, but apparently the available 
tests are suboptimal. For example, the plasma Zn concentration as recommended in the 
Dutch Consensus Guideline is not the accurate way to determine Zn deficiency, as the 
Zn levels may respond to metabolic conditions unrelated to the Zn status.46, 47 Further 
research is necessary to find a reliable marker for Zn deficiency, and to collect data on the 
importance of Zn status for growth in western societies.
Besides the tests described in the Dutch Consensus Guideline, we found evidence that 
performing a sweat test in an infant with a low length or weight for age does not give a 
reliable result, as the prior probability of CF is less than 1%. Although a weight SDS 
deflection of -0.2 to -0.5 per year combined with a weight SDS below -2.5 for infants and 
a BMI SDS decrease of -1 for older children showed a better performance, the positive 
predictive value was still less than 1%. If clinical symptoms or signs suggestive for CF are 
found in combination with growth faltering, further diagnostic steps are warranted, as the 
prior probability is then expected to be higher. 
Radiographic evaluation in the diagnostic work up
Although various guidelines for radiographic analysis of disproportionate short stature 
are available,8-13 no international uniformity exists with respect to the radiographic 
evaluation of children with growth problems. We recommend that in patients with a 
possible diagnosis of a skeletal dysplasia a skeletal survey (Skull (PA and lateral); Spine 
(AP and lateral); Thorax (AP); Pelvis (AP); Upper limb (AP); Left hand and wrist (PA); 
Lower limb (AP), with PA = posteroanterior view, AP = anteroposterior view and lateral 
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= lateral view) must be performed. In patients with proportionate stature radiographic 
analysis of the hand and wrist is sufficient in most cases. However, whenever there are 
clinical abnormalities with a possible underlying bone anomaly, a modified skeletal survey 
is appropriate. The combination of clinical and biochemical features and an appropriate 
skeletal survey can guide the subsequent molecular analysis.
Genetic analyses in the diagnostic work up
As many growth related disorders have a genetic aetiology, chromosome and molecular 
analysis are indispensable in the diagnostic work up of children. This was also supported 
by representatives from countries with guidelines for the assessment of short stature 
(chapter 4). However, few of these disorders present with an isolated growth retardation. 
Therefore, genetic analysis usually takes plays only if additional signs and symptoms 
suggestive for a certain syndrome are present. For a systematic diagnostic approach we 
refer to a review by Kant et al,48 in which they give an overview of the different genetic 
causes of short stature and propose a flow chart for molecular analyses. For a recent 
review on the diagnostic procedures to detect genetic disorders in the growth hormone 
– Insulin-Like Growth Factor-I axis we refer to the paper by Walenkamp et al.49 
Implementation
Enquiries in general practice and primary health care have shown that the Dutch 
Consensus Guideline on the referral of children with short stature is used by very few 
general practitioners and by approximately 50% of the child health physicians. This fits 
the earlier observations that an increasing awareness of guidelines among doctors is not 
automatically accompanied by a wider implementation of the underlying procedures, 
specifically not with respect to non-evidence based guidelines.50-52 As we look into the 
main determinants of a good innovation process (dissemination, adoption, implementation 
and continuation),53 we can conclude that the implementation of the Dutch Consensus 
Guideline failed in several aspects. First, its dissemination only consisted of a single 
publication in a Dutch medical journal, a book that was made available to paediatricians, 
and several postgraduate courses.5,7 Second, even if the guideline was known to the 
doctor, the auxological rules were scarcely adopted in the field, as many doctors found 
it difficult to work with and expected too many referrals due to the auxological rules 
(chapter 5). Third, the implementation process was not supported by the professional 
health organisations in the different fields. As the new guideline is based on evidence we 
now have a better starting point, but still a thorough implementation procedure will be 
needed, with sufficient personal and financial investment during the various stages of the 
process, in order to achieve an acceptable level of implementation. 
Concluding remarks and proposals for future research 
From this thesis we learned that there is little international consensus on the referral and 
diagnostic work-up of children with short stature. Our literature studies and biometrical 
studies have resulted in an algorithm for the referral of children with short stature and 
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recommendations for the diagnostic work up after referral. However, no algorithm can fully 
replace the clinical judgment of the physicians, and in case of an unusual growth pattern, 
certainly if associated with clinical symptoms or signs, even if it would not comply with 
the rules for referral or the recommendations, physicians should still be free to follow their 
clinical judgment. 
The resulting algorithm for the referral of short stature (fig 1) appears suitable for 
industrialized countries, but requires further testing in other populations. Moreover, as 
there is a low efficacy and efficiency of growth monitoring between 0-3 years, particularly 
of rules involving target height and length deflection, further research is necessary to 
define auxological rules for failure to thrive in this age group. In the UK it has been 
suggested to perform frequent weight measurements and calculate the Thrive Index (TI), 
which is a measure of the discrepancy between a child’s predicted and actual weight. 
The TI can be assessed on Cole’s conditional charts to detect children with failure to 
thrive (FTT).54-56 As a threshold for referral these authors use a TI of < -1.48 SDS. The 
authors admit, however, that more study is needed before this can be recommended as a 
formal screening program.
As the diagnostic work-up reported in our evaluation study (chapter 7) was carried out 
incompletely in most cases, and as the frequency of (varying) pathology is in the order 
of 5%, we were not able to construct an evidence-based decision rule for the general 
diagnostic work-up in children with short stature at this point. Further research is 
necessary to find evidence for the continuation of testing of liver diseases in the diagnostic 
work up. Whether an acid-base equilibrium is necessary in every child with short stature 
to rule out renal acidosis is currently being investigated and will be presented later.
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Fig 1. Flowdiagram of proposed criteria for referral of children with growth disorders.
HSDS= Height Standard Deviation Score
THSDS= Target Height Standard Deviation ScoreFig 1. Flowdiagram of new guideline 
Table 2. Updated recommendations for laboratory investigations in the diagnostic work up 
for children with short stature.
Laboratory investigations  In order to diagnose 
Blood  
Hb, Ht, Leukocytes, Cell indices, leukocyte differentiation, 
ESR 
Anemia / infections
Creatinine, Sodium, Potassium, Calcium, Phosphate, Alkaline 
phosphatase, Albumin  
Renal diseases, Calcium/ Phosphate disorders, 
Malabsorption 
Acid-base equilibrium Renal tubular acidosis
IgA-anti endomysium*, anti-tissue glutaminase*, total IgA Celiac disease 
TSH, FT4 Hypothyroidism
IGF-I Growth hormone deficiency
FSH** Turner syndrome
Urine  
pH, glucose, protein, blood and sedimentation Renal diseases
*  If one of these parameters is positive a biopsy is necessary to confirm celiac disease.
**  Only in girls <2 years and > 9 years. If no cause for short stature has been found in 
girls of all ages, a karyotype has to be performed even if FSH is normal. 
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Summary
Growth impairment is considered a relatively early sign of poor health in children. 
Depending on its setting and the age of the child the impairment is expressed in several 
ways. In industrialized countries, where malnutrition is rare, the major purpose of growth 
monitoring, implying regular measurements of weight and length, is early detection of 
growth disorders, such as Turner’s syndrome (TS), Growth Hormone deficiency (GHD) 
and celiac disease (CD). For an early identification of children with abnormal growth it 
is important to have correct and well-defined referral criteria as well as a good growth 
monitoring system, with accurate growth charts and a well defined diagnostic work-up. 
In this thesis an effort is made to collect evidence on referral criteria and diagnostic 
procedures for the assessment of short stature in children, leading to a presentation of new 
guidelines. 
In the first chapter we show that although growth monitoring is widely accepted 
nowadays, this has not always been the case. It took until the 20th century before child 
health care became an important issue. We demonstrate that so far mainly arbitrary 
referral criteria have been used for growth monitoring. Only few guidelines have been 
published on referral criteria for children with impaired growth and little experimental 
evidence can be found on the diagnostic work-up in secondary health care, although 
well-defined referral criteria and a well defined diagnostic work-up are important for an 
early identification of children with abnormal growth.  Besides some general principles 
of auxological screening and diagnostic work-up in the assessment of short stature, 
we present the details of the Dutch consensus guideline, the only guideline so far that 
addresses both the referral and the diagnostic work-up of children with short stature.
Part A (Chapters 2 and 3) reviews the importance of testing for two growth related 
diseases (celiac disease or cystic fibrosis (CF)) in the routine diagnostic work-up for short 
stature. We searched the literature for evidence that screening for these diseases would 
be useful in infants and children with short stature. In chapter two we conclude that 
children with short stature should be evaluated for celiac disease. We base our conclusion 
on the fact that in 2% to 8% of the children with short stature and no gastrointestinal 
symptoms, celiac disease may be the underlying cause and that this risk increases by 
19% to 59% after exclusion of other causes of short stature. In chapter 3  we describe 
the prior-probability of CF in infants and children with short stature and/or poor weight 
gain.  As only one study could be found on the prior-probability of CF in infants and 
children with short stature, we searched for scientific reports on length and weight in 
groups of patients with CF and derived the prior-probability of CF in children with a low 
length or weight for age from these studies. We conclude that in an infant with a low length 
or weight for age the prior probability of CF is less than 1%, so that we can assume that 
in an asymptomatic infant the probability will be even lower. This would argue against 
performing a sweat test in the early diagnostic work-up of an asymptomatic infant with 
growth failure. If clinical symptoms or signs suggestive for CF are found in combination 
with growth faltering, the prior probability is expected to be higher, so that obviously 
further diagnostic steps like a sweat test are warranted. 
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In Part B (Chapters 4 and 5) the current methods of growth monitoring and diagnostic 
work-up of short stature in practice are described. Chapter 4 describes the results of an 
inquiry among pediatric endocrinologists in Europe and most industrialized countries 
around the world about the referral criteria advised for growth monitoring in primary 
care, and about diagnostic procedures for short stature in secondary care. A response was 
received from 36 countries. In 27 countries (75 %) a child health care program exists and 
in 14 (39%) there is a protocol for referral of growth-retarded children. Height for age is 
mostly used as a referral criterion. Sixteen countries (45%) reported having a guideline 
in secondary health care for the diagnostic work-up. Although in all countries there is 
agreement that biochemical, radiological and/or genetic tests are needed for a proper 
diagnostic work-up, there is a wide variety in recommended tests. We conclude that there 
is little consensus on referral criteria and diagnostic work-up of children with short stature 
among industrialized countries. 
Chapter 5  aims at getting more information on the current policy of growth monitoring, 
the definition of failure to thrive and the use of guidelines (especially the DCG) among 
well-baby-clinic doctors and school doctors (doctors of Primary Health Care 0-19 years) 
and general practioners in the Netherlands. Therefore questionnaires were sent to 365 
general practioners from the region South-Holland North and to 460 Primary Health Care 
physicians from the whole country in 2002. Analysable questionnaires were returned 
by 207 general practioners (57%) and 152 Primary Health Care physicians (33%). This 
inquiry demonstrates that the DCG is unknown to most general practitioners, but is used 
by approximately 50% of the primary health care physicians, although many of them think 
that strict application of the referral criteria would lead to too many referrals. 
Part C (Chapters 6 and 7) is concerned with an evaluation of existing guidelines. 
Chapter 6  is an evaluation of the referral pattern of short stature in primary health 
care using the Dutch Consensus guideline and the consensus guidelines from the UK, 
comparing it with cut-off values mentioned in the WHO Global Database on Child 
growth and Malnutrition. Three sets of referral rules were tested on the growth data of 
a random sample (n=400) of all children born between 01-01-1985 and 31-12-1988, 
attending school doctors between 1998 and 2000 in Leiden and Alphen aan den Rijn (the 
Netherlands). Application of the current Dutch consensus guideline would lead to too 
many referrals, mainly due to the deflection of length during the first 3 years of life, but 
also in the pubertal age range. The UKCG leads to far less referrals (0.3%), but may be 
relatively insensitive to detect clinically relevant growth disorders like Turner syndrome. 
The WHO-criteria lead to approximate 10% of referrals. New guidelines for growth 
monitoring are needed, which combine a low percentage of false positive results with a 
good sensitivity.  
Chapter 7 contains the results of a study in two hospitals (Erasmus MC - Sophia 
Children’s Hospital, Rotterdam and Spaarne Hospital, Haarlem), in which we 1) 
investigated how many children are correctly referred to secondary health care according 
to existing consensus guidelines; 2) evaluated the diagnostic work-up in secondary 
health care; and 3) assessed the frequency of underlying medical disorders. Data on 
growth and additional diagnostic procedures were collected from medical records of new 
patients referred for short stature to the outpatient clinics in whom the cause of growth 
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retardation was not yet known (n=542). As the Dutch Consensus Guideline (DCG) is the 
only guideline addressing referral criteria as well as diagnostic work-up, the analyses 
are based on its seven auxological referral criteria to determine whether children are 
correctly referred or not and on all elements of the diagnostic work-up. Of children older 
than 3 years 76% was correctly referred. . 74-88% of these children were short corrected 
for parental height, 40-61% had a height SDS <-2.5 and 21% showed height deflection 
(∆ HSDS < -0.25/ yr or  ∆ HSDS < -1). In none of the children a complete detailed 
routine diagnostic work-up was performed and in more than 30% no routine laboratory 
examination was done at all. Pathologic causes of short stature were found in 27 children 
(5%). A large share of these were due to GHD (n=7), celiac disease (n=7) and Turner 
syndrome (n=3). Other pathological causes were: syndromes (n=2: Noonan syndrome, Leri 
Weill syndrome), anemia (n=3), skeletal diseases (n=4) and emotional deprivation (n=1). 
Eighty children (14.8%) were classified as persistent short stature after born SGA.
Part D (Chapters 8 till 10) contains biometrical studies to determine cut-off points of 
auxological criteria to be used in the decision whether growth-retarded children should be 
referred for further investigations.
 First, we describe the diagnostic performance of a broad set of referral criteria for 
auxological screening for Turner syndrome in the open population in chapter 8. Three 
archetypal screening rules were applied to longitudinal growth data comparing a group 
with TS versus a reference group from birth to the age of 10 years. Clear differences in 
performance of the rules were found. The best rule takes parental height into account. 
Combining rules can improve diagnostic accuracy.  A combined rule that takes absolute 
height SDS, parental height and growth deflection into account is the best way to screen 
for TS.
Thereafter optimal auxological referral criteria for detecting celiac disease were 
determined in chapter 9. For this purpose longitudinal length and weight measurements 
up to 2.5 years of age from 3 groups of CD patients (two groups with clinical 
manifestations, one group diagnosed by screening) (n=134) and a reference group obtained 
from the Social Medical Survey of Children Attending Child Health Clinics (SMOCC) 
cohort (n=2,151) in The Netherlands were used. We found that testing for CD deserves 
a place in the diagnostic work-up in young children with failure to thrive, although the 
efficacy of growth monitoring for the detection of CD is modest. The auxological criteria 
hardly discriminate between the screened CD group and the reference group. Criteria 
based on a decrease of body mass index (BMI) or weight standard deviation score (SDS) 
performed best for the groups with clinical manifestations. Thirty-four percent of the CD 
children and 2% of the reference children had a deflection in BMI SDS of at least -2.5 per 
year and a BMI SDS below -1.3 from the age of 0.5 year. 
Thirdly, we studied the performance of various criteria concerning length, weight and body 
mass index (BMI), using longitudinal length and weight measurements up to 2.5 years 
of age from CF patients visiting three major CF clinics (n=216) and a reference group 
obtained from the Social Medical Survey of Children Attending Child Health Clinics 
(SMOCC) cohort (n=2,151) in The Netherlands (chapter 10). We conclude that a weight 
SDS deflection of -0.2 to -0.5 per year combined with weight SDS below -2.5 has the 
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highest PPV for infants and BMI SDS decrease of -1 for older children, in the absence of a 
newborn screening program for CF.
Part E consists of chapter 11 and contains a literature review on the radiographic 
evaluation of children with growth problems. Short stature as well as tall stature has a 
wide variety of causes. Tall stature is usually experienced as a less important problem 
than short stature, but for both clinical presentations it is important to make a correct 
diagnosis. The identification of the diagnosis frequently relies on radiological criteria. 
However, no international uniformity exists with respect to the radiographic evaluation 
of children with growth problems. We recommend that in patients with a possible 
diagnosis of a skeletal dysplasia a skeletal survey must be performed. In patients with a 
proportionate stature radiographic analysis of the hand en wrist will be sufficient in most 
cases. However, whenever there are clinical abnormalities with a possible underlying 
bone anomaly, a modified skeletal survey is appropriate. The combination of clinical 
and biochemical features and an appropriate skeletal survey can guide the subsequent 
molecular analysis.
New evidence-based guidelines for growth monitoring on a population basis are presented 
in Part F (chapter 12). By combining evidence found in previous studies, several 
auxological referral criteria are formulated and applied to longitudinal growth data of 
four different patient groups, as well as three samples from the general population. The 
proposed guidelines for growth monitoring show a good sensitivity at an acceptably low 
false-positive rate in 3-10 year old children. Below the age of 3 years the sensitivity 
is considerably lower. Almost 30 % of pathology can be detected by a height standard 
deviation score (HSDS) below -3 or at least two observations of HSDS below -2.5 at a 
low false-positive rate (<1%) in 0-3 year old infants. These criteria are the proposed 
auxological screening rules for children in this age group.
For 3-10 year olds, a rule concerning distance to target height of >2 SD in combination 
with HSDS < -2.0 has the best predictive value. In combination with a rule concerning 
severe short stature (<-2.5 SDS) and a minor contribution of a rule concerning height 
deflection, 85.7% of children with Turner’s syndrome and 76.5% of short children due to 
various disorders are detected at a false-positive rate of 1.5-2%. 
In the age category 3-10 years height-SDS below –2.5 or height-SDS below –2.0 in 
combination with various features (small for gestational age, emotional deprivation, 
dysmorphic features and/or disproportion, >2 SD below target height or >1 SD deflection) 
are proposed as auxological screening rules.
Finally in chapter 13, the evidence collected for the algorithm for referral of children 
with short stature and the collected evidence for the diagnostic work-up, are discussed. 
Recommendations for the diagnostic work-up after referral are being made, the 
implementation process of the new guideline in the Netherlands is discussed, and 
some proposals for future research are being offered.  We conclude that there is little 
international consensus on the referral and diagnostic work-up of children with short 
stature. Our literature studies, evaluation studies and biometrical studies have resulted 
in an algorithm for the referral of children with short stature and recommendations 
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for the diagnostic work-up after referral. However, no algorithm can fully replace the 
clinical judgment of the physicians, and in case of an unusual growth pattern, certainly 
if associated with clinical symptoms or signs, even if it would not comply with the rules 
for referral or the recommendations, physicians should still be free to follow their clinical 
judgment. 
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Samenvatting
Groeiachterstand wordt gezien als een relatief vroeg signaal voor slechte gezondheid bij 
kinderen. Afhankelijk van de setting en de leeftijd van het kind wordt de achterstand 
op verschillende wijzen omschreven. In geïndustrialiseerde landen, waar ondervoeding 
zeldzaam is, is de voornaamste reden van het vervolgen van de groei van kinderen 
(verder aangeduid als groeimonitoring), bestaande uit regelmatige metingen van lengte 
en gewicht, het vroegtijdig herkennen van groeistoornissen, zoals Turner syndroom (TS), 
groeihormoondeficiëntie (GHD) and coeliakie (CD).  Voor een vroege identificatie van een 
kind met een afwijkende groei is het belangrijk om zowel correcte en goed omschreven 
verwijscriteria te hebben als een goed groeimonitoring systeem met accurate groeicurven 
en een goed gedefinieerd diagnostisch werkplan. In dit proefschrift zijn wetenschappelijke 
gegevens (‘evidence’) verzameld voor verwijscriteria en diagnostische procedures met 
betrekking tot de evaluatie van kleine lengte bij kinderen, op basis waarvan een nieuwe 
richtlijn is opgesteld.
 
In het eerste hoofdstuk laten we zien dat groeimonitoring, hoewel heden ten dage 
wereldwijd geaccepteerd en  bij bijna ieder kind tijdens zijn of haar jeugd regelmatig 
uitgevoerd, niet altijd van belang is geweest. Pas in de twintigste eeuw werd het belang 
ervan onderkend. Verder laten we zien dat in de literatuur tot op heden voornamelijk 
arbitraire verwijscriteria zijn gebruikt voor groeimonitoring. Slechts enkele richtlijnen zijn 
gepubliceerd over verwijscriteria voor kinderen met achterlopende groei en er is weinig 
experimenteel bewijs over het diagnostisch werkplan in de tweedelijnsgeneeskunde, 
hoewel goed gedefinieerde verwijscriteria en een goed gedefinieerd diagnostisch werkplan 
van belang zijn voor een vroege opsporing van kinderen met abnormale groei. Naast 
enkele algemene principes van auxologische screening en diagnostiek in de evaluatie 
van kleine lengte, presenteren we de details van de Nederlandse Consensus Richtlijn, de 
enige richtlijn tot dusver die zowel aandacht besteedt aan de verwijscriteria als aan de 
laboratoriumdiagnostiek van kleine lengte.
 
Deel A (Hoofdstuk 2 en 3) bespreekt het belang van testen op bepaalde groei gerelateerde 
aandoeningen (coeliakie of cystic fibrosis (CF)) tijdens het routine diagnostische 
werkplan voor kleine lengte. We hebben in de literatuur gezocht naar bewijs voor het nut 
van het screenen op deze aandoeningen bij kinderen met kleine lengte. In hoofdstuk 
twee concluderen we dat kinderen met kleine lengte altijd gescreend moeten worden 
op coeliakie. Wij baseren onze conclusies op het feit dat coeliakie in 2 tot 8% van de 
kinderen met kleine lengte zonder gastro-intestinale symptomen de onderliggende oorzaak 
is. Na uitsluiten van andere oorzaken van kleine lengte neemt dit risico zelfs toe tot 19% 
tot 59%. In hoofdstuk 3  beschrijven we de vooraf-kans van CF bij kinderen met kleine 
lengte of slechte gewichtstoename. Aangezien we slechts één studie konden vinden over 
de vooraf-kans van CF bij kinderen met kleine lengte, hebben we de literatuur gescreened 
op  wetenschappelijke studies over lengte en gewicht bij patiënten met CF en hebben we 
hieruit de vooraf-kans van CF bij kinderen met kleine lengte of laag gewicht voor leeftijd 
berekend. We concluderen dat de vooraf-kans van CF bij jonge kinderen met een kleine 
lengte of laag gewicht voor de leeftijd kleiner is dan 1%, zodat we kunnen aannemen dat 
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dit nog lager zal zijn bij asymptomatische kinderen. Dit zou tegen een zweettest pleiten 
als onderdeel van het vroege diagnostische werkplan van asymptomatische jonge kinderen 
met kleine lengte. Als er klinische symptomen of tekenen suggestief voor CF gevonden 
worden in combinatie met afwijkende groei, zal de vooraf-kans waarschijnlijk hoger 
liggen, waardoor verdere diagnostiek zoals een zweettest wenselijk wordt. 
In Deel B (hoofdstuk 4 en 5) worden de huidige methodes van groeimonitoring en 
diagnostische werkplannen voor kleine lengte in de praktijk beschreven. Hoofdstuk 4 
beschrijft de resultaten van een inventarisatie onder kinderendocrinologen uit Europa en 
de meeste geïndustrialiseerde landen in de wereld over de geadviseerde verwijscriteria 
voor groeimonitoring in de eerstelijnsgeneeskunde, en over de diagnostische procedures 
voor kleine lengte in de tweedelijnszorg. Van 36 landen werd een antwoord verkregen. In 
27 (75 %) landen bestaat er een “child health care program” en in 14 (39%) landen is er 
een protocol voor verwijzing van kinderen met een groeiachterstand. Lengte voor leeftijd 
is het meest gebruikte criterium. Zestien landen (45%) vermeldden dat zij beschikten 
over een richtlijn voor een diagnostisch werkplan in de tweede lijn. Ondanks dat alle 
landen het erover eens waren dat biochemische, radiologische en/of genetische tests 
een noodzakelijk onderdeel zijn van de diagnostiek van groeistoornissen, is er een wijde 
variatie aan aanbevolen tests. We concluderen dat er onder geïndustrialiseerde landen 
weinig consensus is over de verwijscriteria en het diagnostisch werkplan voor kinderen 
met kleine lengte. 
Hoofdstuk  5  probeert meer informatie te verschaffen over de huidige uitvoeringspraktijk 
met betrekking tot groeimonitoring, de definitie van ‘failure to thrive’ en het gebruik 
van richtlijnen (specifiek de Nederlandse Consensus Richtlijn ) onder jeugdartsen en 
huisartsen in Nederland. Daarvoor werden er in 2002, 365 enquêtes verstuurd naar 
huisartsen in de regio Zuid Holland Noord en 460 enquêtes naar jeugdartsen door het 
gehele land. Door 207 huisartsen (57%) en 152 jeugdartsen (33%) werden analyseerbare 
vragenlijsten teruggestuurd. Deze inventarisatie laat zien dat de Nederlandse Consensus 
Richtlijn onder huisartsen bijna niet bekend is, maar dat deze door bijna 50% van de 
jeugdartsen wordt gebruikt, ondanks dat velen van hen denken dat strikte navolging van 
de verwijscriteria tot te veel verwijzingen zou leiden. 
Deel C (Hoofdstuk 6 en 7) bestaat uit evaluaties van bestaande richtlijnen.  Hoofdstuk  
6  is een evaluatie van het verwijspatroon van kleine lengte in de eerstelijnsgeneeskunde 
gebruik makend van de Nederlandse consensus richtlijn en de consensus richtlijn uit 
Engeland, vergeleken met de afkapgrenzen die in de WHO Global Database on Child 
Growth and Malnutrition worden vermeld. Drie groepen van verwijscriteria werden 
getest op groeigegevens van een willekeurige steekproef (n=400) van alle kinderen 
geboren tussen 01-01-1985 and 31-12-1988, die tussen 1998 and 2000 bekend waren 
bij de jeugdartsen in Leiden en Alphen aan den Rijn. Toepassing van de  Nederlandse 
Consensus Richtlijn uit 1996 zou tot te veel verwijzingen leiden, voornamelijk door 
de regel “afbuiging van lengte” gedurende de eerste 3 levensjaren, maar ook in de 
puberteitsleeftijd. Toepassing van de  Engelse consensus richtlijn zou tot veel minder 
verwijzingen leiden (0.3%), maar deze is  relatief ongevoelig zijn voor de detectie van 
klinisch relevante groeiafwijkingen zoals Turner syndroom. Toepassing van de WHO-
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criteria zou aanleiding geven tot ongeveer 10% verwijzingen. Nieuwe richtlijnen voor 
groeimonitoring die een laag percentage fout-positieven combineren met een goede 
sensitiviteit, zijn noodzakelijk. 
Hoofdstuk  7 bevat de resultaten van een studie uitgevoerd in twee ziekenhuizen (het 
Erasmus Medisch Centrum - Sophia Kinderziekenhuis in Rotterdam en het Spaarne 
Ziekenhuis in Haarlem), waarbij wij ten eerste onderzochten hoeveel kinderen volgens de 
bestaande consensus richtlijn correct verwezen waren naar de tweedelijnsgeneeskunde. 
Ten tweede evalueerden wij het diagnostisch werkplan in de tweedelijnszorg en als laatste 
hebben wij de frequentie vastgesteld van de  medische stoornissen die werden opgespoord 
door het toepassen van bovengenoemd onderzoek. Gegevens omtrent groei en aanvullende 
diagnostische procedures werden verzameld van patienten die verwezen werden naar de 
polikliniek en waarvan de oorzaak van de groeistoornis nog niet bekend was ten tijde van 
verwijzing (n=542). Aangezien de Nederlandse Consensus Richtlijn de enige is die zowel 
verwijscriteria als een diagnostisch werkplan omvat, is de analyse gebaseerd op de zeven 
auxologische verwijscriteria die aangeven of kinderen juist verwezen werden en verder 
op alle onderdelen van het diagnostisch werkplan. Van alle kinderen ouder dan drie jaar 
bleek 76% juist verwezen. Van deze kinderen waren 74 tot 88% verwezen volgens de regel 
“klein t.o.v target height”, 40 tot 61% hadden een lengte standaard deviatie score (SDS) 
van <-2,5 en 21% vertoonden een lengte afbuiging (∆ SDS <-0,25/jaar of ∆ SDS <-1). Bij 
geen van deze kinderen bleek een volledig gedetailleerd routine diagnostisch werkplan te 
zijn gevolgd en bij meer dan 30% van de kinderen ontbrak enig gebruikelijk laboratorium 
onderzoek. Pathologische oorzaken voor kleine lengte werden bij 27 kinderen aangetroffen 
(5%). Een aanzienlijk deel hiervan was toe te wijzen aan groeihormoondeficiëntie (n=7), 
coeliakie (n=7) en Turner syndroom (n=3). Andere pathologische oorzaken waren: overige 
syndromen (n=2; het Noonan en het Leri-Weill syndroom), anemie (n=3), botziekten 
(n=4) en emotionele deprivatie (n=1). Bij 80 kinderen (14,8%) werd de kleine lengte 
geclassificeerd als blijvende kleine lengte na SGA (small for gestational age) bij geboorte. 
Deel D (hoofdstukken 8 t/m 10) omvat biometrische studies om te bepalen welke 
afkapgrenzen voor auxologische kernmerken er gebruikt kunnen worden bij de beslissing 
of kinderen met een achterblijvende groei voor verder onderzoek verwezen moeten 
worden.
Als eerste wordt  de diagnostische doelmatigheid van een breed samengesteld pakket van 
verwijscriteria beschreven voor een auxologische screening  naar het Turner syndroom 
(TS) binnen een niet geselecteerde populatie (hoofdstuk 8). Drie archetypische screening 
regels zijn toegepast op lengtegroeigegevens vanaf de geboorte tot 10 jaar waarbij de 
groep met TS werd vergeleken met een referentiegroep. Er werden duidelijke verschillen 
tussen de doelmatigheid van de diverse regels vastgesteld. De beste regel is die waarbij 
de lichaamslengte van de ouders wordt meegenomen. De nauwkeurigheid van de diagnose 
kan verbeterd worden door enkele regels te combineren. Een combinatie van regels die de 
lengte SDS, de lengte van de ouders en de afbuiging van de groei bevat is de beste manier 
om TS te onderkennen. 
Grote_opm_H9_etc_v4.indd   203 22-01-2007   14:08:03
204
Vervolgens zijn in hoofdstuk 9 de auxologische verwijsregels voor de opsporing van 
coeliakie vastgesteld. Hiervoor werden lengte- en gewichtsmetingen gebruikt van drie 
groepen coeliakie patiënten (twee met klinische verschijnselen en één groep ontdekt 
middels screening) in de leeftijdscategorie tot 2,5 jaar  en daarnaast een referentiegroep 
uit het cohort van de Social Medical Survey of Children Attending Child Health Clinics 
(SMOCC) in Nederland (n=2151). Wij hebben aangetoond dat testen op coeliakie een 
plaats verdient in de diagnostiek bij jonge kinderen met groeistoornissen, alhoewel 
de effectiviteit van groeimonitoring voor het aantonen van coeliakie bescheiden is. 
De auxologische criteria laten weinig verschil zien tussen de coeliakie groep en de 
referentiegroep. Criteria gebaseerd op een afname van de body mass index (BMI) 
SDS of van het gewicht SDS kwamen als beste uit de bus voor groepen met klinische 
verschijnselen. Vanaf een leeftijd van 6 maanden hadden 34% van de kinderen met 
coeliakie  en 2% van de kinderen uit de referentiegroep een afwijking van de BMI SDS 
van ten minste -2,5 per jaar en een BMI SDS beneden -1,3.
Ten derde hebben wij de test-eigenschappen van diverse criteria inzake lichaamslengte, 
gewicht en BMI bestudeerd waarbij gebruik gemaakt is van lengte- en gewicht metingen 
van cystic fibrosis (CF) patiëntjes tot twee en een half jaar in drie grote CF klinieken 
(n=216)  en daarnaast de gegevens van een referentiegroep verkregen uit het Nederlandse 
SMOCC cohort (hoofdstuk 10). We hebben hieruit berekend dat bij afwezigheid van 
een CF screening programma bij pasgeborenen een gewicht SDS afwijking beneden -
0,2 tot -0,5 per jaar samengaand met een gewicht SDS onder -2.5 de hoogste positieve 
voorspellende waarde voor peuters vertoont en een BMI SDS afname van -1,0 voor oudere 
kinderen.
Deel E bestaat uit hoofdstuk 11 en bevat een literatuuroverzicht omtrent radiologische 
evaluatie van kinderen met groeistoornissen. Kleine lengte zowel als grote lengte hebben 
een reeks van verschillende oorzaken. Grote lengte wordt gewoonlijk als een minder 
groot probleem gezien dan kleine lengte, echter voor beide klinische presentaties is 
het belangrijk om de juiste diagnose te stellen. Het herkennen van de diagnose hangt 
vaak af van radiologische criteria. Voor de radiologische evaluatie van kinderen met 
groeistoornissen bestaan geen internationaal aanvaarde normen. Wij bevelen aan dat 
bij patiënten met een mogelijke diagnose van botdysplasie er een skelet-status wordt 
uitgevoerd. Bij patiënten met een afwijkende lichaamslengte, gepaardgaande met 
normale lichaamsproporties  zal  een  analyse van hand- en polsfoto in de meeste gevallen 
voldoende zijn. Indien er echter klinische kenmerken zijn die passen bij afwijkingen van 
het  skelet is een  uitgebreider skelet-onderzoek aangewezen. De combinatie van klinische 
en biochemische kenmerken en een gericht skelet onderzoek kan een leidraad zijn voor 
de daaropvolgende moleculaire analyse.
Nieuwe evidence-based richtlijnen voor groeimonitoring worden gepresenteerd in Deel 
F (hoofdstuk 12). Door experimentele gegevens uit voorgaande studies te combineren, 
zijn verschillende auxologische verwijscriteria opgesteld en vervolgens toegepast op 
lengtegroeigegevens van vier verschillende patiëntengroepen alsmede drie steekproeven 
uit de normale populatie. De voorgestelde richtlijnen voor groeimonitoring vertonen een 
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goede sensitiviteit bij een aanvaardbaar lage fout-positieve ratio in de leeftijdscategorie 
van drie tot tien jaar. Bij kinderen jonger dan drie jaar is de sensitiviteit aanzienlijk lager. 
Bijna 30% pathologie wordt aangetroffen bij een lengte SDS beneden -3 of bij tenminste 
twee waarnemingen van lengte SDS beneden -2,5 bij een lage fout-positieve ratio (<1%) 
bij peuters jonger dan drie jaar, dus deze criteria vormen de voorgestelde auxologische 
screening regels voor kinderen in deze leeftijdsgroep. Voor drie- tot tienjarigen heeft een 
regel betreffende een lengte beneden de target height van >-2 SD  gecombineerd met een 
lengte SDS <-2,0 de beste voorspellende waarde. Samen met de regels betreffende zeer 
kleine lengte (<-2,5 SDS) en in mindere mate de regel betreffende lengtegroeiafbuiging 
kunnen 85.7% van de kinderen met Turner syndroom en 76.5% van kinderen met 
kleine lengte als gevolg van andere pathologische oorzaken gevonden worden bij een 
fout-positieve ratio van 1,5 tot 2,0 %. In de leeftijdscategorie van drie tot tien jaar 
wordt voorgesteld om een lengte SDS beneden -2,5 of een lengte SDS beneden -2,0 in 
combinatie met diverse verschijnselen (klein voor de zwangerschapsduur, emotionele 
deprivatie, dysmorfische afwijkingen en/of disproportie, meer dan 2 SD beneden de target 
height of meer dan 1 SD afbuiging) te gebruiken als auxologische regels. 
Tenslotte wordt in hoofdstuk 13 het algoritme voor de verwijscriteria besproken evenals 
het verzamelde bewijsmateriaal voor de diagnostiek. Er worden aanbevelingen gedaan 
voor het diagnostisch werkplan na de verwijzing, het implementatie-proces wordt 
besproken en ideeën voor verder onderzoek worden aangereikt. Er wordt vastgesteld 
dat er weinig internationale overeenstemming is omtrent het verwijzingsproces én het 
diagnostisch werkplan voor kinderen met een kleine lengte. Ons literatuuronderzoek, de 
evaluaties en de biomedische studies hebben geleid tot een algoritme voor de verwijzing 
van kinderen met een kleine lengte en aanbevelingen voor de diagnostiek na verwijzing. 
Echter, geen enkel algoritme kan het klinisch oordeel van een arts volledig vervangen en 
in het geval van een ongewoon groeipatroon (zeker indien samenvallend met klinische 
symptomen) moeten artsen de vrijheid hebben om op hun klinisch oordeel af te gaan, 
zelfs als dit niet mocht sporen met de regels voor verwijzing of de hierboven gedane 
aanbevelingen.
Grote_opm_H9_etc_v4.indd   205 22-01-2007   14:08:04
Grote_opm_H9_etc_v4.indd   206 22-01-2007   14:08:04
Appendices
Grote_opm_H9_etc_v4.indd   207 22-01-2007   14:08:08
208
Grote_opm_H9_etc_v4.indd   208 22-01-2007   14:08:08
209
Appendix I
Definitions of several parameters:
1. Standard deviation scores:  
SDS is the deviation of the individual height, expressed in standard deviations from the 
mean height of the population for the same age and sex. 
Height – mean height for the same age and sex   
 SD for the same age and sex
Using SDS instead of percentiles gives more precision in interpretation, especially when 
concerning decline in growth rate, because of the equidistance between the SDS lines. 
All height SDS and weight SDS will be calculated using the data from the growth 
references for height and weight collected in 1997 (8)
2. Percentiles:
Historically percentiles have been used to define height, although the standard deviation 
scores are more precise. Percentiles can easily be transformed into SD scores and the 
other way around, if the measurements have a Gaussian distribution.  
P0.4  =  -2.67 SDS
P3     =  -1.88 SDS
P10   =  -1.28 SDS
P25   =  -0.67 SDS
P50   =  0 SDS
3. Target range:
Target range is the area around the target height, in which healthy children reach their 
final height. Target height is the mathematical approach of the estimated final height of a 
boy or a girl on the basis of their genetic potential.
TH son = height of father + (height of mother +13) + 4.5
       2
TH-SDSson= (TH – 184.0) / 7.1
THduaghter= height of mother (+height of father -13) + 4.5
       2
TH-SDSdaughter= (TH – 170.6) / 6.5
4. Deflection or change in height SDS:
The Change in height SDS is the difference in height SDS between two measurements. 
In this case the threshold is a change in height SDS of - 0.25 SDS a year, in at least three 
measurements, with an interval of 6 months each time.
5. Disproportion:
Children with abnormal growth, who have a body proportion outside the normal range, are 
prone to have a primary growth disorder and should be referred to a specialist. The most 
suitable parameter for body proportions is the sitting height/ height ratio.
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Since the exact description is missing in the DCG we will use in this protocol the following 
definition: 
Disproportion = sitting height/height ratio SDS < -1.88 or > + 1.88
6. Dysmorphology:
A large number of syndromes associated with short stature are also associated with 
dysmorphology. Because the dysmorphology may be the first sign of the primary growth 
disorder it is important to refer these children to a specialist. For a list of dysmorphic 
features associated with small stature see appendix IV.
7. IUGR without catch-up growth:
Most of the children who are small for gestational age show a catch-up growth in the first 2 
years after birth. Approximately 15 % do not show catch-up growth and still have a height 
< -1.88 SDS after two years of age. 
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Appendix II.
In chapter 3 we report on the results of our analysis of the available literature on growth 
data in CF aiming at assessing the prior-probability of CF in infants and children with 
short stature and/or poor weight (taken from a general population). In our literature search 
we encountered the following difficulties:
1.  There is much controversy on the definition of failure to thrive in the literature, and to a 
lesser extent also on the definition of short length (height) and weight for age.
2. There are no published studies with longitudinal growth data before diagnosis of CF.
3.  Except for one single publication in Portuguese (Oliveira et al. J Pediatr (Rio J ) 
1998;74:213-6), we found no publications that showed data on the prevalence of CF in 
growth retarded children.
To overcome these difficulties and answer our initial question we had to use an indirect 
approach based on the following definitions/ assumptions:
1.  Short stature is defined as poor length for age (with -1.5 SDS, -2.0 SDS and -2.5 SDS as 
cutt-offs). 
2.  We used a low length for age or weight for age (with -1.5 SDS, -2.0 SDS and -2.5 SDS 
as cutt-offs) as a proxy parameter for failure to thrive (in the absence of longitudinal 
data) 
3.  The average incidence of CF in the general Caucasian population is 1:3000 (Bobadilla 
JL et al. Hum Mutat 2002;19:575-606) 
We hope to clarify the indirect approach implying statistical procedures that are difficult 
to explain in a short report like the CAT in chapter 3, with the following  “two-by-two 
table”:
CF + CF-
Short stature + a b
Short stature - c d
1.  To answer our question we wish to estimate the percentage of CF in children with short 
stature (taken from a general population): (a/a+b) *100 (= positive predictive value as a 
percentage) 
2. Based on the assumption on the incidence of CF: a+c= 1 and b+d= 3000.
3.  b = (percentage of children with short stature in a population given a certain cut-off) * 
3000/100.  
Length, height and weight for age have a Gaussian distribution in this age range, so 
that standard deviation scores are easily converted into percentiles. The percentages of 
children with short stature in a population are calculated from the different cut-offs. 
4.  “a” is the average percentage of short stature in the CF-populations mentioned in the 
articles: To be able to calculate this percentage we had to follow several steps: 
a.  The mean length and weight at diagnosis expressed as standard deviations scores (SDS) 
were either directly derived from the data or by converting percentile positions to SD-
scores. 
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b.  From the available studies it became clear that the SD of the length, height and weight 
for age distributions differed considerably from 1. We therefore calculated the weighted 
average SD for length (1.41) and weight (1.28) from the data given in  three articles 
(Farrell PM et al. Pediatrics 2001;107:1-13, Ranganathan SC et al. Am J Respir Crit 
Care Med 2004;169:928-33, and Waters DL et al. Arch Dis Child Fetal Neonatal Ed 
1999;80:F1-F7.)
c.  For each paper the mean SD-scores for length and weight were then subtracted from 
the different cut-off points for low weight and short stature and divided by the weighted 
average SD, in order to derive the SD scores corresponding with the different cut-off 
points for low weight and short stature. 
d.  The results of these subtractions were converted into percentiles and the percentages of 
children with low weight and short stature were calculated. 
e. Finally the weighted average from the estimated percentages of step d  was calculated.
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